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Macrophages have important roles in the lung, in homeostasis and in the immune 
response. Inappropriate activation of macrophages can cause aberrant inflammation, 
although the mechanisms leading to this are not fully understood. Studying these cells 
could be useful for understanding their possible involvement in the pathogenesis of 
inflammatory lung diseases. Most studies of macrophages have involved using 
monocyte-derived macrophages, monocytic cell lines or murine models. In this study, 
macrophages were isolated from resected human lung tissue, as they may be of more 
pathophysiological relevance. The overarching aim of this study was to characterize the 
phenotype of lung macrophages, principally by investigating functional responses to 
disease-relevant stimuli. 
Initial studies were performed to attempt to isolate macrophages from lung tissue to a 
high level of purity and viability, which was achieved successfully. Flow cytometry 
studies showed that these were mature macrophages, with expression of CD206 and low 
expression of CD14. The cells were found to secrete TNF-α, IL-6 and IL-8 but much 
lower levels of IL-10 in response to lipopolysaccharide (LPS) stimulation as measured 
by ELISA. Further studies using Proteome Profiler Array indicated the cells had a pro-
inflammatory phenotype in response to LPS, poly(I:C) and gardiquimod. Preliminary 
qPCR studies assisted in suggesting that the cells were predominantly of an M1, pro-
inflammatory phenotype. LPS stimulation also resulted in the release of prostaglandin 
E2 (PGE2). Endogenously-derived PGE2 was found to act in a paracrine fashion to 
inhibit cytokine release, as a mechanism to limit macrophage activation. Further studies 
indicated that LPS-induced PGE2 was driven by the inducible isoform of 
cyclooxygenase (COX), COX-2. Moreover, it was found that PGE2 acts at the EP4 
receptor to stabilize macrophages. Agonists at the EP4 receptor were found to be 
considerably more effective than both short-acting and long-acting β2-agonists, at 
producing anti-inflammatory effects, suggesting that targeting the EP4 receptor could be 
an effective approach to stabilize macrophages. 
This study demonstrates that the isolated lung macrophage is a tractable model 
amenable to a range of experimental applications. Overall, the results indicate that lung 
macrophages express a predominantly pro-inflammatory M1 phenotype and this could 
be important in the context of respiratory diseases. Further work will be necessary to 
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Chapter 1: Introduction 
Macrophages, also referred to as mononuclear phagocytes, are present in all tissues of 
the body (Chow et al., 2011). Metchnikoff, in 1882, recognized the importance of these 
cells that could phagocytose (“eat”) and destroy bacteria, in innate immunity (Gordon, 
2007, Gordon, 2008). The term ‘macrophages’ comes from Greek, meaning ‘big eaters’. 
In addition to phagocytosis, macrophages have other important roles, not only in 
immunity but also in development, homeostasis and repair. Specialized features allow 
macrophages to carry out their various functions. Macrophages also exhibit phenotypic 
heterogeneity and plasticity, which is currently of great research interest. Different 
macrophage phenotypes subserve the various roles of the cells. Macrophages are 
implicated in various conditions, such as rheumatoid arthritis and chronic lung diseases. 
Furthermore, different macrophage subsets can be implicated in different conditions. 
Therefore, the ability to modulate phenotypes makes the cells an attractive potential 
target for treatments.   
 
1.1. Macrophage origins 
Haematopoietic stem cells (HSC) in the embryonic yolk sac are believed to develop into 
primitive macrophages that are not differentiated from monocytes (Shepard and Zon, 
2000). Later, haematopoiesis in the fetal liver begins, leading to the development of 
monocytes, which differentiate into macrophages (Shepard and Zon, 2000, Gordon and 
Taylor, 2005, Metcalf, 2007). HSC from the yolk sac may also move to the fetal liver 
but it is not clear whether the resulting macrophages persist into adulthood (Lichanska 
and Hume, 2000, Hume et al., 2002).  
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Macrophages in adults are derived from monocytes, which in turn originate from 
multipotent HSC in the bone marrow. These precursor stem cells undergo 
differentiation, first along the myeloid pathway (as opposed to the lymphoid pathway) 
producing Granulocyte/Macrophage Colony-Forming Unit (GM-CFU), then along the 
monocyte/macrophage pathway (Metcalf, 2007, Mosser and Edwards, 2008). 
Differentiation of GM-CFU in the presence of macrophage colony stimulating factor 
(M-CSF) produces monocytes, which initially move into the bloodstream. Migration of 
the monocytes into tissues is believed to result in their differentiation into tissue-
specific macrophages (figure 1.1) (Murray and Wynn, 2011b, Gordon and Taylor, 
2005). This system is termed the ‘mononuclear phagocyte system’ (van Furth et al., 
1972). 
 
Although this described system, of derivation of macrophages from circulating 
monocytes is generally accepted, there are some conflicting views concerning 
macrophages in the absence of infection (the ‘steady state’). Some early studies 
indicated that in the steady state, certain macrophages including alveolar macrophages 
were mainly derived from local proliferation of colony-forming cells present in the 
tissue rather than from monocytes recruited from the blood (Tarling et al., 1987). A 
more recent report claimed that in the steady state, tissue-resident macrophages, 
including alveolar macrophages, are not derived from blood monocytes. Instead, the 
macrophages proliferate in situ in response to M-CSF and granulocyte macrophage 
(GM)-CSF (Hashimoto et al., 2013).
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Figure 1.1. Macrophage development from haematopoietic stem cells. 
A simplified figure of the development of macrophages along the myeloid pathway, as 
opposed to the lymphoid pathway, from bone-marrow precursor cells is shown. 
Monocytes are believed to move from the peripheral blood into tissues to develop into 
tissue-specific macrophages in adults. [GM-CFU, granulocyte macrophage-colony 
forming unit; M-CFU, macrophage-colony forming unit; M-CSF, macrophage-colony 
stimulating factor](Gordon and Taylor, 2005, Metcalf, 2007).
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By contrast, the views of macrophages in infection conditions have been less 
conflicting. It has been understood that it is often necessary for monocytes to be 
recruited to infected tissues, and subsequently differentiate into macrophages, as the 
numbers of macrophages present in the tissues are not always sufficient to manage the 
infection alone (Murray and Wynn, 2011b). However, as well as differentiation from 
monocytes, there is evidence from a recent study in mice, of macrophages proliferating 
in the tissue, in certain types of infections. The study demonstrated that in response to a 
nematode infection, in which IL-4 is present, alternatively activated macrophages 
(discussed in 1.3.2) can proliferate in situ, although the exact mechanisms are not clear 
(Murray and Wynn, 2011b, Jenkins et al., 2011). 
 
1.2. Principal roles of the macrophage 
1.2.1. Phagocytosis 
Phagocytosis is a method by which large particles and pathogens that require removal 
from the body are taken up by cells to be destroyed. Macrophages (along with 
monocytes and neutrophils) are termed ‘professional phagocytes’ because unlike many 
other cells that can also phagocytose, they carry out the process with a high level of 
efficiency (Aderem and Underhill, 1999, Grimsley and Ravichandran, 2003). The main 
way in which this is facilitated is through the presence of many different receptors that 
have affinity for a number of different particles. The density of receptors present also 
enables phagocytosis to occur at a high rate. 
 
For the recognition and phagocytosis of pathogens, the receptors on macrophages are 
mainly Fc receptors for antibodies bound to pathogen surfaces (FcγRs), complement 
receptors for C3b that bind bacteria that have been opsonised by complement protein 
and mannose receptors which recognise mannose on pathogen surfaces (figure 1.2) 
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(Aderem and Underhill, 1999). Complement is a system of 20 proteins that, in response 
to pathogens, initiate a proteolytic cascade that leads to destruction of the pathogens 
(Roozendaal and Carroll, 2006). The different receptors are associated with different 
signalling pathways leading to phagocytosis (Aderem and Underhill, 1999). In Fc 
receptor mediated phagocytosis, Fc receptor cross-linking leads to phosphorylation of 
receptor domains by src kinase. Phagocytosis then results via a pathway involving 
activation of the tyrosine kinase Syk, phosphoinositide 3-kinase (PI3-kinase) and 
phospholipase C. Complement receptor mediated phagocytosis occurs by protein kinase 
C activation, requiring the presence of stimuli to do this.   
 
The process of phagocytosis involves actin polymerisation (Aderem and Underhill, 
1999). Receptor-ligand interactions on the cell surface stimulate the polymerisation of 
actin, resulting in the plasma membrane surrounding the pathogen, forming a 
phagosome. The actin is then lost by depolymerisation, leaving the vacuolar membrane 
free to fuse with endosomes (that have been acidified) and lysosomes (containing acid 
hydrolases and lysozyme), forming a mature phagolysosome in which pathogens can be 





Figure 1.2. Macrophage receptors. 
The macrophages receptors involved in phagocytosis are Fc receptors, complement 
receptors, mannose receptors and scavenger receptors. The macrophage receptors 
involved in detecting pathogen associated molecular patterns are Toll-like receptors, 































A major role of macrophages in the healthy host is the removal of apoptotic cells (a 
process termed efferocytosis) for maintenance of tissue homeostasis and in development 
(Mosser and Edwards, 2008, Erwig and Henson, 2007). Removal of large numbers of 
erythrocytes from the blood to be replenished is one essential requirement for correct 
functioning of the host. In development, tissue remodelling leaves apoptotic cells that 
need to be removed. Neutrophils are constantly circulating short-lived cells that begin to 
undergo constitutive apoptosis within a matter of hours, requiring clearance to enable 
their replacement to occur. Apoptotic cells in the healthy host that have undergone 
constitutive apoptosis (as opposed to apoptosis as the result of injury or infection) need 
to be removed in large quantities, at a high rate, before substances that could be 
damaging to the surrounding tissue are leaked from the cells (Grimsley and 
Ravichandran, 2003). This constantly occurring process needs to take place without 
eliciting a pro-inflammatory response (Aderem and Underhill, 1999, Meagher et al., 
1992). Macrophages are suggested to be able to recognise the difference between cells 
that have undergone constitutive apoptosis and those that have become apoptotic as a 
result of infection, then generate an appropriate pro-inflammatory response to the 
infected cells (Perskvist et al., 2002). 
 
Macrophages (and other phagocytes) possess receptors on their surface that can 
recognise certain markers expressed by apoptotic cells that are not present on cells that 
are alive. Phosphatidylserine (PtdSer) is normally present in the inner leaflet of the cell 
membrane lipid bilayer. In apoptotic cells, it is translocated to the outer leaflet 
(Grimsley and Ravichandran, 2003, Savill and Fadok, 2000). In addition to PtdSer, 
other markers indicating apoptotic cells are changes in glycosylation of surface proteins, 
changes in lipids, change in the cell surface charge and modifications of molecules such 
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as intercellular adhesion molecule-3 (ICAM-3) and cluster of differentiation 31 (CD31 
or platelet endothelial cell adhesion molecule (PECAM)-1) (Savill, 1997, Platt et al., 
1998, Brown et al., 2002). Some of the receptors on macrophages that can recognise 
these markers are the class A scavenger receptor, the class B scavenger receptor CD36 
and CD14 (figure 1.2) (Fadok et al., 2001, Febbraio et al., 2001). It has been proposed 
that phagocytosis of apoptotic cells does not elicit a pro-inflammatory response as 
occurs when pathogens are taken up because the presence of PtdSer engages 
phosphatidyl serine receptor in a dominant manner over the other receptors present on 
the macrophage (Fadok et al., 2001). 
 
Ingesting apoptotic neutrophils results in macrophages down-regulating pro-
inflammatory responses (in contrast to when ingesting pathogens) by not secreting IL-8 
(which is a neutrophil chemoattractant), TNF-α (tumour necrosis factor-alpha) and 
MCP-1 (monocyte chemotactic protein-1) (Fadok et al., 1998). Furthermore, anti-
inflammatory responses are actively produced, involving up-regulation of secretion of 
mediators such as prostaglandin E2, TGF-β1, IL-10 and platelet-activating factor (Fadok 
et al., 2001, Fadok et al., 1998), demonstrating the importance of macrophage 
engulfment of apoptotic cells in tissue homeostasis. 
 
1.2.3. Pattern recognition receptors and inflammatory responses 
An important role for macrophages in disease states is the production of soluble 
mediators of inflammation in response to pathogens, such as cytokines and chemokines, 
which have important effects on other cells involved in immune and inflammatory 
responses (Puneet et al., 2005). Toll-like receptors (TLRs) are pattern recognition 
receptors (PRRs) that recognise specific pathogen-associated molecular patterns 
(PAMPS) (figure 1.2) (Aderem and Underhill, 1999). However, unlike with some other 
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macrophage receptors, phagocytosis is not induced when pathogen binding occurs 
(Gordon, 2007). Instead, intracellular signalling leads to cytokine gene activation 
resulting in cytokine production and secretion, producing an inflammatory response.  
 
TLRs are transmembrane receptors with an intracellular domain referred to as TIR 
(Toll/IL-1 receptor homologous) domain and there are ten TLRs known to be present in 
humans (Kaisho and Akira, 2006). Different TLRs respond to different ligands but most 
of them signal via the NF-κB pathway (figure 1.3). The signalling pathway utilized 
depends on the combination of TIR domain-containing adapter molecules, such as 
MyD88 (myeloid differentiation primary response protein 88) and TRIF (TIR domain-
containing adapter protein inducing IFN-β), recruited from the cytoplasm (Martinez et 
al., 2009, Kaisho and Akira, 2006). Some of the TLRs are expressed and detect PAMPs 
at the cell surface, for example, TLR2 which is mainly activated by bacterial 
lipoteichoic acid or bacterial lipoproteins and TLR4 which is mainly activated by 
lipopolysaccharide (LPS) which is a component of gram-negative bacterial cell walls 
(Sabroe et al., 2003, Martinez et al., 2009). 
 
Some pathogens are phagocytosed before there is a chance for them to be detected at the 
cell surface. Their PAMPs can be detected by TLRs intracellularly, as TLR2 and TLR6 
form a heterodimer which can connect with phagolysosomes and detect the pathogens 
within them. TLRs can also detect viral single-stranded RNA and CpG DNA present 
within endosomes, for example TLRs 7 and 9, leading to the production of Interferon-α 
(IFN-α) and Interferon-β (IFN-β) in addition to inflammatory cytokines (Gordon, 2007, 




Figure 1.3. Pathway of TLR2 and TLR4 signalling via MyD88. 
Stimulation by pathogens causes TLR2 and TLR4 to associate with MyD88/TIRAP. 
IRAK-4 is recruited. TRAF6 recruitment leads to activation of TAK1 and IKKβ. 
Phosphorylation of IκB results in its degradation, allowing NF-κB to become activated, 
move to the nucleus and cause transcription of cytokine genes. [MyD88: Myeloid 
differentiation primary response protein 88; TIRAP: TIR domain-containing adapter 
protein; IRAK: IL-1 receptor-associated kinase; TRAF: TNF receptor-associated factor; 




















In addition to TLRs, the other pathogen recognition receptors associated with 
macrophages are the NOD (nucleotide-binding oligomerization domain)-like receptors 
and RIG (retinoic acid-inducible gene 1)-like helicase receptors (Gordon, 2007). These 
receptors can detect viral and bacterial PAMPs in the cytosol (figure 1.2). The NOD-
like receptors include NOD1, NOD2, NALP1 and NALP3 (Kawai and Akira, 2011). 
Inflammasomes are formed by the NALP proteins, resulting in activation of caspase-1, 
which is required for the release of certain pro-inflammatory cytokines, such as IL-1β. 
More investigation needs to be done on these receptors to bring the level of information 
about them up to that known about TLRs. 
 
1.2.4. Antigen presentation to T cells 
Macrophages have a further important role, acting as antigen presenters to T 
lymphocytes (T cells). Macrophages are considered to be, like dendritic cells, 
professional antigen presenting cells (APCs) (Nickoloff and Turka, 1994). Antigen 
presentation to T cells activates T cells, resulting in a T helper 1 (Th1) or T helper 2 
(Th2) response (Martinez et al., 2009). 
 
Pathogens binding to macrophages stimulate the macrophages to release chemokines 
which induce the recruitment of other immune cells that secrete either Interferon-γ 
(IFN-γ) (for Th1 responses) or interleukin (IL)-4 and IL-13 (for Th2 responses) 
depending on the macrophage receptor that is activated by the pathogen (Martinez et al., 
2009). IFN-γ together with the pathogens binding stimulates the macrophage to release 




Antigenic peptides from pathogens that are internalised but not able to be immediately 
destroyed in phagolysosomes bind to MHC (major histocompatibility complex) Class II 
molecules. Naive T cells that express CD4 (CD4-positive T helper cells) have affinity 
for MHC Class II molecules. The Peptide-MHC II complex moves to the cell 
membrane, displaying the antigenic peptide on the surface of the macrophage. 
Macrophages migrate from the site of infection to the lymph nodes (Hawrylowicz et al., 
2001), where naive CD4-positive T helper cells can interact with the complex via the T 
cell receptor (TCR), with CD4 acting as a co-receptor. Co-stimulation for T cell 
activation is provided by co-stimulatory molecules B7.1 (CD80) and B7.2 (CD86) on 
the macrophage interacting with CD28 on the T cell (Lenschow et al., 1996, Grewal and 
Flavell, 1997). The cytokines (IL-12 or IL-10 released by the macrophage after 
pathogen binding) that are present during this process of T cell activation determine 
whether the naive T helper cells differentiate into Th1 or Th2 effector T cells 
respectively (Martinez et al., 2009). 
 
Th1 and Th2 effector cells release different cytokines resulting in different roles 
(Martinez et al., 2009). Th1 release IFN-γ, which can then activate the macrophages 
with co-stimulation from CD40 ligand (CD40L) (which is expressed on the activated, 
effector T cells) binding to CD40 on the antigen-presenting macrophage (Grewal and 
Flavell, 1997). CD40-CD40L also up-regulates expression of the B7 co-stimulatory 
molecules (Peng et al., 1996, Grewal and Flavell, 1997). This Th1 response results in 
macrophages that are able to enhance the killing of pathogens in their phagolysosomes 
(Martinez et al., 2009). Th2 release IL-10 (which supresses Th1) and IL-4. Their main 
role is to help B cells to produce antibodies. 
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1.3. Macrophage heterogeneity and polarization 
Macrophages demonstrate heterogeneity of function according to the requirements of 
their specific environment (Gordon and Taylor, 2005). Macrophages in the lung express 
certain receptors (discussed in 1.2.1) allowing them to recognise and remove or kill the 
pathogens that the lung is constantly exposed to. The cells also produce pro-
inflammatory cytokines, which assists with this. These macrophages are different to 
those found in the lamina propria of the gut, for example, which also have the ability to 
phagocytose and kill harmful bacteria. However, they do not normally have a good 
ability to produce pro-inflammatory cytokines (Gordon and Taylor, 2005), which is 
important, as their other role is to ensure there is tolerance to the food antigens and 
resident flora constantly present in the gut (Murray and Wynn, 2011b).  
 
Heterogeneity is also demonstrated by macrophages that reside in different locations of 
the same tissue. In the lung, alveolar macrophages are present in the alveoli, whereas 
interstitial macrophages reside in in the interstitium, which is a sterile environment, 
except when infection has taken place (Triggiani et al., 2004). The location of alveolar 
macrophages results in them easily coming into contact with inhaled foreign particles 
(Rankin, 1989). In line with their location-based requirements, alveolar macrophages 
have been reported to be better at carrying out phagocytosis than interstitial 
macrophages (Fathi et al., 2001) whereas a study using rhesus macaques found that 
interstitial macrophages acted as better antigen presenters than alveolar macrophages 
and were better at cytokine release (Cai et al., 2014). Macrophages in the lung have 
been referred to by some researchers as ‘low density’ macrophages or ‘high density’ 
macrophages (Triggiani et al., 2004). These have the properties described in other 
studies, of alveolar and interstitial macrophages respectively. Most of the studies into 
this area have been carried out using murine, not human, macrophages. It can also be 
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difficult to distinguish between the two types of macrophages, and the criteria used to 
discriminate between the types can vary between studies. 
 
Tissue macrophages are generally believed to arise from circulating blood monocytes 
that are recruited to the tissue (Murray and Wynn, 2011b), although alternative 
proposals to this have been discussed in section 1.1. Monocytes are believed to exhibit 
heterogeneity themselves and have been reported to have either an ‘inflammatory’ or 
‘resident’ phenotype, with different chemokine receptors expressed by each of the two 
subsets (Weber et al., 2000). Therefore, the differentiation of different monocyte subsets 
into macrophages could result in heterogeneous macrophage populations. The 
‘inflammatory’ monocytes (CD14hiCD16-CCR2+) are believed to be recruited (in 
response to pro-inflammatory CCL2 which is the ligand for CCR2) to inflamed tissues 
where they differentiate into macrophages that can contribute to resolution of 
inflammation (Gordon and Taylor, 2005, Shi and Pamer, 2011). The ‘resident’ 
monocytes (CD14+CD16+CCR2-) are believed to be recruited to normal tissue, where 
they differentiate into macrophages to replenish the tissue macrophages. It should be 
noted that these reported results were partially extrapolated to humans from the results 
of murine studies, as there appeared to be phenotypic similarities between murine and 
human monocyte subsets (Geissmann et al., 2003, Ingersoll et al., 2010). 
 
Macrophage heterogeneity can arise from differential activation. The definition of 
macrophage activation varies in the literature, depending on the context in which the 
term ‘activation’ is being used. The term can be used to refer to macrophages that have 
been stimulated in some manner resulting in them responding in a way that changes 
their state, or used in an immune context, where macrophages have been stimulated by a 
T helper cell cytokine response (Martinez et al., 2009) resulting in them acquiring a 
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particular phenotype. For the purposes of this discussion on macrophage activation in 
heterogeneity, it is used in the latter context. Macrophages can also be activated in vitro 
by various stimuli in the absence of T cells. An alternative term to ‘activation’ often 
used by many researchers is ‘polarization’ (Murray et al., 2014). There is considered to 
be a ‘spectrum’ of macrophage activation, with overlap in the characteristics of the 
different phenotypes (Mosser and Edwards, 2008). However, the major classifications 
of macrophages are into two groups. These are ‘classically activated’, by the Th1 
response and ‘alternatively activated’, by the Th2 response, also known as M1 and M2 
phenotypes respectively (Martinez et al., 2009). 
 
1.3.1. Classically activated macrophages 
Classical activation is believed to result in a macrophage phenotype that has increased 
intracellular pathogen killing capacity and produces increased levels of pro-
inflammatory cytokines (figure 1.4) (Mosser and Edwards, 2008). The stimuli resulting 
in classical activation are IFN-γ and LPS. Originally it was believed that IFN-γ 
produced by Th1 cells during the immune response and TNF-α produced by TLR 
activation were both required to classically activate macrophages. However it has since 
been reported that LPS is one of the TLR ligands that can alone activate a pathway that 
results in IFN-β production, which can, instead of IFN-γ, contribute to macrophage 
activation along with TNF-α (Mosser and Edwards, 2008). The cytokines released by 
these M1 macrophages are pro-inflammatory and the broad description of M1 cells is 
that they produce high pro-inflammatory IL-12 and low anti-inflammatory IL-10. Much 
of the research into this area has been carried out using murine macrophages. The 
characteristics of murine macrophage phenotypes are therefore much better defined than 
those of human macrophages and there are some known differences between 
macrophages from the two species. However, attempts to better characterize human 
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macrophages have been made in recent studies. Recently it has been recommended that 
instead of describing stimuli as simply being M1 (or M2), the specific stimuli used 
should be reported, as for example, cells stimulated by LPS alone or by LPS+IFN-γ 
result in slightly different cytokine profiles (Murray et al., 2014). Human macrophages 
generate TNF-α, IL-6, IL-1β and the chemokines CXCL10 and IL-8 in response to LPS. 
In response to LPS+IFN-γ, macrophages generate IL-12, IL-23 and the chemokines 
CXCL10, CXCL9, CXCL11 and CCL5 (Murray et al., 2014). 
 
M1 macrophages are believed to express certain cell surface markers, although these 
markers can also be expressed on cells other than macrophages. Expression of mannose 
receptor C type 1, MRC-1 (CD206) and FcγR II (Fc receptor for IgG) is down-regulated 
(Mosser, 2003). The cells are good antigen presenters to T cells, as expression of MHC 
II and co-stimulatory molecules (CD80 and CD86) is increased (Martinez et al., 2008). 
Whole pathogens can be considered to be M1 stimuli (Martinez and Gordon, 2014). It 
has been demonstrated that activation by bacteria can occur by the components of the 
bacteria, such as LPS, lipoteichoic acid, muramyl dipeptide and heat shock proteins 
activating TLRs. This has been shown to cause induction in gene expression of various 
pro-inflammatory cytokines and chemokines (Nau et al., 2002). The increased bacterial 
killing capacity of M1 macrophages is a result of increased production of reactive 




Figure 1.4. Macrophage activation producing phenotypic heterogeneity. 
Activation of macrophages with different stimuli results in macrophage heterogeneity. 
M1 macrophages have a pro-inflammatory ‘classically activated’ phenotype with the 
increased ability to kill bacteria. M2a macrophages have decreased production of pro-
inflammatory cytokines and have a ‘wound healing’ phenotype. M2b and M2c 
macrophages are both considered to have a ‘regulatory’ phenotype. M2b macrophages 
have increased production of anti-inflammatory cytokines but can also produce 
considerable levels of pro-inflammatory cytokines. M2c macrophages have decreased 
production of pro-inflammatory cytokines and their phenotype is more anti-
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1.3.2. Alternatively activated macrophages 
In addition to responding to infection, macrophages also have homeostatic roles. These 
are primarily the roles of the M2, ‘alternatively activated’ macrophages. M2 
macrophages are also important in the resolution of inflammation. Classifying 
macrophages into just two categories has been found to be rather simplistic and not 
representative of all the phenotypes that can be produced. It has been proposed that the 
M2 macrophages category should be divided into further categories that better describe 
the phenotypes within (Mosser and Edwards, 2008). These categories are M2a, M2b 
and M2c (figure 1.4) (Martinez et al., 2008). M2a macrophages are the result of IL-4 or 
IL-13 stimulation and have also been referred to as ‘wound-healing macrophages’. M2b 
and M2c macrophages have been referred to as ‘regulatory macrophages’ (Mosser and 
Edwards, 2008). M2b macrophages (also referred to as type II macrophages) are the 
result of stimulation by LPS or IL-1β plus immune complexes (Edwards et al., 2006). 
The stimuli leading to generation of M2c macrophages are IL-10, TGF-β or 
glucocorticoids. These can act in combination but the individual stimuli each have 
slightly different effects on macrophages (Martinez et al., 2008, Arango Duque and 
Descoteaux, 2014). 
 
M2a macrophages are the result of the effects of IL-4 or IL-13 produced in Th2 
responses (Gordon, 2003). IL-4 and IL-13 have very similar effects on macrophages. 
The wound-healing phenotype arises through activation of arginase, resulting in 
production of ornithine from L-arginine, rather than nitric oxide as is the case for M1 
cells (Kreider et al., 2007, Chang et al., 1998). Ornithine is metabolized to proline 
which is a constituent of collagen and to polyamines which are important in cell 
proliferation (Varin and Gordon, 2009). However, arginase presence has been 
demonstrated in mice, not humans (Martinez et al., 2008). M2a macrophages express 
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MHC II and therefore can present antigen to T cells but not as well as M1 macrophages. 
Production of pro-inflammatory cytokines and efficiency at destroying intracellular 
pathogens is also down-regulated compared to M1 (Edwards et al., 2006, Gordon, 
2003). In response to IL-4/IL-13, several pro-inflammatory cytokines are down-
regulated, rather than anti-inflammatory cytokines being up-regulated (Martinez et al., 
2008). Cell surface markers and genes that are up-regulated include scavenger receptor 
SR-A and mannose receptor MRC-1 (Gordon, 2003, Martinez et al., 2008, Murray et 
al., 2014). All of this indicates that wound healing appears to be the primary role of this 
macrophage phenotype, hence the proposed classification term. 
 
M2b macrophages have a cytokine profile that is opposite to M1 cells, with high IL-10 
and low IL-12 production (Edwards et al., 2006). However, the cells are not considered 
to be anti-inflammatory, as they also produce TNF-α, IL-1β and IL-6 (Martinez et al., 
2008). The cells have up-regulated MHC II and therefore antigen presentation can 
place, resulting in a Th2 response, hence the cells being known as ‘type II 
macrophages’ (Martinez et al., 2009, Mosser, 2003). The cells have been reported to 
produce I-309 (CCL1), which could be important for the recruitment of regulatory T 
cells (Martinez et al., 2009, Arango Duque and Descoteaux, 2014). 
 
M2c macrophages can arise when glucocorticoids stimulate macrophages, inhibiting the 
transcription of pro-inflammatory cytokine genes including IFN-γ-induced genes and 
cause up-regulation of the scavenger receptor CD163 (Martinez et al., 2009). IL-10 as a 
stimulus results in inhibition of production of pro-inflammatory cytokines such as TNF-
α, IL-6 and IL-12. IL-10 also down-regulates MHC II and therefore, antigen 
presentation by the M2c macrophage phenotype to T cells is inhibited (Martinez et al., 
2008). These effects of glucocorticoids and IL-10 are more inhibitory than those of IL-
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4/IL-13 and therefore, M2c macrophages can be considered to be further from an M1 
phenotype than M2a macrophages are (Gordon, 2003, Edwards et al., 2006). IL-10 also 
reduces collagen synthesis, which is another example of this phenotype being different 
to the ‘wound healing’ M2a phenotype and also, the production of ROS is down-
regulated. TGF-β as a stimulus regulates expression of CD163 and inhibits LPS-induced 
pro-inflammatory cytokines (Pioli et al., 2004, Martinez et al., 2008). In addition to 
being activation stimuli for M2c macrophages, IL-10 and TGF-β (transforming growth 
factor-β) are also produced by the cells. IL-10 and TGF-β can induce regulatory T cells 
and Th2 cells (Arango Duque and Descoteaux, 2014, Franchimont, 2004). 
 
1.3.3. Macrophage plasticity 
Activated macrophages have been shown to have the ability to change phenotypes 
depending on the environmental conditions that they are in. It is possible to produce 
hybrid macrophage phenotypes, for example. M2a macrophages (IL-4-stimulated) can 
be stimulated with TLRs and immune complexes to produce a phenotype which exhibits 
high IL-10 and low IL-12 secretion as would be expected from a regulatory macrophage 
but also expresses resistin-like molecule alpha (RELMα/ FIZZ1) in mice which is a 
marker of M2a macrophages (Raes et al., 2002). 
 
Macrophages can be differentiated in vitro into an M1 phenotype from monocytes 
cultured in the presence of GM-CSF and into an M2 phenotype from monocytes 
cultured in the presence of M-CSF (Fleetwood et al., 2009, Ambarus et al., 2012). It has 
been demonstrated that these macrophages can reversibly re-differentiate into M2 and 
M1 phenotypes respectively when the growth factors are switched so that the M1 
macrophages are cultured in M-CSF and the M2 macrophages are cultured in GM-CSF 
(Xu et al., 2013). Further supporting this, GM-CSF (M1)-differentiated macrophages 
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that were subsequently incubated with IL-4 (M2 stimulus) showed up-regulation of M2 
markers. M-CSF (M2)-differentiated macrophages that were subsequently incubated 
with IFN-γ (M1 stimulus) showed induction of M1 markers (Ambarus et al., 2012). The 
plasticity of macrophages is important in disease conditions, as cytokines and other 
potential stimuli that are present in the tissue could alter the phenotype of the 
macrophages. The transient nature of macrophage phenotypes could therefore have 
implications for exacerbation or resolution of the clinical condition. 
 
1.4. Macrophage model systems in research 
1.4.1. Human cell systems 
Monocyte-derived macrophages (MDMs) are widely used as a model for human tissue 
macrophages. MDMs are produced by the in vitro differentiation of monocytes obtained 
from whole blood. Peripheral blood mononuclear cells (PBMCs) are isolated from the 
blood by density gradient centrifugation and seeded onto cell culture plates. Monocytes 
from the PBMCs can be enriched before seeding, using selection columns. Alternatively 
most lymphocytes, which are non-adherent, can be removed after plastic adherence of 
the monocytes from the PBMCs to the cell culture wells. The differentiation protocols 
used can vary between research groups, with variations in the lengths of time deemed 
necessary to produce mature macrophages. A major disadvantage can be the variable 
yield of cells obtained from blood and the subsequent large numbers of cell loss during 
the differentiation process. An advantage is that venipuncture is less invasive than 
surgery and therefore it is possible to obtain ethical approval to recruit healthy 
volunteers for studies, which ensures sufficient numbers of control samples when 
comparing to disease conditions. As stated in 1.3.3, culturing monocytes in GM-CSF or 
M-CSF can result in differentiation into M1 or M2 macrophage phenotypes. Some 
researchers activate these differentiated macrophages further with LPS/IFN-γ or IL-
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4/IL-13 for an M1 or M2 phenotype respectively (Murray et al., 2014). Alternatively, 
monocytes can be cultured with the cytokines without prior culture in GM-CSF or M-
CSF (Ambarus et al., 2012). However, it has been shown by looking at gene expression, 
that differentiation of monocytes to macrophages in GM-CSF/M-CSF does not result in 
the exact same phenotypic markers as the markers resulting from differentiation of 
monocytes in the presence of the cytokines (Ambarus et al., 2012, Mia et al., 2014). 
This suggests that perhaps the two methods of differentiation should not be considered 
to be interchangeable. 
 
Monocytic cell lines are often used as a substitute for MDMs (and ultimately, tissue 
macrophages), eliminating the issue of low cell yield. THP-1 cells were established 
from the blood of a one year-old male with acute monocytic leukaemia (Tsuchiya et al., 
1980). Another monocytic cell line is U937, for which the cells were isolated from the 
histiocytic lymphoma of a 37 year-old male (Medeiros et al., 2012). However, it has 
been demonstrated that different protocols to produce differentiated, mature 
macrophages can result in variation in the level of similarity to MDMs. The protocols 
generally used involve treatment with phorbol-12-myristate-13-acetate (PMA) or 1,25-
dihydroxyvitamin D3 (VD3). A recent study was carried out comparing macrophages 
resulting from different THP-1 differentiation protocols to monocytes and MDMs 
(Daigneault et al., 2010). It was found that differentiating THP-1 cells by VD3 resulted 
in cells more like monocytes in comparison to MDMs. The results of differentiating by 
PMA followed by resting in culture indicated that the cells more closely resembled 
MDMs in terms of morphology and responses to TLR ligands. 
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1.4.2. Murine cells 
Bone marrow-derived macrophages (BMDMs) isolated from mice are commonly used 
as a macrophage model. BMDMs can be cultured in vitro like human MDMs, in GM-
CSF or M-CSF and cytokines to produce M1 or M2 phenotypes (Murray et al., 2014). 
Other murine macrophages that are often used are peritoneal macrophages, which are 
obtained by peritoneal lavage. Thioglycollate injection prior to lavage can elicit a 
greater yield of peritoneal macrophages (Zhang et al., 2008, Murray et al., 2014). Tissue 
macrophages can also be obtained from the organs of mice and also alveolar 
macrophages, although the yield is generally low (Murray et al., 2014, Zhang et al., 
2008). A major issue with the use of murine macrophages as a model for human 
macrophages for certain types of studies is that there are known differences in 
phenotypic markers between the two systems. There are phenotypic markers exhibited 
by murine cells, which are either not expressed by human macrophages or which have 
no human analogues (Murray and Wynn, 2011a, Geissmann et al., 2010, Murray and 
Wynn, 2011b). There are also many differences in expression of other markers such as 
various cytokines/chemokines and transcription factors in response to different stimuli 
(Murray et al., 2014).  
 
RAW 264.7 cells have been used in many studies as models for macrophages. The cells 
were established from an Abselon leukaemia virus-induced tumour in a male Balb/c 
mouse (Medeiros et al., 2012). There are advantages to using RAW 264.7 cells. The 
cells can be transfected, unlike the primary cells that have been discussed, which may 
be useful for certain experiments. However, there is a possibility that sources of cell 
lines could be problematic. For example, the RAW 264.7 cells available from American 
Type Culture Collection (ATCC) have in the past been tested and reported to produce 
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ecotropic murine leukaemia virus (Hartley et al., 2008). This could affect the results 
obtained from certain types of experiments.       
 
Recently, Max Planck Institute cells (MPI cells) were proposed as a model for alveolar 
macrophages (Fejer et al., 2013). These cells are produced from murine fetal liver cells 
cultured in GM-CSF and are self-renewing in the presence of GM-CSF. MPI cells are 
reportedly more similar to alveolar macrophages than M-CSF-cultured bone marrow-
derived macrophages. This is in terms of similarities in their pro-inflammatory response 
to TLR ligands and pathogens such as Mycobacterium tuberculosis which can infect the 
lungs, expression of certain cell surface markers, in addition to similarities in 
morphology. 
 
1.4.3. Human lung macrophages 
The cell systems discussed earlier in this section can be useful models for human 
macrophages. There are more obstacles to overcome in order to obtain primary cells of 
interest from human tissue and the process can be more technically challenging. 
However, the cells are expected to be more relevant for studies into conditions affecting 
the specific tissue. In the present study, macrophages were isolated from surgically 
resected human lung tissue and used as a model for investigations into respiratory 
diseases. Alternatively, macrophages can be obtained from the human lung by 
bronchoalveolar lavage (BAL). 
 
Both macrophages obtained by BAL and macrophages obtained from lung tissue are 
considered to be alveolar macrophages. To obtain interstitial macrophages, it is 
generally believed that enzymatic digestion of the tissue is required. However, even 
after enzymatic digestion, it has been reported that the majority of macrophages present 
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in the digested fraction appear to be alveolar macrophages and only a small number are 
interstitial (Cai et al., 2014). It has also been demonstrated in other studies that the 
majority of macrophages obtained from the lung are alveolar macrophages and only a 
small proportion are interstitial macrophages. For example, a study in mice reported that 
in the steady state, 93% of the total macrophages obtained from the lung were alveolar 
macrophages and 7% were a mixture of alveolar and interstitial (van oud Alblas and van 
Furth, 1979). It is difficult to distinguish between the two types of macrophages 
morphologically although alveolar macrophages are reported to be larger (Cai et al., 
2014, Fathi et al., 2001). One study, using rhesus macaque macrophages reported that 
both alveolar and interstitial macrophages are HLA-DR (human leukocyte antigen-DR), 
CD11b and CD163 positive but in addition, alveolar macrophages are also CD206 
positive whereas interstitial macrophages are CD206 negative (Cai et al., 2014). 
However, this selection of cell surface markers is not definitive for distinguishing 
between the two types of macrophages and studies by other researchers are ongoing 
(Dewhurst et al., 2014). This is one of the reasons why separating the two types of 
macrophages is difficult, for example by using a process such as fluorescence-activated 
cell sorting (FACS). 
 
The macrophages used for the studies in this thesis were isolated by manual chopping 
and washing of lung tissue. Therefore, based on the information from other studies 
discussed in the previous paragraphs, it can be assumed that they are predominantly 
alveolar macrophages. However, as the possibility of a very small number being 




1.5. Macrophages in inflammatory lung diseases 
Macrophages may be involved in the progression of inflammatory lung diseases such as 
chronic obstructive pulmonary disease (COPD) and asthma. Different phenotypes of 
macrophages have been reported to be present in different diseases (Murray and Wynn, 
2011b).  It has been suggested that the plastic nature of macrophage phenotypes makes 
them susceptible to modulation by environmental factors. Risk factors for COPD and 
asthma include smoking and airborne particles, which macrophages in the lungs are 
exposed to. These factors could have adverse effects on macrophages, although the 




COPD is a progressive condition in which inflammation of the lungs causes airflow to 
be severely restricted (Sutherland and Martin, 2003). It is a condition of which the 
incidence throughout the world is increasing to the extent that it is predicted that by 
2020 it will be the fifth biggest public health problem (Sutherland and Martin, 2003, 
Barnes, 2008a) and according to World Health Organization predictions, it will be the 
third biggest cause of death in the world in 2030 (www.who.int/en/).  
 
The clinical manifestation of COPD reflects two major pathological conditions. The 
first is chronic bronchitis, which is caused by chronic inflammation of the small and 
medium airways and the symptoms, in addition to irreversible reduced airflow, are 
chronic cough and production of sputum. Fibrosis can also occur (Sarir et al., 2008). 
The second condition is emphysema, in which the release of proteases from 
inflammatory cells causes destruction of the elastic tissue in the lung and lung 
parenchyma, such as alveolar walls, resulting in low oxygen concentration in the blood 
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(Sutherland and Martin, 2003, Barnes, 2008a). Emphysema can also involve mucus 
blocking the airways (Sarir et al., 2008).  
 
The most prominent inflammatory cells in COPD, in addition to neutrophils, are 
macrophages (Sutherland and Martin, 2003). The numbers of alveolar macrophages in 
COPD patients are significantly higher than normally found (Finkelstein et al., 1995, 
Sarir et al., 2008). This could be due to increased recruitment of monocytes from the 
blood into the tissue or due to decreased macrophage apoptosis (Tomita et al., 2002, 
Barnes, 2008b). One of the main ways in which macrophages are believed to be 
involved in COPD is through their ability to secrete cytokines and factors (Barnes, 
2008a). In response to cigarette smoke, for example, which is a major risk factor, 
inappropriate or aberrant cytokine/chemokine release from macrophages in COPD may 
occur (Barnes, 2008a). The recruitment of monocytes and other immune cells in 
response to the chemokines may lead to persistent inflammation, causing damage to the 
airways (Barnes, 2008a). Also, in response to cigarette smoke, macrophages and 
recruited neutrophils can release proteases such as MMP-9 (matrix metalloproteinase-
9), which can degrade elastin, causing emphysema (Lim et al., 2000, Barnes, 2008b). 
 
It has been reported that the phagocytic ability of macrophages in COPD could be 
defective. This could be another way in which macrophages are implicated in the 
pathogenesis of COPD and contribute to exacerbations of the condition. The defects 
could be both in the phagocytosis of pathogens and in efferocytosis of apoptotic cells 
(Henson et al., 2006, Krysko et al., 2010). Dysregulated phagocytosis of pathogens 
could result in persistence of bacterial load and inflammation, contributing to 
pathogenesis and exacerbations of COPD. A previous study reported that MDMs 
derived from COPD patients showed a decrease in phagocytosis of Streptococcus 
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pneumoniae compared to MDMs from smokers and non-smokers without COPD 
(Taylor et al., 2010). However, a study using alveolar macrophages from COPD 
patients showed that there was no defective phagocytosis of Streptococcus pneumoniae 
by these cells compared to non-COPD macrophages. However, there was defective 
phagocytosis of non-typeable Haemophilus influenzae by alveolar macrophages from 
both ex and current smokers with COPD compared to healthy non-smokers (Berenson 
et al., 2013). An earlier study by the same group showed that phagocytosis of this 
pathogen was defective in ex-smokers with COPD compared to ex-smokers without 
COPD, indicating that smoking may not be impairing the ability of macrophages to 
phagocytose Haemophilus influenzae in COPD (Berenson et al., 2006). It has been 
shown in other studies that clearance of bronchial epithelial cells by alveolar 
macrophages from BAL is impaired in patients with COPD (Hodge et al., 2003). 
Furthermore, the efferocytic ability of macrophages from smokers with COPD has been 
reported to be decreased compared to those from ex-smoker COPD patients and one 
mechanism suggested for this is that cigarette smoke may alter the expression of 
macrophage surface markers that are required for apoptotic cell detection (Hodge et al., 
2007). Further research is required for clarification but it may be possible that the effect 
of smoking on macrophages may result in impairment of efferocytosis but not 
impairment of pathogen phagocytosis in COPD.  
 
It has been suggested that the dysregulation of the normal macrophage processes may 
be due to the phenotype of the macrophages being altered in COPD and/or in response 
to smoking. It has been observed in a previous study that in smokers with and without 
COPD, down-regulation of genes for M1 macrophage-related chemokines occurs 
overall, rather than marked up-regulation of M2 macrophage-related genes (Shaykhiev 
et al., 2009). This study indicated that smoking causes the phenotype of alveolar 
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macrophages to switch to a mixed phenotype that is skewed towards an M2 phenotype. 
This effect is further emphasised in smokers with COPD (Shaykhiev et al., 2009). 
Mixed phenotypes have also been reported in another study in alveolar macrophages 
from healthy smokers, COPD patients and ex-smoker COPD patients, although the 
trends were less clear (Hodge et al., 2011). It appears that the phenotype can be altered 
in macrophages from smokers and COPD patients. However one particular phenotype 
does not seem to be associated with the pathogenesis of COPD. Rather, markers 
associated with both M1 and M2 phenotypes can be either up-regulated or down-
regulated, which could result in the dysregulation of certain macrophage functions. 
 
1.5.2. Asthma 
Asthma has clinical manifestations that are similar to COPD but there are many 
differences in the underlying inflammation, distinguishing the two diseases (Barnes, 
2008a). The inflammation in severe asthma, however, is closer in phenotype to that in 
COPD compared to that in mild asthma, for example, in terms of the numbers of certain 
inflammatory cells being present. The incidence of asthma is increasing globally, as is 
the case for COPD and according to the World Health Organization, it is estimated that 
300 million people currently have the condition (www.who.int/en/). The major 
similarity to COPD is that asthma is also an inflammatory lung condition in which 
airflow is restricted but unlike in COPD, it is reversible, in response to bronchodilators 
(Sutherland and Martin, 2003). The differences compared to COPD are that asthmatic 
airways exhibit hyperresponsiveness which consists of reacting in an exaggerated 
manner to stimulants that are inhaled, such as pollutants (Peachell, 2005); mucus 
hypersecretion results in blocking of the airways (Rankin, 1989); the lung parenchyma 
is not destroyed as in COPD; basement membrane thickening occurs and the large 
airways are involved more than the small airways in asthma (Barnes, 2008a).  
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Asthma can be categorized as atopic (allergic) and non-atopic. Most asthma cases are 
atopic. The most important cells in asthma are eosinophils and mast cells (Sutherland 
and Martin, 2003). However, macrophages are also involved (Rankin, 1989, Gosset et 
al., 1999, Yang et al., 2012). The number of macrophages in the lungs are increased in 
asthma (Barnes, 2008b). The position of alveolar macrophages in the lung enables them 
to easily come into contact with allergens (Rankin, 1989). Alveolar macrophages in 
asthma show increased antigen (allergen) presentation compared to non-asthmatics, 
eliciting a Th2 cytokine response, resulting in allergic inflammation (Martinez et al., 
2009, Kay, 2002). However, not only Th2 cytokines are seen in asthma. A decrease in 
the release of anti-inflammatory cytokine IL-10 has been seen from macrophages from 
asthmatics and an increase in pro-inflammatory MIP-1α (macrophage inflammatory 
protein-1α) and IFN-γ (John et al., 1998). 
 
A greater percentage of macrophages from allergic asthmatics express low affinity 
receptors for IgE (FcεRII) than control subjects, suggesting that macrophages can be 
activated by allergens via IgE-dependent mechanisms (Rankin, 1989, Williams et al., 
1992, Gosset et al., 1999). The release of pro- and anti-inflammatory cytokines has been 
reported to be increased in IgE-dependent activation in both control and asthmatic 
alveolar macrophages (Gosset et al., 1999). In asthmatics, release of pro-inflammatory 
cytokines is increased over release of anti-inflammatory cytokines. Therefore, activation 
by IgE receptors could result in increased inflammation in allergic asthmatics (Gosset et 
al., 1999). Alveolar macrophages from severe asthmatics also show reduced 
phagocytosis of apoptotic cells (Huynh et al., 2005). Phagocytosis of apoptotic cells is 
important for inducing the release of anti-inflammatory or immunosuppressive 
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mediators such as IL-10, TGF-β and PGE2 from macrophages (Fadok et al., 1998, 
Huynh et al., 2005). 
 
A higher number of M2 phenotype macrophages are present in the lungs in asthma 
compared to controls (Moreira and Hogaboam, 2011). M2 macrophages are important 
in the lungs for tissue repair and the resolution of inflammation but excessive numbers 
could contribute to the pathogenesis of asthma, by resulting in increased recruitment of 
cells, mucus secretion and airway remodelling (Moreira and Hogaboam, 2011, Liu et 
al., 2014). However, it has been suggested that the increased numbers of M2 
macrophages could be a result of the Th2 cytokine environment after allergen challenge, 
rather than the M2 macrophages having an important role in actively contributing to the 
pathogenesis of asthma (Boorsma et al., 2013). Supporting this notion, a study using 
mice with macrophages lacking the receptor to respond to IL-4/IL-13 activation 
developed allergic airway disease that was comparable to controls (Nieuwenhuizen et 
al., 2012). 
 
M1 macrophages have also been reported to be present in asthma. M1 markers have 
been found in macrophages from BAL fluid in severe asthma but high levels of LPS 
were also present (Goleva et al., 2008). Studies in humans and mice indicate that it is 
possible that macrophages switch to an M1 phenotype in severe asthma, releasing pro-
inflammatory mediators which can contribute to damage to the airways and may 
contribute to exacerbations (Moreira and Hogaboam, 2011, Goleva et al., 2008, Kim et 
al., 2007). M1 macrophages could also contribute to the pathogenesis of asthma by 
recruiting neutrophils, through the release of chemokines such as IL-8. Neutrophilia in 
the lung is associated with severe asthma (Kamath et al., 2005). 
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1.6. Current therapies for COPD and asthma 
The treatments available for COPD and asthma act to alleviate symptoms and to 
dampen the inflammation associated with the conditions. The difficulties in producing 
novel effective treatments arise partly because these are complex diseases involving 
several different cell types. Targeting a particular pathway of mediator release may be 
effective in one cell type but may not be effective in another. This could decrease the 
overall efficacy of the treatment or even produce adverse effects. Novel, more specific 




One of the symptoms of both COPD and asthma is bronchoconstriction. Beta-
adrenoceptor agonists (β2-agonists) and muscarinic antagonists are available as 
bronchodilators. β2-agonists act on β2-adrenoceptors, which are G-protein (Gs)-coupled 
receptors (GPCRs) linked to adenylyl cyclase. Receptor activation leads to an increase 
in cyclic-AMP (cAMP) and activation of protein kinase A, which results in smooth 
muscle relaxation (Tashkin and Fabbri, 2010). The action of muscarinic antagonists is 
less direct. The neurotransmitter acetylcholine binds to M3 muscarinic receptors on 
smooth muscle. As M3 receptors are G-protein (Gq)-coupled, this results in an increase 
in intracellular calcium, causing contraction of the muscle. Muscarinic antagonists 
block acetylcholine binding, enabling smooth muscle relaxation (Tashkin and Fabbri, 
2010).  
 
Both types of bronchodilators are used in inhaler form in current therapies. 
Bronchodilator therapy has improved over the years, progressing from short-acting 
compounds that had effects lasting 4-6 hours to long-acting β2-agonists (LABA) and 
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long-acting muscarinic antagonists (LAMA) with effects lasting 12 hours (Domingo, 
2013). Some of these compounds have effects lasting up to 24 hours. Tiotropium is one 
such muscarinic antagonist and indacaterol is one such β2-agonist. Vilanterol, also has 
effects of 24 hours but is termed an ‘ultra-LABA’ and has been authorized for use in 
treatments very recently (Domingo, 2013, Theron et al., 2013). Combinations of LABA 
and LAMA may also be used in treatments. The bronchodilators are generally effective 
for reversing airflow obstruction in asthma. In COPD, the reduction of airflow upon 
using the bronchodilators is not fully reversible but the treatments can provide some 
symptomatic relief.  
 
1.6.2. Corticosteroids 
The pathogenesis of both COPD and asthma involves inflammation of the airways. 
Corticosteroids are the most potent anti-inflammatory treatments available. These were 
initially used as effective anti-inflammatories in asthma therapy but are now also used 
in COPD treatment. Corticosteroids work by binding to their intracellular cognate 
receptor in the cytosol. The complex can then translocate to the nucleus to bind to 
response elements in the promoter regions of genes. This is known as ‘transactivation’ 
and can result in an up-regulation or down-regulation of gene transcription (Johnson, 
2004, Taylor and Hancox, 2000). This could result in an up-regulation of anti-
inflammatory cytokines and a down-regulation of inflammatory cytokines. Another 
mechanism is termed ‘transrepression’, in which the steroid-receptor complex interacts 
directly with transcription factors, inhibiting gene transcription, which could inhibit the 
production of pro-inflammatory cytokines (Johnson, 2004, Taylor and Hancox, 2000).  
 
Corticosteroids are generally effective in asthma but are usually much less effective in 
COPD (Barnes, 2010). It has been suggested that corticosteroid insensitivity is a result 
 51 
of the oxidative stress that is present in COPD causing reduction of expression of 
histone deacetylase-2, which is a co-factor of the glucocorticoid receptor (Kirkham and 
Barnes, 2013, Rossios et al., 2012). This results in reduced corticosteroid function, 
allowing gene transcription to occur (Rossios et al., 2012, Ito et al., 2001). Inhaled 
corticosteroids (ICS) are used in treatments, which bypass the side-effects of oral 
corticosteroids to a large extent. Currently, commonly used treatments for anything but 
the least severe cases of asthma are combination inhalers, consisting of ICS with a 
LABA. It has been suggested that in future treatments, LAMA may be combined with 
LABA and ICS, as a triple therapy (Tashkin and Ferguson, 2013, Domingo, 2013). 
 
1.6.3. Other therapies 
Whilst β2-agonists and ICS are the main and most effective therapies used for COPD 
and asthma, other therapies are available. One of the first compounds available as a 
bronchodilator was theophylline, which has limited use today due to its associated side 
effects (Barnes, 2006a). Theophylline is a non-selective phosphodiesterase (PDE) 
inhibitor. PDE acts to regulate the cyclic nucleotide signalling pathway by carrying out 
hydrolysis of cyclic nucleotides such as cAMP. PDE exists as at least 11 isoforms, 
although PDE4 is the one most widely expressed by inflammatory cells and specifically 
breaks down cAMP (Souness et al., 2000). PDE4 inhibitors are available, which can 
prolong the effects of cAMP (Barnes, 2003). This is beneficial in treatments as cAMP 
can act on smooth muscle cells to cause bronchodilation, as discussed earlier. Increases 
in cAMP can also lead to inhibition of cytokine release from inflammatory cells 
(Serezani et al., 2008, Aronoff et al., 2004). Roflumilast is one PDE4-selective inhibitor 
that has been approved recently as a treatment for COPD. Roflumilast has been shown 
in a study to reduce chemokine and cytokine release from human lung macrophages 
(Buenestado et al., 2012). It is this reported anti-inflammatory effect on macrophages 
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that makes roflumilast more effective in COPD than asthma, as macrophages are 
implicated to a greater extent in COPD (Peachell, 2005). 
 
Bronchoconstriction and inflammation can be caused by eicosanoid release from 
inflammatory cells in COPD and asthma. In this context, cysteinyl-leukotrienes 
produced from the metabolism of arachidonic acid by the 5’-lipoxygenase (5’-LO) 
pathway play an important role. Cysteinyl-leukotrienes are mainly released from mast 
cells upon activation by stimuli such as allergens. Cysteinyl-leukotriene receptor 
antagonists are available for asthma, such as montelukast, which has been shown to be 
effective in patients with severe asthma, when used in addition to corticosteroids 
(Dahlen et al., 2002, Barnes, 2006b). A 5’-LO inhibitor, zileuton, is also available to 
block production of cysteinyl-leukotrienes (Holgate, 2013). 
 
Cromones such as nedocromil and cromoglycate were used in early treatments for 
asthma and were introduced as mast cell stabilizers (Holgate, 2013, Peachell, 2005). 
However, although cromones are effective stabilizers of rodent mast cells, the evidence 
of such an effect on human mast cells is weak (Peachell, 2005). Therefore, their mode 
of action has not been determined. It has recently been suggested that one mechanism of 
action that results in an inhibitory effect on mast cells involves the stimulation of the 
release of anti-inflammatory protein annexin-A1, which can act in an autocrine or 
paracrine fashion to inhibit mast cell activation (Yazid et al., 2013). This is interesting, 
as anti-inflammatory glucocorticoids can also stimulate the synthesis and release of 
annexin-A1 (D'Acquisto et al., 2008). The use of cromones has now been usurped by 
the use of current inhaled therapies but there is interest in determining the mechanisms 
by which these drugs work, as it could contribute to development of other treatments 
(Holgate, 2013, Barnes, 2006a, Peachell, 2005). 
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Antibody therapies have been developed for use in severe asthma. Omalizumab is a 
monoclonal antibody to IgE which binds to IgE, preventing it binding to high affinity 
Fcε receptors on cells such as mast cells and basophils, reducing allergic responses 
(Holgate, 2014). Omalizumab has been found to be effective in severe asthma that has 
an allergic basis, although not in all patients (Holgate, 2013). Antibody therapies have 
also been developed to block cytokines and chemokines. IL-5 recruits eosinophils 
resulting in eosinophilic inflammation seen in asthma (Holgate, 2013). Anti-IL-5 has 
been developed and tested in asthma but showed variable efficacy (Holgate, 2013, 
Haldar et al., 2009, Castro et al., 2011, Flood-Page et al., 2007). 
 
Over the years, attempts have been made to develop novel therapies. Despite this, the 
frontline treatments for respiratory diseases have remained similar since the 1970s 
although there have been significant improvements in the selectivity and duration of 
action of the compounds used (Peachell, 2005, Domingo, 2013, Barnes, 2006b). β2-
agonists and corticosteroids are the mainstay therapies but are not always effective, 
particularly in COPD. It is also possible that some of the compounds currently used 
may be reaching their limit for improvement, for example, β2-agonists have been 
developed to the stage of being ultra long-acting (Domingo, 2013). Novel therapies are 
much needed. 
 
1.7. Macrophages as targets for therapy 
Although a range of treatments is available for COPD and asthma, none specifically 
targets macrophages. This is despite the prominence of macrophages in these diseases, 
particularly in COPD. Corticosteroids have been shown to inhibit cytokine release from 
lung macrophages, indicating that this anti-inflammatory function could be important in 
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treatments for respiratory diseases. Although β2-agonists are used as bronchodilators, it 
has been reported that they also have some anti-inflammatory activity. Currently, ICS 
can often be used at high doses in treatments but over the long-term, this can produce 
side-effects in patients. The ability to use β2-agonists as anti-inflammatories and 
potentially enable lower doses of ICS to be used would be desirable. There are varying 
reports on the abilities of different β2-agonists to inhibit cytokine release from 
macrophages and this may be due to the different model systems used for investigations 
(Donnelly et al., 2010, Theron et al., 2013, Buenestado et al., 2012, Zetterlund et al., 
1998). The potential anti-inflammatory effects of a range of β2-agonists on human lung 
macrophages have therefore been evaluated in the present study. 
 
As discussed earlier, β-adrenoceptors are GPCRs coupled to adenylyl cyclase and 
activation of the receptors by agonists leads to cAMP increases. Elevations in cAMP are 
believed to underpin the inhibitory effects of β2-agonists. Other classes of agonist can 
also induce cAMP increases. Prostanoids act on GPCRs and the action of certain 
prostanoids on GPCRs that are coupled to adenylyl cyclase can lead to cAMP increases 
(Sugimoto and Narumiya, 2007). 
 
Prostanoids are lipid mediators produced as a result of the metabolism of arachidonic 
acid, which is a 20 carbon unsaturated fatty acid (Ricciotti and FitzGerald, 2011). 
Arachidonic acid is released from phospholipids in the plasma membrane of the cell by 
the action of phospholipase A2, upon cell activation. Arachidonic acid can be 
metabolized via two different pathways – the 5-lipoxygenase pathway to produce 
leukotrienes or via the cyclooxygenase (COX) pathway to produce prostanoids. The 
latter pathway involves arachidonic acid being metabolized to an intermediate, 
Prostaglandin H2, by COX enzymes. Prostaglandin H2 can then be converted by specific 
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synthases to five different prostanoids: prostaglandin D2, prostaglandin E2, 
prostaglandin F2α, prostaglandin I2 (prostacyclin) and thromboxane A2. Different cells 
express each synthase at different levels, resulting in certain prostanoids being 
predominantly produced in certain cell types over others. Thromboxane A2 (TXA2) is 
mainly produced by activated platelets and acts on TP receptors. Prostaglandin D2 
(PGD2) is predominantly produced by mast cells. PGD2 acts on DP or CRTH2 receptors 
but can also act on TP receptors. Prostaglandin F2α is produced mainly in the uterus and 
acts on FP receptors. Prostaglandin I2 (prostacyclin) is produced by vascular endothelial 
cells and acts on IP receptors. PGE2 is the prostanoid that is predominantly produced by 
macrophages and acts on EP1, EP2, EP3 and EP4 receptors. The prostanoid receptors that 
can be coupled to adenylyl cyclase are DP, TP, IP, EP2 and EP4 (Ricciotti and 
FitzGerald, 2011). Prostanoid production can be blocked by inhibition of the COX 
enzymes (figure 1.5). COX inhibitors include non-steroidal anti-inflammatory drugs 
(NSAIDs). Both non-selective inhibitors and inhibitors selective to either of the two 






Figure 1.5. Prostanoid generation and inhibition by COX inhibitors. 
A simplified figure of the generation of prostanoids from the metabolism of arachidonic 
acid. Prostanoid generation can be blocked by the inhibition of cyclooxygenases COX-1 
and COX-2. (PGH2: prostaglandin H2; NSAIDs: non-steroidal anti-inflammatory drugs; 
TXA2: thromboxane A2; PGD2: prostaglandin D2; PGE2: prostaglandin E2; PGF2α: 
prostaglandin F2α; PGI2: prostaglandin I2) (Peters-Golden et al., 2006, Medeiros et al., 
2012).
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PGE2 is the most widely found prostanoid in the body and has been shown to be 
important in the lung. PGE2 has been shown to have bronchodilatory effects but can 
also induce cough, depending on which of the four possible EP receptors it acts on 
(Maher et al., 2011). It has been reported that the bronchodilatory effects are mediated 
either by the EP2 receptor or the EP4 receptor and it has been suggested that targeting 
the EP4 receptor could be an effective bronchodilator treatment (Buckley et al., 2011, 
Norel et al., 1999, Benyahia et al., 2012). PGE2 is anti-inflammatory in macrophages, 
although it is not clear which EP receptor mediates this effect. Investigating the EP 
receptor(s) that PGE2 acts on in lung macrophages may enable determination of whether 
targeting EP receptors would be a valid strategy for potential novel anti-inflammatory 
therapies for respiratory diseases. 
 
Development of more targeted treatments for respiratory diseases may be beneficial. In 
order to identify potential novel targets, more research is needed into the characteristics 
and roles of lung macrophages, which are prominent in respiratory diseases. This 
requirement underpins the rationale for the aims of this thesis. Much of the research into 
lung macrophages has involved investigating principal roles such as phagocytosis, in 
relation to inflammation. The role of PGE2 is lesser investigated but as a mediator 
involved in regulation of inflammation, there is currently interest from the 
pharmaceutical industry in investigating its effects. There is also interest in the possible 
use of existing drugs for more than one purpose. As beta-agonists are one of the 
principal bronchodilatory treatments for respiratory diseases, ascertaining whether they 
have an additional anti-inflammatory role would be of great benefit in treatments. 
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1.8. Aims and objectives 
1) Isolate macrophages from lung tissue and assess their suitability for use as a model 
system 
2) Investigate the phenotype and functional characteristics of the isolated macrophages 
3) Investigate the involvement of PGE2 in regulation of macrophage function 
4) Evaluate the anti-inflammatory effects of beta-agonists in macrophages 
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Chapter 2: Materials and Methods 
2.1. Materials 
Acrylamide Bio-Rad, Hemel Hempstead, UK 
Agarose Melford Laboratories Ltd., Ipswich, UK 
Amersham Hybond-ECL Membrane GE Healthcare, Little Chalfont, UK 
Anti-IgE  Stratech, Newmarket, UK 
Butaprost (free acid)  Cayman Chemical Company, Ann Arbor, 
MI, USA 
Celecoxib  BioVision Inc., CA, USA 
CJ-042794 Pfizer Global R&D, Sandwich, UK 
ColorPlus Prestained Protein Ladder, 
Broad Range (10-230 kDa) 
New England Biolabs, Hitchin, 
Hertfordshire, UK 
Complete, EDTA-free Protease 
Inhibitor Cocktail Tablets  
Roche Applied Science, Mannheim, 
Germany 
Cyclic-AMP ACE EIA Kit Cayman Chemical Company, Ann Arbor, 
MI, USA 
Dexamethasone Sigma, Poole, UK 
Dimethyl Sulphoxide (DMSO) Sigma, Poole, UK 
DNA-free DNase Treatment & Removal  Ambion (Life Technologies), Paisley, UK 
DPX Mounting Medium Fisher Scientific, Loughborough, UK 
ECL Western Blotting Detection 
Reagent  
 
GE Healthcare, Little Chalfont, UK 
Ethidium Bromide Sigma, Poole, UK 
Ficoll-Paque Plus GE Healthcare, Little Chalfont, UK 
FcR Blocking Reagent  Miltenyi Biotec, Surrey, UK 
Formoterol Gift from Novartis, Surrey, UK 
FR122047 (hydrate) Cayman Chemical Company, Ann Arbor, 
MI, USA 
Fetal Calf Serum (FCS)  Promocell, Heidelberg, Germany 
Gardiquimod  InvivoGen, CA, USA 
GoTaq Flexi  Promega, Southampton, UK 
Human Ready-Set-Go Cytokine ELISA  eBioscience, Hatfield, UK 
HEPES Buffer Solution (1M) Lonza, Slough, UK 
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HI NBCS (heat inactivated newborn 
calf serum) 
 
Gibco (Life Technologies), Paisley, UK 
High Capacity cDNA RT Kit  Applied Biosystems, Paisley, UK 
Iloprost Cayman Chemical Company, Ann Arbor, 
MI, USA 
Indacaterol Gift from Novartis, Surrey, UK 
Indomethacin Sigma, Poole, UK 
(-) -Isoprenaline Bitartrate Sigma, Poole, UK 
JW8-IgE BioServ UK Ltd, Sheffield, UK 
Lipopolysaccharide (LPS) from E. coli 
serotype R515 (Re) 
 
Enzo Life Sciences, Exeter, UK 
Live/Dead Fixable Dead Cell Stain Kit 
Near IR 
 
Life Technologies, Paisley, UK 
L-161,982 Tocris Bioscience, Bristol, UK 
L-902,688 Cayman Chemical Company, Ann Arbor, 
MI, USA 
MinElute Gel Extraction Kit Qiagen, Crawley, UK 
Misoprostol Cayman Chemical Company, Ann Arbor, 
MI, USA 
Mouse anti-human CD14-PE Miltenyi Biotec, Surrey, UK 
Mouse anti-human CD206-APC Miltenyi Biotec, Surrey, UK 
Mouse IgG2a R-PE Isotype Control  Life Technologies, Paisley, UK 
Mouse mIgG1-APC Isotype control Life Technologies, Paisley, UK 
NIP20-HSA Gift from Dr Birgit Helm, University of 
Sheffield, UK 
Quick load 100 bp DNA ladder  New England Biolabs, Hitchin, 
Hertfordshire, UK 





Lonza, Slough, UK 
Percoll Sigma, Poole, UK 
PF-04418948 Pfizer Global R&D, Sandwich, UK 
PF-04852946 Pfizer Global R&D, Sandwich, UK 
Prostaglandin E2 EIA Kit - Monoclonal Cayman Chemical Company, Ann Arbor, 
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MI, USA 
Prostaglandin E2 (PGE2) Sigma, Poole, UK 
Prostaglandin D2 Biomol, Plymouth Meeting, PA, USA 
Prostaglandin F2α Biomol, Plymouth Meeting, PA, USA 
Proteome Profiler Human Cytokine 
Array Panel A Kit 
 
R&D Systems, Abingdon, UK 
Poly (I:C)-LMW InvivoGen, CA, USA 
Quick-Diff Reagena, Toivala, Finland 
RNase Inhibitor Applied Biosystems, Paisley, UK 
RPMI-1640 medium with L-Glutamine Lonza, Slough, UK 
Salbutamol Sigma, Poole, UK 
Salmeterol Gift from Glaxo R&D, Stevenage, UK 
Sulprostone Sigma, Poole, UK 
Sterile H2O for injections B.Braun, Sheffield, UK 
TaqMan Gene Expression Assay Applied Biosystems, Paisley, UK 
Terbutaline Sigma, Poole, UK 
Trichloroacetic acid Sigma, Poole, UK 
TRI Reagent Sigma, Poole, UK 
Tween-20 Fisher Scientific, Loughborough, UK 
U-46619 Biomol, Plymouth Meeting, PA, USA 
Whatman™ chromatography paper GE Healthcare, Little Chalfont, UK 
 
2.2. Buffers and solutions 
All chemicals were from Sigma, Poole, UK unless otherwise specified. 
10x PIPES: 
PIPES (free acid) (7.6 g), NaCl (6.43 g), KCl (0.37 g), made up to 100 ml with ddH2O 
and to pH 7.4 with NaOH. 
 
1x PBS: 
NaCl (8 g), Na2HPO4.7H2O (2.16 g), KCl (200 mg), KH2PO4 (200 mg) (BDH, Poole, 
UK), made up to 1 L with ddH2O. 
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Erythrosin-B: 
Made to a stock concentration of 0.15% in 1x PIPES, with 5% FCS. Aliquots were 
frozen at -20 0C until required. 
 
FACS Buffer: 
1x PBS (469 ml), FCS (5 ml), 0.1 M EDTA (25 ml), 10 % Sodium Azide (1 ml), for 
500 ml. 
 
50x TAE buffer: 
Tris(hydroxymethyl)aminomethane (Tris-base) (242 g) (Fisher Scientific, 
Loughborough, UK), Glacial acetic acid (57.1 ml) (Fisher Scientific, Loughborough, 
UK), 0.5 M EDTA (100 ml), made up to 1 L with H2O. 
 
Protein lysis and Western blotting buffers: 
Tris-EDTA buffer: 
H2O (202.5 ml), 1 M Tris-HCL pH 7.4 (5 ml), 1 M NaCl (37.5 ml), 0.5 M EDTA (2.5 
ml), 0.5 M EGTA (2.5 ml), for 250 ml. 
 
Tris-EDTA-SDS lysis buffer: 
H2O (72 ml), 1 M Tris-HCl pH 7.4 (2 ml), 1 M NaCl (15 ml), 0.5 M EDTA (1 ml), 0.5 
M EGTA (1 ml), 20% SDS (5 ml) (Fisher Scientific, Loughborough, UK), for 96 ml. 
 
2x Sample loading buffer: 
20% Sodium Dodecyl Sulphate (SDS) solution (200 µl), 0.5 M Tris-HCl pH 6.8 (125 
µl), Glycerol (200 µl) (Fisher Scientific, Loughborough, UK), 0.2% Bromophenol blue 
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(20 µl), 1 M DTT (100 µl), 25x Protease Inhibitor Cocktail (1 tablet added to 2 ml H2O)  
(40 µl), made up to 1 ml with H2O. Aliquots stored at -20 °C. 
 
10x Running buffer: 
Tris(hydroxymethyl)aminomethane (30.3 g), Glycine (190 g), 20% SDS solution (50 
ml), made up to 1 L with H2O. 
 
10x Transfer buffer: 
Tris(hydroxymethyl)aminomethane (29 g), Glycine (14.5 g), 20% SDS solution (9.25 
ml), made up to 400 ml with H2O. 
 
1x Transfer buffer: 
10x Transfer buffer (100 ml), Methanol (200 ml), H2O (700 ml). 
 
10x Tris-buffered saline (TBS): 
1 M Tris-HCl pH 8.0 (100 ml), Sodium chloride (97.3 g), made up to 1 L with H2O. 
 
TBS-(0.05%) Tween (TBS-Tween): 
As for TBS but with Tween-20 (5 ml) (Fisher Scientific, Loughborough, UK). 
 
5% TBS-milk solution: 
Non-fat dry milk powder (5 g) (Bio-Rad, Hemel Hempstead, UK), TBS (100 ml). 
 
2.3 Preparation of compounds 
The following compounds were prepared as stock solutions of 10 mM unless otherwise 
stated. Indomethacin, prostaglandin E2, misoprostol, L-902,688, prostaglandin F2α, U-
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46619, prostaglandin D2, iloprost, FR122047, celecoxib, butaprost (free acid) and 
sulprostone were prepared in ethanol and stored at -20 °C. L-161,982, PF-04418948, 
PF-04852946, CJ-042794, formoterol, indacaterol and salmeterol were prepared in 
dimethyl sulphoxide and stored at 4 °C. Dexamethasone was prepared as a stock 
solution of 100 mM in dimethyl sulphoxide and stored at 4 °C. ONO-AE1-259 was 
prepared in distilled H2O and stored in aliquots at -20 °C. Salbutamol and terbutaline 
were prepared in distilled H2O and stored at 4 °C. (-) -isoprenaline bitartrate was 
prepared in 0.05% sodium metabisulphite (dissolved in 0.9% NaCl) and stored at 4 °C. 
LPS from E. coli serotype R515 (Re) was a ready-to-use stock solution (1 mg/ml) in 
double distilled pyrogen-free H2O and was stored in aliquots at 4 °C. 
 
2.4. Human lung tissue 
Macroscopically normal resected lung tissue was obtained from adult patients 
undergoing thoracic surgery mainly for carcinoma, at the Northern General Hospital, 
Sheffield, UK. The present project, ‘Studies on lung cells involved in respiratory 
diseases’, falls within the remit of the Sheffield Lung Tissue Research Bank, for which 
ethical approval was granted by the National Research Ethics Service (REC ref. 
10/H1010/50). All participants gave informed written consent in the form of a 
completed questionnaire (Appendix II). Participants’ smoking history and relevant 
clinical information (such as allergies) was noted where available. The ratio of 
male:female participants was approximately 50:50 and the median age was 70 years, 
with a range of 19-84 years. The percentage of participants that were non-smokers was 
22%, the percentage of current smokers was 30% and 48% were ex-smokers. 
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2.5. Human lung macrophage isolation and culture 
2.5.1. Tissue processing 
Tissue was manually chopped in RPMI-1640 medium containing 5% fetal calf serum 
(FCS) and placed on to a 100 µm nylon mesh (Incamesh, Warrington, UK) over a 
collection vessel. The medium was used to “wash through” the cells from the tissue into 
the vessel. This was repeated twice, resulting in a final volume of ‘wash through’ of 
100-200 ml in the vessel. This was decanted into 50 ml centrifuge tubes and centrifuged 
at 300 g x 10 min at room temperature (RT) (MSE Mistral 2000). The supernatant was 
carefully aspirated and the pellets resuspended in 40-50 ml of RPMI-1640 
supplemented with 10% FCS, 1x Penicillin-Streptomycin-Amphotericin B antibiotic 
solution and HEPES buffer (25 mM). (This medium will be referred to as 
‘supplemented RPMI-1640’ throughout the thesis). After inverting gently several times, 
the cell suspensions were left to sediment at 4 °C for 1 h. The supernatant was aspirated 
to remove debris and the sedimented material was resuspended in supplemented RPMI-
1640. The sedimentation step at 4 °C was repeated. Alternatively, one of the 
sedimentations was substituted with an overnight sedimentation at 4 °C. The sedimented 
material was resuspended in 30 ml 1x PIPES and centrifuged (300 g x 10 min, RT). The 
resulting pellet was resuspended in 20 ml of 1x PIPES and the suspension was filtered 
through a 100 µm nylon mesh, before being layered onto a discontinuous Percoll 
gradient. This protocol was a modification of one described elsewhere (Liu et al., 1984). 
 
2.5.2. Percoll density gradient centrifugation 
One 20 ml Percoll gradient was used for cells harvested from every 5 g of tissue (pre-
chopped weight). Isotonic Percoll was produced by mixing Percoll:10x PIPES at a 9:1 
ratio. This isotonic Percoll was then known as ‘100% Percoll’ and was diluted with 1x 
PIPES to produce an 80% Percoll gradient. The 20 ml cell suspension was layered onto 
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the gradient and centrifuged (400 g x 20 min, RT) resulting in a flocculent layer 
containing macrophages. The layer was transferred to a new 50 ml tube and 2 
centrifugations were carried out (488 g x 10 min and 488 g x 7 min, both RT) after 
resuspensions to 50 ml with 1x PIPES, to wash the cells from the residual Percoll. The 
resulting cell pellet was resuspended in 10 ml of supplemented RPMI-1640. A 
haemocytometer cell count was performed using a light microscope (Motic SFC-
100FLA). The resulting cells were seeded at 2 x 105 per well in 24-well cell culture 
plates with 1 ml of supplemented RPMI-1640 or at 1x106 per well in 6-well cell culture 
plates with 5 ml of supplemented RPMI-1640 and incubated overnight (37 °C, 5% 
CO2). 
2.5.3. Cell purity assessment 
The macrophage purity of the cell suspension obtained post-Percoll density gradient 
centrifugation was determined by cytospin preparations. An aliquot of cell suspension at 
1 x 106/ml (90 µl) was pipetted into a cytospin chamber and cytocentrifuged at 400 rpm 
x 3 min, RT (Thermo Shandon Cytospin 3).  The cytospin slides were air-dried before 
fixation with 100% methanol. The cytospins were stained with Quick-Diff, according to 
the manufacturer’s instructions and air-dried before coverslips were mounted using 
DPX (di-n-butyl phthalate in xylene) mounting medium. Cytospins were produced in 
duplicate. Macrophages were counted as a proportion of all immune cells present by 
morphological assessment using a light microscope (Nikon Eclipse TE300). 
 
2.5.4. Cell viability assessment 
Cell viability was assessed pre and post-experiment by erythrosin-B exclusion. To 
assess viability of cells in the wells, cell culture medium was aspirated and the wells 
washed once with 1x PBS. Erythrosin-B (stock diluted 1:1 with 1x PBS) was pipetted 
into each well at a volume of 200 µl and incubated for 2 min at room temperature. The 
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erythrosin-B was aspirated and the wells washed once with 1X PBS before visualization 
using an inverted microscope (Zeiss ID 02). Viability was determined by counting the 
number of macrophages that had taken up the pink dye (non-viable) as a proportion of 
the total macrophages present. The average of duplicate wells was calculated. 
 
2.6 Peripheral blood mononuclear cell (PBMC) isolation and culture 
2.6.1. Ficoll-Paque isolation from whole blood 
PBMC isolation was carried out by Jonathan Kilby (Department of Infection and 
Immunity). Peripheral blood was obtained from healthy volunteers who gave informed 
written consent as part of the study entitled ‘Investigation of how macrophage responses 
to micro-organisms programme the innate immune response to human disease’, for 
which ethical approval was granted by the National Research Ethics Service (REC ref. 
07/Q2305/7) (Appendix II). Blood (25 ml) was layered onto Ficoll-Paque (12.5 ml) in a 
50 ml tube and centrifuged (500 g x 23 min, 18 °C) (MSE Falcon 3/300). The plasma 
above the resulting layers of cells was discarded. The PBMC layer was transferred to a 
new 50 ml tube and centrifuged (225 g x 13 min, 4 °C) after resuspension to 50 ml with 
1x PBS. The supernatant was discarded. The cells were washed by combining all pellets 
in one 50 ml tube and resuspending in 1x PBS (to 50 ml) before centrifugation (225 g x 
13 min, 4 °C). The resulting cell pellet was resuspended in RPMI-1640 with newborn 
calf serum (HI NBCS) (10%). A haemocytometer cell count was performed using a 
light microscope. A cell suspension at 1 x 106/ml was pipetted into 24-well cell culture 
plates (1 ml/well) and incubated (37 °C, 5% CO2) for 24 h. 
  
2.6.2. Differentiation into monocyte-derived macrophages (MDM) 
After 24 h, the media was aspirated from the 24-well plates to remove any non-adherent 
cells, which were likely to be cells other than monocytes. The adherent cells were 
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cultured in supplemented RPMI for 14 days. The media was changed at 7 days or earlier 
if it was found to be changing colour due to an increase in cell confluency. At day 14, 
approximately 2 x 105 MDMs were present in each well, estimated by scraping and 
counting the cells. The cells were used for experiments on day 14. 
 
2.7. Functional studies 
Macrophages (2 x 105) in the wells of the 24-well cell culture plates were challenged 
with various stimuli. The cell culture medium was changed 2 h before the start of the 
experiment, to remove any non-adherent cells and spontaneously released cytokines. 
Where pharmacological agents were used, pre-treatment of the cells for 30 min (or 1h 
for antagonists) at 37 °C, 5% CO2 was carried out before addition of stimulants to the 
wells. The cells were then incubated for 22 h with the stimulants (37 °C, 5% CO2). The 
cell culture supernatants were then harvested by pipetting the cell culture medium (1 
ml) from each well into a 1.5 ml microfuge tube and centrifuging (488 g x 4 min, RT) to 
pellet any cells present. The resulting cell-free supernatant was transferred into a new 
1.5 ml tube and stored at -80 °C until required for analysis. Investigation of IgE- 
dependent responses by passive sensitization was carried out using a different 




Figure 2.1. Schematic diagram of passive sensitization of macrophages with IgE. 
Macrophages were incubated for 22 h without or with JW8-IgE. Wells were washed 
twice with supplemented RPMI and then incubated with supplemented RPMI for 2 h. 
Cells were then incubated without or with anti-IgE (2 µg/ml) or NIP20-HSA (5-iodo-4-
hydroxy-3-nitrophenacetyl-Human Serum Albumin) (100 ng/ml) for 22 h after which 
cell culture supernatants were assayed for TNF-α, IL-4 and IL-17a.
- JW8-IgE 
+ JW8-IgE 
    (1/200) 
22 h 
Wells washed with RPMI 
2 h 




    (1/200) 
anti-IgE NIP20-HSA Control 
Supernatants assayed for cytokine content by ELISA 
22 h 
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2.8. Cytokine/chemokine release detection 
2.8.1. Enzyme-linked immunosorbent assay (ELISA) 
Cytokine levels in cell culture supernatants were detected by ELISA. Wells of 96-well 
high binding plates (Corning Costar 3590) were coated with capture antibody (100 
µl/well) and incubated overnight at 4 °C. Wells were then blocked with 200 µl of 1x 
Assay Diluent for 1 h at RT. Standards and samples were diluted in 1x Assay Diluent 
before being pipetted onto the plate (100 µl/well). The plate was incubated for 2 h at RT 
or overnight at 4 °C. The wells were then incubated with detection antibody (100 
µl/well) for 1 h at RT, followed by incubation with Avidin-HRP for 30 min at RT. The 
ELISA was developed with addition of tetramethylbenzidine (TMB) substrate (100 
µl/well) for 15 min at RT. The development was stopped with 1 M H2SO4 (50 µl/well). 
The plate was read at 450 nm using a microplate reader (Thermo Multiskan EX).  
 
During incubation steps, the plate was sealed with sealing film (Sigma, Poole, UK). 
After each incubation step, wells were aspirated and washed 4 times with 1x PBS 
containing 0.05% Tween-20. All antibodies were used at a 1/250 dilution. The limit of 
detection of the IL-8, TNF-α and IL-17a ELISAs was 4 pg/ml. For the IL-6, IL-10 and 
IL-4 ELISAs the limit was 2 pg/ml. Standard curves were produced and the 
concentrations of the unknowns were determined by interpolation from the curves using 
GraphPad Prism (figure 2.2). Before each experimental assay was carried out, selected 
cell culture supernatants of those to be assayed were tested at different dilutions using 
the above protocol. This enabled a suitable dilution to be determined for assaying the 
rest of the supernatants, to ensure the cytokine levels of the stimulated samples would 
be within the range of detection.
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Figure 2.2. Representative cytokine ELISA standard curve. 
The above standard curve for an IL-6 ELISA was produced using non-linear regression 
and a third order polynomial (cubic) fit. The comfortable range of detection based on 
the linear section of the curve was determined as 6.25 - 200 pg/ml. Values outside of 
this were excluded as being above or below the range of detection.










2.8.2. Proteome Profiler Array 
Identification of a range of cytokines present in cell culture supernatants was carried out 
using Proteome Profiler Human Cytokine Array Panel A Kit, which consists of 
nitrocellulose membranes spotted with 36 different capture antibodies and array buffers 
(of which the composition is unknown). The proteome profiler array was performed 
according to the manufacturer’s instructions. Briefly, each membrane was placed into a 
separate well of a 4-well rectangular multi-dish and blocked in array buffer for 1 h on a 
rocking platform at RT. Simultaneously, cell culture supernatants (from 2x105 cells) to 
be tested (≤ 1 ml) were added to array buffers in separate tubes to obtain a final volume 
of 1.5 ml. Detection antibody cocktail (15 µl) was added to each diluted sample and the 
mixtures were incubated at RT for 1 h. Array buffer was aspirated from the wells and 
the sample-antibody mixtures were pipetted into the relevant wells. The dish was 
incubated overnight at 2-8 °C on a rocking platform. Each membrane was placed into 
separate containers and 3 x10 min washes were carried out with 1x wash buffer (20 ml) 
on a rocking platform at RT. The wells of the 4-well multi-dish were washed with dH2O 
and streptavidin-HRP (2 ml) was then pipetted into each well. The membranes were 
incubated in the streptavidin-HRP for 30 min at RT before being washed as above. The 
membranes were exposed to enhanced chemiluminescence (ECL) reagents according to 
the manufacturer’s instructions and covered in clingfilm. The membranes were 
developed using Bio-Rad ChemiDoc XRS+ System, resulting in spots of different 
densities where cytokines/chemokines were detected. Semi-quantitative analysis was 
carried out using Image Lab software (version 5.1, Bio-Rad). Mean background-
adjusted pixel intensity (or ‘density’) was calculated. 
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2.9. Prostaglandin E2 assay 
Prostaglandin E2 (PGE2) levels in cell culture supernatants were quantified using a 
commercially available competitive enzyme immunoassay (Cayman Chemical EIA Kit 
- Monoclonal). The assay was performed according to the manufacturer’s instructions. 
The absorbance was measured at 405 nm using a microplate reader (Thermo Multiskan 
EX). The data were analysed as directed by the manufacturer’s instructions to provide 
PGE2 values in pg/ml. The lower detection limit of the assay was 15 pg/ml. Before each 
experimental assay was carried out, a series of dilutions of selected cell culture 
supernatants were tested using the above protocol. This enabled a suitable dilution to be 
determined for assaying the rest of the supernatants, ensuring the PGE2 levels would be 
within the range of detection. 
 
2.10. Cyclic-AMP assay 
Cyclic-AMP (cAMP) levels in cells were determined using a commercially available 
competitive enzyme immunoassay (Cayman Chemical ACE EIA Kit). Cell culture 
medium was removed from the wells post-experiment and 1 ml of acidified ethanol (1 
ml hydrochloric acid: 99 ml ethanol) per well was added for 5 min. The acidified 
ethanol was pipetted up and down before being transferred to 1.5 ml microfuge tubes. 
The samples were stored at -80 °C unless proceeding immediately to the next step. The 
samples were centrifuged (13,000 rpm, 10 min, 4 °C) and 900 ml of the supernatant was 
transferred to a new 1.5 ml tube. The tubes were centrifuged with the lids removed, in a 
rotary evaporator (Eppendorf Concentrator 5301) until all of the ethanol had 
evaporated. The resulting cAMP-containing pellet/residue was resuspended in 1x EIA 
buffer (220 µl) and vortexed before being stored at -80 °C until analysis. The assay was 
then performed according to the manufacturer’s instructions. The standards and samples 
were acetylated before being added to the cAMP-specific IgG coated 96-well plate. The 
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absorbance was measured at 405 nm using a microplate reader (Thermo Multiskan EX). 
The data was analysed as directed by the manufacturer’s instructions to provide 
acetylated cAMP values in pmol/ml. This was used to calculate cAMP per million cells. 
The lower detection limit of the assay was 0.1 pmol/ml. Before each experimental assay 
was carried out, a series of dilutions of selected cell culture supernatants were tested 
using the above protocol. This enabled a suitable dilution to be determined for assaying 
the rest of the supernatants, ensuring the cAMP levels would be within the range of 
detection. 
2.11. Gene expression 
EP receptor and COX gene expression was determined by Polymerase Chain Reaction 
(PCR). RNA was converted to cDNA by Reverse Transcriptase PCR and the cDNA was 
amplified using EP receptor and COX subtype-specific primers. Expression of a range 
of macrophage M1 and M2 marker genes was measured by quantitative real-time PCR 
(qPCR).  
 
2.11.1. RNA extraction and quantification 
RNA was extracted from cells (2-3 x 106) by lysis with TRI Reagent® (1 ml). For phase 
separation of the protein, DNA and RNA, chloroform (0.2 ml) was added. After 
vigorously shaking, the samples were left to stand for 10 min at RT. The RNA-
containing aqueous layer was transferred to a new microfuge tube. Isopropanol (0.5 ml) 
was added and mixed before leaving the samples to stand for 10 min at RT. The 
samples were centrifuged (12,000 x g, 10 min, 4 °C). The resulting pellet was washed in 
75% ethanol (1 ml) by inverting the tube, after the supernatant was removed using a 
syringe. The tube was centrifuged at 7500 x g for 5 min at 4 °C. The supernatant was 
removed using a 21G needle (BD Microlance™ 3) and 5 ml syringe (BD Plastipak™). 
The pellet was left to air dry by leaving the tube lid open at RT. The pellet was 
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resuspended in sterile H2O (20 µl) and this RNA solution was stored at -80 °C unless 
proceeding directly to the next step. 
 
Removal of any DNA present in the extracted RNA was done by DNase I digestion 
using a commercially available kit (DNA-free DNase Treatment & Removal, Ambion). 
DNase I buffer (10x) was added to the RNA solution at 0.1x volume along with rDNase 
I (1 µl) and mixed by pipetting gently. The microfuge tube was incubated at 37 °C for 
25 min in a heat block (Techne Dri-Block DB-2A). DNase inactivation reagent was 
then added (after vortexing) at 0.1x volume to the RNA and the solution was mixed by 
pipetting. The tube was incubated for 1 min at RT, mixed by pipetting and incubated for 
a further 1 min before centrifuging (10, 000 x g, 1.5 min, RT). The top, clean layer 
containing the RNA was transferred to a 0.5 ml microfuge tube. The RNA concentration 
in ng/µl was quantified using a NanoDrop ND-1000 Spectrophotometer (Thermo 
Scientific) and the 260/280 nm ratio enabled determination of sample purity. The RNA 
was stored at -80 °C unless proceeding directly to the next step. 
 
2.11.2. Reverse transcriptase PCR (RT-PCR) 
RNA (1 µg) was reverse-transcribed to cDNA. The NanoDrop concentration reading 
was used to calculate the volume of RNA that was equal to 1 µg and sterile H20 was 
added to produce a total volume of 20 µl in a PCR tube. A master mix (MM) of the 
components required for the PCR reaction was made up as shown in table 2.1 for the 
number of RNA samples plus a negative control. The MM was added to the RNA (20 
µl/RNA sample). A ‘no enzyme’ negative control was required consisting of RNA (20 
µl) and the MM (20 µl) with H2O replacing the RT (reverse transcriptase) enzyme, to 
ensure any amplification that occurred was not of any genomic DNA in the sample. The 
reverse transcriptase PCR conditions were 1 cycle at 25 °C (10 min), 37 °C (120 min) 
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and 85 °C (5 min) followed by holding at 4 °C (∞) (DNA Engine PTC-200 Peltier 




Table 2.1. Master mix for reverse transcriptase PCR. 
 
  Volume (µl) per PCR reaction 
10X RT buffer 4 
25X dNTPs mix (100 nM) 1.6 
Multiscribe RT enzyme 2 
RNase Inhibitor 2 




Table 2.1 shows the composition of the master mix to be added to RNA for conversion 
to cDNA by reverse transcriptase PCR. The cycling conditions for the reverse 
transcriptase PCR reactions are given in section 2.11.2.
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2.11.3. Polymerase chain reaction (PCR) 
The cDNA was amplified by PCR to determine the gene expression of EP1, EP2, EP3, 
EP4, COX-1 and COX-2. Expression of β-actin (housekeeping gene) was determined to 
compare to expression of the genes of interest. The MM used for all PCR reactions is 
shown in table 2.2. MM (24 µl) and cDNA (1 µl) were added to a PCR tube and 
overlayed with mineral oil (20 µl) to prevent evaporation (Techne TC-312 Thermal 
Cycler). Primers were designed by Dr Linda J. Kay and then synthesized by Sigma 
(Poole, UK). The primer sequences are shown in table 2.3A and PCR conditions are 
shown in table 2.3B.
 
Table 2.2. Master mix for standard PCR. 
 
 Volume (µl) per PCR reaction 
5X GoTAQ® Flexi Green Buffer 5 
dNTPs (10 mM) 0.5 
Forward primer (2 µM) 2.5 
Reverse primer (2 µM) 2.5 
MgCl2 (25 mM) 2 
Sterile H2O 11.25 
GoTAQ® Flexi DNA polymerase 0.25 
  
 
Table 2.2 shows the composition of the master mix for the PCR reactions to amplify 
cDNA. The sequences of the primers are shown in table 2.3A and the cycling conditions 
for the PCR reactions are shown in table 2.3B.
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Table 2.3A. Primer sequences for standard PCR 
Primer 
pair no. 
Gene Primer sequences in 5’-3’ direction Product 
size (bp) 




























Table 2.3A shows the sequences of the primers used for amplification of cDNA. The 
cycling conditions for the PCR reaction for each primer pair is given in table 2.3B.
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Denaturation Annealing Polymerisation Final 
elongation 




































Table 2.3B shows the magnesium (MgCl2) concentration required in the master mix and 
the thermal cycling conditions for the primers listed in table 2.3A. The number of 




2.11.4. Agarose gel electrophoresis 
PCR products were visualized on a 2% agarose gel. Agarose (3 g) was added to 1x TAE 
buffer (150 ml) in a conical flask and heated in a microwave. Ethidium bromide (15 µl) 
was added when the melted gel was slightly cooled. The gel was cast in a cassette with 
a well comb inserted. After ~ 1 h the comb was removed from the set gel which was 
then placed into a gel tank and covered with 1x TAE buffer. Samples (5 µl/well) and a 
100 base pair DNA ladder (5 µl) were loaded onto the gel. The gel was run at 100V for 
50 min (Bio-Rad PowerPac 300) and the DNA bands were visualized using the Bio-Rad 
ChemiDoc XRS+ System. Densitometry was performed using Image Lab software 
(version 5.1, Bio-Rad). 
 
In order to ensure that the correct amplification had taken place, PCR products were cut 
from the agarose gel and purified using a MinElute Gel Extraction Kit (Qiagen, 
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Crawley, UK), according to the manufacturer’s instructions. Genotypic analysis was 
performed in-house by automated sequencing (ABI 3730 DNA Analyser; Applied 
Biosystems, Carlsbad, CA, USA). 
 
2.11.5. Real-time quantitative PCR (qPCR) 
Determination of the expression of a range of genes in macrophages incubated without 
or with a range of stimuli for 22 h was determined using qPCR. RNA was reverse-
transcribed to cDNA as described in 2.11.2. A master mix (MM) of the components 
required for each PCR reaction was made up, consisting of 2x TaqMan Universal 
Master Mix including AmpErase® UNG (uracil-N-glycosylase) (5 µl), 20x Taqman 
Gene Expression Assay primer/probe mix (0.5 µl) and RNase-free H2O (3 µl). The 
probe consisted of a 6-FAM (6-carboxy fluorescein) fluorescent reporter dye at the 5’ 
end and a non-fluorescent quencher at the 3’ end. Where TaqMan Gene Expression 
Assays were not available, primers and probes were designed by and obtained from 
Primerdesign (Southampton, UK) or from Sigma-Aldrich (Suffolk, UK). For the 
primers and probes from Sigma-Aldrich, the MM for each reaction consisted of 2x 
Universal Master Mix (5 µl), sense primer (0.1 µl), antisense primer (0.1 µl), probe 
(0.02 µl) and RNase-free H2O (3.28 µl). Primer and probe sequences are shown in table 
2.4.
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Table 2.4. Primer/probe sequences for qPCR 
 








NOS2 NOS2_8296 (Primer mix/PerfectProbe) 
 
Primerdesign 
ARG ARG1_14369 (Primer mix/PerfectProbe) 
 
Primerdesign 


























Table 2.4 shows the sequences or identification codes for the commercially available 
and custom made primers and probes used in qPCR, along with the company they were 
obtained from.
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The MM (8.5 µl) was added in triplicate to the wells of a 384-well plate. Each well was 
loaded with 37.5 ng of cDNA (1.5 µl) resulting in a total volume of 10 µl per well. The 
plate was sealed with a plate cover and run in a CFX384 Real-Time PCR Detection 
System (Bio-Rad) according to the thermal cycling conditions in table 2.5. The data was 
analysed using the comparative Ct method. The expression of each gene of interest was 
normalized to the expression of the β-actin housekeeping gene in each sample. 
DeltaDelta Ct values were obtained by subtracting the Delta Ct value of the non-treated 
control sample from the Delta Ct value of the treated samples. The fold change between 
the untreated sample and the treated sample was then calculated as 2(-DeltaDeltaCt). 
 
 
Table 2.5. Thermal cycling conditions for qPCR 
 






Temperature  50 °C 95 °C 95 °C 60 °C 
Time 2 min 10 min 15 sec 1 min 
 
Table 2.5 shows the cycling conditions for the qPCR reactions for the primers and 
probes given in table 2.4.
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2.12. Protein expression 
2.12.1 Protein lysis 
Protein lysis was carried out using the trichloroacetic acid precipitation method (Wang 
et al., BioTechniques 1996, 20 p662-668). The following steps were carried out on ice. 
Macrophages in 6-well plates (1x106/well) were washed once with 1x PBS (1 ml/well). 
The PBS was removed and the wells were washed once in Tris-EDTA buffer (1 
ml/well). All of the Tris-EDTA was removed from the wells. Tris-EDTA-SDS lysis 
buffer (600 µl) with Protease Inhibitor Cocktail added at 1:25 dilution was pipetted into 
each well and swirled around to lyse the cells. A cell scraper was used to gently scrape 
the lysate from the edge of the wells. Trichloroacetic acid (6.1 N) was added (100 
µl/well) and the plate swirled immediately, to precipitate the protein. The supernatant 
was pipetted into microfuge tubes, leaving the DNA behind and centrifuged (13,000 
rpm, 5 min, 4 °C). The supernatant was discarded and the resulting pellet was washed 
once in 2.5% trichloroacetic acid in H2O (500 µl) and centrifuged (13,000 rpm, 5 min, 4 
°C). The supernatant was discarded. A short centrifugation was carried out to enable 
any residual supernatant to be removed. Tris(hydroxymethyl)aminomethane (Tris-base) 
(3 M) containing Protease Inhibitor Cocktail at 1:25 dilution was pipetted onto each 
pellet (≤40 µl depending on the size of the pellet). The microfuge tubes were incubated 
for 1 h at RT or overnight at 4 °C to solubilize the protein. A volume of sterile H2O 
equal to the volume of Tris-base added before incubation was added to the microfuge 
tubes and pipetted up and down to mix. The resulting 1.5 M Tris-base solution was 
pipetted into new microfuge tubes, leaving behind any non-soluble material. The protein 
lysate was stored at -80 °C until required for analysis. 
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2.12.2. SDS-PAGE and Western blotting 
Protein lysates were reduced by adding equal volume of 2x sample loading buffer and 
placing in a heat block at 95 °C for 10 min. The molecular weight markers (ColorPlus 
Prestained Protein Ladder, New England Biolabs) were also heated. The lysates were 
then centrifuged (13,000 xg, 1 min). Protein separation was performed using SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) using the Bio-Rad Mini-PROTEAN 
system. Glass plates were cleaned with 70% industrial methylated spirits before being 
assembled for gel casting. Resolving and stacking gels were made up as follows: 
 
10% Resolving gel (for 2 gels): 
H2O 6.1 ml 
1.5 M Tris-HCl pH 8.8 3.75 ml 
30% Acrylamide 4.95 ml 
10% Sodium Dodecyl Sulphate (SDS) 150 µl 
10% Ammonium persulphate (APS) 75 µl 
Tetramethyl-ethylenediamine (TEMED) 18 µl 
 
4% Stacking gel (for 2 gels):  
H2O 6.1 ml 
0.5 M Tris-HCl pH 6.8 2.5 ml 
30% Acrylamide 1.3 ml 
10% SDS 100 µl 
10% APS 100 µl 
TEMED 20 µl 
 
APS and TEMED were added immediately before pouring the gel. The resolving gel 
was poured first and overlaid with isopropanol until set. The isopropanol was decanted 
before the stacking gel was poured and a well comb inserted. When the stacking gel was 
set, the comb was removed and the gels were placed into a tank with 1x running buffer. 
The protein lysate samples and protein ladder were loaded into the wells. The gels were 
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run at 70 V 15 min until the samples migrated into the resolving gel and run at 150 V 
for ~1 h until the samples reached the bottom of the gel (Bio-Rad PowerPac Basic). 
 
Wet transfer of the proteins from the gel to a nitrocellulose membrane was carried out, 
by sandwiching in a transfer cassette. Two sponges and four pieces of filter paper 
(Whatman™ chromatography paper) were soaked in a tray containing 1x transfer 
buffer. A transfer cassette was placed into the transfer buffer. A sponge was placed onto 
the black side, followed by two pieces of filter paper and then the gel (face up). The 
membrane was placed on top of the gel, followed by two pieces of filter paper and then 
a sponge. The cassette was closed, ensuring no air bubbles. The cassette was placed into 
a cassette holder in a transfer tank, with the black side of the cassette facing the black 
side of the cassette holder. An ice pack was placed into the tank, and the tank was filled 
with 1x transfer buffer. Transfer was carried out at 100 V for 1 h on a magnetic stirrer. 
 
The membrane was blocked in 5% TBS-milk solution in on a shaker for 1 h at RT 
before being washed in TBST (2x 10 min). The primary antibody was diluted in 5% 
TBS-milk (5 ml). The membrane was incubated with the primary antibody in a 50 ml 
tube overnight at 4 °C on a rolling platform. The membrane was then washed in TBST 
(2x 10 min) at RT on a rolling platform. The secondary antibody was diluted in 5% 
TBS-milk (5 ml). The membrane was incubated with the secondary antibody for 1 h at 
RT on a rolling platform and then washed in TBST (2x 10 min). Antibody 
concentrations are shown in table 2.6.
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Table 2.6. Western blotting antibody concentrations 
 
Primary antibody Concentration 
used 











polyclonal IgG  
(Santa Cruz Biotechnology 
sc-1752) 
0.8 µg/ml Donkey anti-goat IgG- 
HRP  




polyclonal IgG  
(Santa Cruz Biotechnology 
sc-1745) 
 
0.8 µg/ml Donkey anti-goat IgG- 
HRP  




Table 2.6 shows the primary and the corresponding secondary antibodies used for 
Western blotting. The concentrations that the antibodies were used at and the companies 
that the antibodies were obtained from are also given.
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Protein detection was carried out using ECL reagent. Reagent A was mixed with 
reagent B at 1:1. The membrane was placed onto clingfilm and covered with the ECL 
reagent for 1 min. Excess ECL reagent was removed from the membrane before placing 
between two pieces of plastic, ensuring no air bubbles were present. The membrane was 
developed using Bio-Rad ChemiDoc XRS+ System and densitometry was performed 
using Image Lab software (version 5.1, Bio-Rad). 
 
2.12.3. Membrane stripping and re-probing:  
To prepare for re-probing, the membrane was stripped. The membrane was incubated as 
follows: in H2O (10 min), in 0.2 M NaOH (15 min), in H2O (10 min), in TBS (15 min). 
The membrane was then blocked in 5% TBS-milk (1 h), followed by incubation with 
primary and secondary antibodies as previously described in 2.12.2. 
 
2.13. Flow cytometry 
Flow cytometry was performed on an LSRII flow cytometer (BD Biosciences). Cell 
populations were identified using forward and side-scatter characteristics in addition to 
positive staining with antibodies to CD14 (present on monocytes and macrophages) and 
CD206 (present on macrophages). The antibodies used were CD14-PE (clone TÜK4, 
Miltenyi Biotec) and CD206-APC (clone DCN228, Miltenyi Biotec). The 
corresponding isotype controls used were mIgG2a R-PE (Life Technologies) and 
mIgG1-APC respectively (Life Technologies). A total of 10,000 events were captured.  
 
Positive staining with Live/Dead Fixable Dead Cell Stain Kit Near IR (Life 
Technologies) was used to eliminate dead cells from the analysis. Doublet 
discrimination was carried out to ensure only single cells were included in the analysis. 
Mean fluorescence intensity values were calculated by subtracting the geometric mean 
 88 
fluorescence values for isotype control staining from the geometric mean fluorescence 
values for antibody staining. All analysis was performed using FlowJo® software 
(version 9.3.3, Tree Star, Inc.).  
 
2.13.1. Cell-specific staining 
The cell suspension obtained after Percoll gradient centrifugation was plated into 6 well 
cell culture plates at 1x106 cells/well. The cells were incubated overnight (37 °C, 5% 
CO2) and the cell culture medium was changed the next day. Cells were scraped from 
the wells using a rubber cell scraper (Sarstedt) in the presence of cell culture medium. 
The cell culture medium containing the cells was pipetted into a 50 ml centrifuge tube 
and centrifuged (488 g x 5 min, RT). The resulting pellet was resuspended in 1 ml of 
FACS buffer and a haemocytometer count was carried out. The cell suspension was 
adjusted as necessary with FACS buffer and pipetted equally into microfuge tubes 
(ideally 1x106 cells/tube). The tubes were centrifuged (488 g x 5 min, RT). The 
resulting pellets (except in the tube to be left unstained) were resuspended in FcR 
Blocking Reagent (at 1:5 dilution in 100 µl final volume of FACS Buffer) for 15 min at 
4 °C. Washes (2 x) were carried out in FACS buffer by resuspending in 750 µl and 
centrifuging (488 g x 5 min, RT). The pellets were resuspended in their respective 
antibody mixtures (antibodies at a 1:10 dilution in 100 µl final volume of FACS buffer) 
and the live/dead stain was added (1 µl for no more than 1x106 cells) to each tube. The 
pellet to be left unstained was resuspended in 100 µl of FACS buffer alone. The tubes 
were incubated for 30 min on ice, in the dark. Washes (2 x) were carried out before 
resuspension of the pellets in 500 µl of FACS buffer and pipetting into glass sample 
tubes for the flow cytometer. 
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Compensation controls were produced using BD™ CompBeads Anti-Mouse Ig, κ 
/Negative Control (FBS) Compensation particles set according to the manufacturer’s 
instructions. FACS buffer (100 µl) was added to each sample tube (one tube for each 
fluorochrome used and one negative control tube). The BD™ CompBeads were 
vortexed before use. One drop of BD™ CompBeads negative control (has no binding 
capacity) was added to each tube and one drop of BD™ CompBeads Anti-Mouse Ig, κ 
beads (binds any mouse κ light chain-bearing Ig) was added to each tube except the 
negative control tube. Antibodies conjugated to each fluorochrome used in the 
experiment were diluted 10x in FACS buffer and of the diluted antibodies (20 µl) were 
added to their respective tubes. Following vortexing, the tubes were incubated in the 
dark for 30 min. FACS buffer (2 ml) was then added to each tube, followed by 
centrifugation (488 g x 5 min) to wash. The supernatant was decanted and the beads 
were resuspended in FACS buffer (350 µl) before running on the flow cytometer to set 
compensation values. 
 
The positive control for live/dead discrimination was produced by heating an aliquot of 
cells to 65 °C for 1 min immediately followed by incubating on ice for 1 min, before 
combining 1:1 with non-treated cells. This mixture of live and dead cells was then 
stained with the live/dead stain. 
 
2.14. Data analysis and statistics 
Data were displayed as mean ± standard error of the mean (SEM). Antagonist affinity 
(pKB) was calculated using the Gaddum equation: pKB = log(dose ratio – 1) - 
log(antagonist concentration). Statistical analyses involved one-way ANOVA or paired 
t test followed by Tukey’s or Dunnett’s Multiple Comparison test to determine the 
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statistical significance. Significant values were defined as p<0.05. Statistical tests were 
performed using GraphPad Prism Version 6.0c (GraphPad Software, Inc.). 
  
 91 
Chapter 3: Preliminary characterization of human lung 
macrophage phenotype 
3.1. Introduction 
Macrophages are believed to be implicated in inflammatory lung diseases, which makes 
them the focus of many investigations into this area (Barnes, 2008b, Pons et al., 2005, 
Moreira and Hogaboam, 2011). However, owing to the lack of availability or 
accessibility of tissue, much of the research into lung diseases is carried out using 
substitutes for human lung macrophages, such as monocytic cell lines or monocyte-
derived macrophages (MDMs) (Daigneault et al., 2010). Whilst there are a number of 
advantages to using these alternatives, it is possible that human lung macrophages may 
provide a more accurate representation of what occurs in vivo. This formed the premise 
for this study, which comprised a new initiative in our laboratory to isolate human lung 
macrophages for use as a model system. This chapter outlines the initial attempts at 
isolating macrophages, followed by preliminary functional and phenotypical 
characterization to enable validation of their use for investigations into potential roles in 
inflammatory lung diseases.  
 
Macrophages exhibit phenotypic heterogeneity and can be broadly classified as having 
an M1 (classically activated) or M2 (alternatively activated) phenotype (Mosser and 
Edwards, 2008). A good indicator of the phenotype is the cytokines that are released in 
response to activation by different stimuli. M1 macrophages are associated with release 
of pro-inflammatory cytokines (and low levels of anti-inflammatory cytokines) whereas 
M2 macrophages are associated with release of anti-inflammatory cytokines (Mosser 
and Edwards, 2008, Mantovani et al., 2007). In this study, the profile of cytokine 
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release from macrophages was determined by ELISA and Proteome Profiler Array 
following activation by various stimuli.  
 
A range of TLR (toll-like receptor) agonists was employed in this study. The gram-
negative bacterial cell wall component LPS (TLR4 agonist) and the synthetic triacylated 
lipoprotein Pam3CSK4 (TLR2 agonist) are both mimics for bacterial infection. Mimics 
for viral infection that were used were the double-stranded RNA analog poly(I:C) 
(TLR3 agonist) and the imidazoquinoline compound, gardiquimod (TLR7(/8) agonist). 
The macrophage response to infections in vivo is believed to contribute to exacerbations 
of chronic lung diseases (Barnes, 2008a, Berenson et al., 2014). Therefore, in addition 
to investigating phenotypes, TLR agonists were also useful for observing whether the 
cytokines released in response to bacterial mimics were different to those released in 
response to viral mimics.  
 
In addition to assessment of cytokine release, expression of cell surface markers can 
indicate the phenotype of macrophages. Therefore experiments were carried out 
investigating the expression of M1 and M2 macrophage markers by flow cytometry. 
Another approach to investigate markers associated with a particular phenotype is to 
explore gene expression. A preliminary qPCR experiment was carried out to determine 
whether this technique could assist in phenotyping. 
 
In addition to the preliminary characterization of the function and phenotype of the 
isolated macrophages, some comparative studies were also performed with the 
commonly used alternative cells, MDMs. This enabled investigation into whether there 




3.2.1. Isolation of macrophages from human lung tissue 
Macrophages were isolated from lung tissue according to the methods described in 
section 2.5.1 and 2.5.2. These methods were a result of modification of the initial 
protocol used (Liu et al., 1984). It was discovered during early attempts to use the 
protocol, that there were various issues that needed to be addressed in order to 
adequately isolate macrophages from the ‘wash through’ from the chopped lung tissue. 
 
Initially, the ‘wash through’ was centrifuged and the pelleted material was resuspended 
in supplemented RPMI-1640. This mixed cell suspension was left to sediment overnight 
at 4 °C in 50 ml centrifuge tubes. For comparison, some was pipetted into 6-well cell 
culture plates to be kept in the incubator at 37 °C overnight. In order to make a valid 
comparison, the cells from the two conditions were then counted using a 
haemocytometer and seeded into 6-well plates at the same density of 1 x 106 cells per 
well. (To count the cells that had been kept in plates in the incubator, the cells had to be 
scraped from the wells). The cells were incubated for 1 h at 37 °C before the 
supplemented RPMI-1640 was changed, to wash the wells to remove non-adherent 
cells. The cells were incubated for a further 1 h at 37 °C. This was repeated for a total of 
three washes and then both sets of plates were examined using an inverted microscope. 
The cells from the ‘wash through’ that had initially undergone sedimentation at 4 °C 
appeared to look healthier than those from the ‘wash through’ that had been 
immediately incubated at 37 °C. This test was carried out twice before it was decided 
that for subsequent cell isolations, sedimentations of the ‘wash through’ would be 
performed at 4 °C. An issue that was found to be common between both sets of plates 
was that there were a large number of erythrocytes present, in addition to many other 
cells that were unlikely to be macrophages based on their size, as visualized with an 
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inverted microscope. In order to minimize the presence of these cells, utilizing a Percoll 
gradient was attempted as a possible solution. 
 
Incorporating a Percoll gradient step into the isolation procedure greatly minimized the 
presence of the contaminating cells. Resulting cells were seeded at a range of densities 
and it was determined after two tests that the most suitable density for 6-well plates was 
1 x 106 cells per well and for 24-well plates, the most suitable density was 2 x 105 cells 
per well, based on the confluency in the wells. This coincided with the density used by 
monocyte-derived macrophage researchers within the department, providing further 
support for this decision. The ‘wash through’ contained debris, which interfered with 
cell separation on the Percoll gradient. In particular, tissue from patients who were 
smokers often contained large amounts of black particles. After two isolations 
performed using a Percoll gradient, it was determined that it was necessary to 
incorporate a filtering step before layering the cells onto the gradient, to minimize the 
effects of this issue. 
 
As the cells were isolated using a Percoll gradient alone, it was possible that there 
would still be some contaminating cells present. To determine the macrophage purity, 
cytospins of the cell suspension that was plated into cell culture wells were produced 
after every cell isolation, as described in section 2.5.3. As the cell culture medium was 
changed before starting each experiment, it was also necessary to check the purity in the 
wells after this ‘wash’, as it was believed that some non-adherent contaminating cells 
would be removed. As macrophages adhere to the wells, the wash would potentially 
increase the macrophage purity. Although not done routinely, this was achieved by 
placing coverslips into two of the wells before seeding. The coverslips were removed at 
the time of starting an experiment then fixed and stained as in section 2.4.3 before being 
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mounted onto microscope slides cell side up with DPX to seal the edges. Comparison of 
cytospins and coverslips from the same cell preparation revealed that the cell counts 
were the same or very similar with both showing a high level of macrophage purity 
(figure 3.1). The macrophage purity was routinely 80-97 % and contaminating cells 
were monocytes, neutrophils and lymphocytes. 
 
To check that the differential cell counts that were routinely performed were not being 
influenced by subjectivity, a selection of cytospins were blind counted by senior 
histopathologist Dr SK Suvarna from the Royal Hallamshire Hospital, Sheffield. The 
resulting assessments of macrophage purity were comparable to our assessments, 
providing further confidence in the method used for determination of macrophage 
purity. Cell preparations with a low level of macrophage purity were either discarded or 
used only for pilot experiments. Cell preparations were mostly of good macrophage 
purity and very few preparations were of low purity, represented by the images of 
cytospins of cell suspensions from the final protocol shown in figure 3.2. 
 
It was necessary to determine the viability of the cells, before starting the experiments 
and after incubation with agents. Viability was determined using the method described 
in section 2.5.4. As macrophages are adherent to cell culture wells, this method was a 
modification of the method generally used to test the viability of cells that are in 
suspension. Initially, attempts were made to scrape cells or use EDTA to remove cells 
from the wells, to enable viability to be tested of cells in a suspension. However, the cell 
recovery from the wells was low, making this an unreliable method, as the cells in 
suspension may not have been representative of all the cells in the wells. Adapting the 
method to enable erythrosin-B to be added directly to the wells enabled routine, reliable 
checking of viability. Viability pre- and post-experiment was routinely 85-95 %. 
 96 
      
 
Figure 3.1. Determination of macrophage purity. 
Representative (A) cytospin (1x106 cells/ml) and (B) coverslip (2x105 cells/well) of 
macrophages from the same lung preparation, stained with Quick-Diff. Macrophage 
purity was determined by differential cell counts. The mean cell counts of duplicate 
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Figure 3.2. Representative cytospins of macrophage preparations. 
Representative cytospins (1x106 cells/ml) of cells from six different lung preparations 
showing macrophage purities of (A) 99%, (B) 99%, (C) 92%, (D) 86%, (E) 81% and 
(F) 64%. Cytospins were stained with Quick-Diff. Macrophage purity was determined 
by differential cell counts. The mean cell counts of duplicate cytospins were calculated. 
Macrophage (red block arrow), neutrophil (red arrow), monocyte (white arrow), 
lymphocyte (black arrow), erythrocyte (dashed black arrow).
50 µm  
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An average of two million macrophages were obtained from one gram of lung tissue. It 
was important to isolate the cells as soon as possible after processing the tissue. Some 
cell preparations contained large numbers of erythrocytes and it was found that these 
ideally required longer sedimentation steps before being isolated using a Percoll 
gradient. It was therefore possible that some cell loss occurred in those situations where 
the isolation procedure was started before the second sedimentation was optimally 
complete. This could have resulted in a less than maximum yield on occasions. 
Information on the lung preparations carried out in this project is provided in Appendix 
III. 
 
3.2.2. Cytokine release from macrophages in response to LPS challenge 
Macrophages were challenged with LPS (10 ng/ml) for 22 h, after which the release of 
the pro-inflammatory cytokines TNF-α, IL-6, IL-8 (figure 3.3A, B, D) and the anti-
inflammatory cytokine IL-10 (figure 3.3C) into the cell culture media was measured. 
LPS challenge caused a significant (p<0.05) increase in the release of all four cytokines 
compared to spontaneous cytokine release. However, quantitative differences in the 
extent of cytokine generation were observed. The extent of IL-8 generation was greatest 
(40,937±3877 pg/ml) and substantial levels of both IL-6 (7344±1534 pg/ml) and TNF-α 
(4558±1075 pg/ml) were generated whereas IL-10 generation was considerably lower 
(108±34 pg/ml). In the absence of LPS, spontaneous release of TNF-α, IL-6 and IL-10 
was negligible whereas considerable levels of spontaneous IL-8 release were detected 
(5158±1377 pg/ml) (figure 3.3D).  
 
Although a high release of IL-8 from lung macrophages has been reported in other 
studies, there was a concern that the cells were being activated spontaneously by the 
culture conditions. Low levels of endotoxin can be present in some types of FCS. To 
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investigate the possibility of this having an effect, macrophages were cultured in media 
containing different types of FCS for 22 h, without and with LPS challenge. As cells 
were routinely cultured in media containing 10% FCS from Promocell, the IL-8 release 
from these cells was compared to that from cells cultured under other conditions. Ultra 
low endotoxin FCS (10%) from Autogen Bioclear or a lower concentration of 
Promocell FCS (5%) resulted in no significant (p>0.05) difference in IL-8 release 
compared to 10% Promocell FCS. Only the absence of FCS resulted in a significant 
(p<0.05) 46% decrease in spontaneous IL-8 (figure 3.4A) and 70% decrease in LPS-
induced IL-8 (figure 3.4B). Moreover in the absence of any FCS, cells exhibited lower 
viability (64% viable) than those cultured in media containing FCS (84-90% viable), as 




Figure 3.3. Cytokine release from LPS-stimulated macrophages. Macrophages were 
incubated without or with LPS (10 ng/ml). After 22 h, cell culture supernatants were 
harvested and assayed by ELISA for (A) TNF-α, (B) IL-6, (C) IL-10 and (D) IL-8. 
Solid horizontal lines represent the mean for 13 (TNF-α, IL-6, IL-8) and 10 (IL-10) 
individual experiments. (Paired t test between spontaneous and LPS-challenged, 































































               
Figure 3.4. Comparison of the effect of different FCS conditions on IL-8 release 
from macrophages. Macrophages were cultured in RPMI containing different types 
and concentrations of FCS without (A) or with (B) LPS (10 ng/ml). After 22 h, cell 
culture supernatants were assayed for IL-8. Values are mean ± SEM for 4 individual 
experiments. (One-way ANOVA with Dunnett’s post test, *p<0.05, **p<0.01, 




















































































3.2.3. Concentration and time dependency of LPS-induced cytokine release 
Macrophages were challenged with a range of LPS concentrations for 22 h after which 
the levels of TNF-α were measured. The lowest concentration of LPS (0.1 ng/ml) did 
not result in a significant (p>0.05) increase in TNF-α release relative to spontaneous 
release. Higher concentrations of LPS (1-100 ng/ml) induced significant (p<0.05) 
increases in TNF-α release. Although 100 ng/ml of LPS resulted in a significant release 
of TNF-α, the level was lower than that generated by 10 ng/ml (figure 3.5). 
 
To investigate the release of pro-inflammatory cytokines in response to LPS over time, 
macrophages were challenged with LPS (10 ng/ml) for 2, 5, 16 and 22 h. The levels of 
TNF-α, IL-6 and IL-8 were measured. Although some variation in the levels of 
cytokines released at each time point was seen between individual experiments, it was 
possible to identify an overall pattern of release by observing the mean data. The release 
of TNF-α (figure 3.6A) increased up to 16 h and then decreased slightly at 22 h. A 
similar pattern of release overall was seen for IL-6 (figure 3.6B). By contrast, IL-8 
release (figure 3.6C) continued to increase over 22 h. Spontaneous time-dependent IL-8 
release was also detected. This was in contrast to the other cytokines, for which the 
spontaneous release was below the level of detection.
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Figure 3.5. Effect of a range of concentrations of LPS on TNF-α release. 
Macrophages were incubated without or with LPS (0.1 - 100 ng/ml). After 22 h, cell 
culture supernatants were harvested and assayed by ELISA for TNF-α. Values are mean 
± SEM for 4 individual experiments. (One-way ANOVA with Dunnett’s post test, 
*p<0.05, **p<0.01, compared with spontaneous release). 




















Figure 3.6. Time-dependent LPS-induced cytokine release. 
Macrophages were incubated without or with LPS (10 ng/ml). At 2, 5, 16 and 22 h, cell 
culture supernatants were harvested and assayed for (A) TNF-α, (B) IL-6 and (C) IL-8. 
Data shown are of 4 individual experiments (left panels) alongside the mean ± SEM 
data (right panels). Spontaneous cytokine release was below the level of detection 
except for IL-8, for which the individual experiment values shown are net values (gross 
IL-8 – spontaneous IL-8).    
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3.2.4. Cytokine release induced by TLR agonists 
To determine if TLR agonists other than LPS induced TNF-α release, the TLR3 agonist 
poly(I:C) (0.1-10 µg/ml) and the TLR7 agonist gardiquimod (0.1-10 µg/ml) were used 
to challenge macrophages in addition to LPS (0.1-10 ng/ml) for 22 h. Only the highest 
concentration of LPS (10 ng/ml) or poly(I:C) (10 µg/ml) induced a significant (p<0.05) 
increase in TNF-α release relative to spontaneous release (figure 3.7). The only 
concentration of gardiquimod that induced TNF-α release was 10 µg/ml but the increase 






Figure 3.7. Effect of LPS, poly(I:C) and gardiquimod on TNF-α release. 
Macrophages were incubated without or with LPS, poly(I:C) or gardiquimod. After 22 
h, cell culture supernatants were harvested and assayed for TNF-α. Values are mean ± 
SEM for 4 individual experiments. (One-way ANOVA with Dunnett’s post test, 
*p<0.05, **p<0.01, compared with spontaneous release). 























Macrophages were challenged with the TLR1/2 agonist Pam3CSK4 (100 ng/ml) or LPS 
(10 ng/ml) for 22 h for comparison of the release of TNF-α. The Pam3CSK4-induced 
TNF-α was below the level of detection (figure 3.8A). To test whether a higher 
concentration of Pam3CSK4 was required to elicit a response, 200 ng/ml was used to 
challenge cells, alone or combined with LPS. Pam3CSK4 alone did not elicit release of 
TNF-α (figure 3.8B) and did not enhance LPS-induced TNF-α release. 
 
Macrophages were challenged with LPS (10 ng/ml), poly(I:C) (10 µg/ml) or 
gardiquimod (10 µg/ml) for 22 h. TNF-α, IL-6, IL-8 and IL-10 release from five 
corresponding cell preparations was measured. Poly(I:C) and gardiquimod challenge, in 
addition to LPS challenge, resulted in the release of all four cytokines (figure 3.9A-D). 
Overall, the levels of cytokine release induced by both poly(I:C) and gardiquimod were 
lower by comparison than those induced by LPS. However, there was some variation in 
the cytokine release by different cell preparations, in response to the different TLR 
agonists. In particular, a higher level of IL-8 release was detected from three of the cell 
preparations, in response to gardiquimod compared to LPS (figure 3.9C). The levels of 
IL-10 induced by all of three TLR agonists were considerably lower than the levels of 
the other cytokines measured. 
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Figure 3.8. Effect of the TLR 1/2 agonist Pam3CSK4 on TNF-α release.  
(A) Macrophages were incubated without or with LPS (10 ng/ml) or Pam3CSK4 (100 
ng/ml). After 22 h, cell culture supernatants were harvested and assayed for TNF-α. 
Values are mean ± SEM for 2 individual experiments. (B) Macrophages were incubated 
without or with Pam3CSK4 (200 ng/ml) combined with LPS (10 ng/ml). After 22 h, cell 








































Figure 3.9. Cytokine release upon challenge with TLR agonists.  
Macrophages were incubated without or with LPS (10 ng/ml), poly(I:C) (10 µg/ml) or 
gardiquimod (10 µg/ml). After 22 h, cell culture supernatants were harvested and 
assayed for (A) TNF-α, (B) IL-6, (C) IL-8 and (D) IL-10. Spontaneous cytokine release 
was below the level of detection except for IL-8, for which the values shown are net 
values. Coloured dots represent matched cell preparations. Solid horizontal lines 













































































































3.2.5. Proteome profiler array of lung macrophages in response to TLR agonists 
To determine if lung macrophages released a wider range of cytokines in addition to 
those already examined by ELISA, cell culture supernatants from macrophages (2 x105 
cells) that were challenged with LPS (10 ng/ml), poly(I:C) (10 µg/ml) or gardiquimod 
(10 µg/ml) for 22 h were diluted 1:3 with assay buffer (provided in the kit) and run on 
separate proteome profiler arrays, as were the corresponding control (spontaneous 
release) supernatants. The expression detected on the arrays is qualitative. Therefore, 
the supernatants tested on each of the arrays were also tested by ELISA for the 
cytokines routinely assayed in this project - TNF-α, IL-6 or IL-8. This provided an 
indication of the level of expression of at least one ‘known’ cytokine and provided a 
reference for the expression of the previously untested cytokines to be compared with. 
  
The array analysis of Human Lung Macrophages challenged with LPS (figure 3.10C, 
D) compared to its corresponding control array, showed that there was an increase from 
spontaneous expression in GROα (CXCL1) and IL-1ra (IL-1 receptor antagonist). There 
was not much change in expression of MIF (macrophage migration inhibitory factor) or 
serpin E1 (plasminogen activator inhibitor-1). Some cytokines that were not detected in 
the spontaneous sample were detected upon LPS challenge. These were complement 
protein C5/C5a, at a low level. IP-10 (IFN-γ induced protein 10/CXCL10), MCP-1 
(monocyte chemotactic protein 1/CCL2), MIP (macrophage inflammatory protein)-1α 
(CCL3) and MIP-1β (CCL4) were detected at higher levels. RANTES (regulated on 
activation normal T cell expressed and secreted/CCL5) and TNF-α were also detected 
upon LPS challenge. IL-8 expression after LPS challenge was detected on the array as 
being slightly lower than the spontaneous expression. This was a discrepancy between 




Figure 3.10. Proteome profiler array analysis of LPS-challenged macrophages. 
Potential expression of (A) 36 cytokines/chemokines was assessed in cell culture 
supernatants of human lung macrophages incubated without (B) or with (C) LPS (10 
ng/ml) for 22 h. (D) Quantification of the pixel intensity of the detected spots. (PC, 
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The array analysis of Human Lung Macrophages challenged with poly(I:C) (figure 
3.11C, D) showed an increase from the spontaneous level in expression of IL-1ra. The 
high expression of IL-8 was not altered after poly(I:C) challenge and there was also no 
change in expression of MIF and serpin E1, which both remained faintly expressed. The 
cytokines that were not detected in the corresponding spontaneous release sample but 
were detected upon poly(I:C) challenge were IP-10 and MCP-1. Also only expressed 
upon challenge were C5/C5a, GROα and IL-6, MIP-1α and RANTES, which were all 
faintly expressed. 
 
The array analysis of Human Lung Macrophages challenged with gardiquimod 
(figure 3.12C, D) showed an increase from the spontaneous level in expression of 
GROα, IL-1ra and MCP-1. There was no change in expression of MIF and serpin E1, 
which remained faintly expressed. The cytokines that were not detected in the 
corresponding spontaneous release sample but were detected upon gardiquimod 
challenge were C5/C5a, IL-6, MIP-1α, MIP-1β and TNF-α. IL-8 expression after 
gardiquimod challenge was detected on the array as being lower than the spontaneous 
expression but this was a discrepancy between the array and previous ELISA data. 
 
The key differences between LPS, poly(I:C) and gardiquimod challenge of human lung 
macrophages can be summarized. IP-10 and RANTES were detected after challenge 
with LPS and poly(I:C) but not gardiquimod. MIP-1β and TNF-α were detected after 




Figure 3.11. Proteome profiler array analysis of poly(I:C)-challenged 
macrophages. 
Potential expression of (A) 36 cytokines/chemokines was assessed in cell culture 
supernatants of human lung macrophages incubated without (B) or with (C) poly(I:C) 
(10 µg/ml) for 22 h. (D) Quantification of the pixel intensity of the detected spots. (PC, 

















































































































































Figure 3.12. Proteome profiler array analysis of gardiquimod-challenged 
macrophages. 
Potential expression of (A) 36 cytokines/chemokines was assessed in cell culture 
supernatants of human lung macrophages incubated without (B) or with (C) 
gardiquimod (10 µg/ml) for 22 h. (D) Quantification of the pixel intensity of the 
















































































































































The spontaneous release of cytokines/chemokines from human lung macrophages was 
assessed in 3 separate experiments (figures 3.10, 3.11, 3.12 B and D). In all three cell 
preparations, high release of IL-8 and some release of IL-1ra was detected. Low/faint 
expression of spontaneous MIF and serpin E1 was also detected in all three cell 
preparations. Some expression of GROα was detected in two of the three cell 
preparations (figures 3.10, 3.12 B and D). Expression of MCP-1 was detected in one 
cell preparation (figure 3.12 B and D) and faint expression of IL-6 was detected in one 
cell preparation (figure 3.10B and D). 
 
Several cytokines and chemokines were not detected in any of the supernatants. These 
were CD40L, G-CSF (granulocyte-colony stimulating factor), GM-CSF (granulocyte 
macrophage-colony stimulating factor), IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-10, 
IL-12p70, IL-13, IL-16, IL-17, IL-17E, IL-32α, SDF-1 (stromal cell-derived factor-1) 
and sTREM-1 (soluble triggering receptor expressed on myeloid cells-1). Although 
most of these cytokines/chemokines are not associated with macrophages, some are 
associated and it is possible that they were not present at a high enough concentration to 
be detected on the array. These are IL-1α, IL-1β, IL-10, IL-12p70 and IL-17. For some 
there is uncertainty as to whether they would be released by macrophages, such as IL-
16. 
 
3.2.6. Proteome profiler array of monocyte-derived macrophages in response to LPS 
The spontaneous release of cytokines/chemokines from monocyte-derived 
macrophages (MDMs) was assessed in one experiment (figure 3.13B and D) for 
comparison to that of HLMs. As with HLMs, high release of IL-8 was detected, as was 
some release of GROα and IL-1ra. The cytokines that were detected with MDMs but 
were not seen with HLMs were C5/C5a and IP-10. High release of MCP-1 was also 
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detected with MDMs but only seen with one HLM preparation out of three. Serpin E1 
was not seen with MDMs but was seen with HLMs. 
 
The array analysis of MDMs challenged with LPS (figure 3.13C, D) showed an 
increase from the spontaneous level in expression of IP-10. There was not much change 
in expression of C5/C5a, GROα, IL-1ra, IL-8 and MCP-1 (although the mean pixel 
intensity values appeared to indicate that expression of IL-1ra and MCP-1 decreased 
slightly after LPS challenge, this is not obvious on the actual array films). The cytokines 
that were not detected in the corresponding spontaneous release sample but were 
detected upon LPS challenge were IL-6, I-TAC (Interferon-inducible T cell alpha 
chemoattractant/CXCL11), MIP-1α, MIP-1β, RANTES and TNF-α. Faint expression of 
I-309 (CCL1) and MIF was also detected after LPS challenge. 
 
The cytokines that were expressed by MDMs after LPS challenge were the same ones 
as those expressed by human lung macrophages after LPS challenge, although there 
may have been some variation in the level of expression. The differences between LPS-
challenged MDMs and human lung macrophages were that faint expression of I-309 




Figure 3.13. Proteome profiler array analysis of LPS-challenged MDMs. 
Potential expression of (A) 36 cytokines/chemokines was assessed in cell culture 
supernatants of monocyte-derived macrophages (MDMs) incubated without (B) or with 
(C) LPS (10 ng/ml) for 22 h. (D) Quantification of the pixel intensity of the detected 
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3.2.7. The effect of long-term culture on response to LPS 
Experiments investigating cytokine release were routinely initiated the day after cell 
isolation (day one), when the cells had been in culture for ~24 h. To determine the 
effect of a longer time in culture, macrophages were challenged with LPS (10 ng/ml) on 
day one, two and five. TNF-α release was measured 22 h after each LPS challenge. The 
differences in the release after stimulation on day two or day five compared to the 
release after stimulation on day one were not significant (p>0.05) (figure 3.14). The cell 
viability post-experiment remained high (88-93%) for all of the conditions tested. 
 
3.2.8. Assessment of cytokine release in response to allergic stimuli 
Macrophages were challenged with anti-IgE (2 µg/ml) to simulate conditions of allergy 
or with LPS (10 ng/ml) for 22 h after which levels of cytokines were measured. In 
response to LPS, all five experiments resulted in release of TNF-α, IL-6 and IL-10 
(figure 3.15A). Only one of the five experiments carried out resulted in release of TNF-
α (11922 pg/ml), IL-6 (15264 pg/ml) and IL-10 (309 pg/ml) after challenge with anti-
IgE (figure 3.15B). These levels of release in response to anti-IgE were higher than the 
levels of each of the cytokines observed in response to LPS. All of the other 





Figure 3.14. Effect of long-term culture of macrophages on LPS response. 
Macrophages were cultured for 1, 2 or 5 days before incubation with or without LPS 
(10 ng/ml). Cell culture supernatants were harvested at 22 h and assayed for TNF-α. 
Values are mean ± SEM for 3 individual experiments. (One-way ANOVA with 
Dunnett’s post test, all p>0.05 compared with day 1). 






















Figure 3.15. Effect of anti-IgE on cytokine release. 
Macrophages were incubated without or with (A) LPS (10 ng/ml) or (B) anti-IgE (2 
µg/ml). After 22 h, cell culture supernatants were assayed for TNF-α, IL-6 and IL-8. 
Data shown are of 5 individual experiments. Spontaneous cytokine release was below 












































Release of IL-8 was also measured from cells challenged with anti-IgE using a further 
five different macrophage preparations. LPS challenge of these cell preparations 
resulted in IL-8 release in all five experiments (38,823±1729 pg/ml). However, there 
was no discernible increase in IL-8 after anti-IgE challenge (8425 ± 3136 pg/ml) 
compared to the level of the spontaneous release (8312 ± 3088 pg/ml). In addition, the 
cell preparation that resulted in release of TNF-α, IL-6 and IL-10 in response to anti-IgE 
was also tested for IL-8 release. This cell preparation was the only one that resulted in 
an increase in IL-8 after anti-IgE challenge compared to the spontaneous release. As for 
TNF-α, IL-6 and IL-10 release, the release of IL-8 release was higher after anti-IgE 
challenge than LPS challenge (data not shown). 
 
Two of the experiments in which macrophages were challenged with LPS or anti-IgE 
were also tested by ELISA for release of the Th2 cytokines IL-4 and IL-17a. One of 
these experiments was the one that resulted in release of TNF-α, IL-6 and IL-10 in 
response to anti-IgE. The release of IL-4 and IL-17a in both experiments was below the 
level of detection in response to both LPS and anti-IgE (data not shown). 
 
To further investigate IgE dependent responses, an experiment was carried out in which 
macrophages were passively sensitized with NIP-specific IgE (JW8-IgE) prior to 
challenge with anti-IgE (2 µg/ml) or antigen NIP20-HSA (100 ng/ml), as described in 
figure 2.1. The cell culture supernatants were assayed for TNF-α, IL-4 and IL-17a. The 
release of all three cytokines was below the level of detection for all of the samples 
(data not shown). 
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3.2.9. The effect of IL-4 pre-incubation on LPS-induced cytokine release 
To determine whether LPS-induced TNF-α release from macrophages could be 
modulated by pre-incubation with a Th2 cytokine, the cells were incubated with IL-4 
before challenging with LPS. The release of TNF-α in response to IL-4 alone was below 
the level of detection. Incubating the cells with IL-4 (10 ng/ml) for 24 h before 
challenging with LPS (10 ng/ml) for 24 h, resulted in a significant (p<0.05) 33% 
inhibition of the TNF-α release induced in cells challenged with LPS alone (figure 
3.16A). The release of IL-10 was also measured, which followed the same pattern as the 
release of TNF-α. Pre-incubation with IL-4 resulted in a significant (p<0.05) 26% 





Figure 3.16. Effect of IL-4 pre-incubation on LPS-induced cytokine release. 
Macrophages were incubated in the absence or presence of IL-4 (10 ng/ml) for 24 h and 
then without or with LPS (10 ng/ml) for a further 24 h. After a total of 48 h, cell culture 
supernatants were harvested and assayed for (A) TNF-α and (B) IL-10. Values are mean 
± SEM for 3 individual experiments. (Paired t test, *p< 0.05, for LPS challenge after 



















































3.2.10. Comparison of lung macrophage and MDM cell surface marker expression 
Flow cytometry was carried out to determine the CD14/CD206 cell surface marker 
profile of lung macrophages compared to that of MDMs. CD14 is considered to be a 
monocyte marker but can be expressed on macrophages. CD206 is a mannose receptor 
specific to macrophages but is regarded as being a marker of the M2 phenotype. It was 
found that most of the cells that were gated on the FSC/SSC plot (both MDMs and lung 
macrophages) were CD206+ (figure 3.17A, B). Analysis of lung macrophage staining 
showed that a very low percentage of cells were CD14+ (figure 3.17A). This was in 
contrast to the staining profile of MDMs, which showed considerable expression of 
CD14 (figure 3.17B). Most of the cells were CD14+CD206+. A corresponding cytospin 
of the human lung macrophage preparation that was analysed by flow cytometry 
showed 86% macrophage purity (figure 3.17C). As the flow cytometric analysis 
demonstrated that most of the cells in the preparation were CD206+, it could be assumed 
that all of the macrophages expressed CD206. These profiles were representative of 
three preparations for each cell type. The expression of CD14 on CD206+ lung 
macrophages and CD206+ MDMs was then determined for the three preparations of 
each cell type studied (figure 3.17D). The expression of CD14 was significantly higher 
on MDMs than lung macrophages. 
 
A major issue of flow cytometry studies using human lung macrophages is that the cells 
quite often exhibit autofluorescence, mainly due to particles taken up in the lungs of 
smokers. This autofluorescence can be severe, preventing detection of fluorochromes. 
This was the case for many of the cell preparations in the present study. It was 
necessary to exclude the results of experiments using these cell preparations from 
inclusion in this thesis, as they could not be fully analysed. Therefore, it is necessary to 
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use methods in addition to flow cytometry to investigate phenotypic marker expression 




Figure 3.17. Flow cytometric analysis of CD14 expression on macrophages.  
Unstimulated human lung macrophages (A) and monocyte-derived macrophages (B) 
were analysed for CD14 and CD206 expression by flow cytometry. Data are 
representative of a total of 3 individual experiments for each cell type. (C) Cytospin 
showing 86% purity of the human lung macrophage preparation analysed. (D) Graph of 
the geometric mean fluorescence intensity (MFI) of CD14 expressed on CD206+ human 
lung macrophages compared to CD206+ monocyte-derived macrophages (Unpaired t 
test, *p< 0.05). 
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3.2.11. Gene expression of M1 and M2 markers 
In addition to investigating cytokine release and cell surface markers to explore 
phenotypes, a preliminary experiment using qPCR was performed. Macrophages were 
incubated for 22 h without or with LPS, IFN-γ, TNF-α, IL-13, dexamethasone or PGE2 
either alone or in combination. These stimuli were considered to be either pro or anti-
inflammatory and in addition, some were considered to be M1 or M2-inducing. LPS, 
IFN-γ and TNF-α were the pro-inflammatory stimuli used. LPS and IFN-γ in 
combination are, in addition to being pro-inflammatory, considered to be M1-inducing. 
The anti-inflammatory stimuli used were IL-13 and dexamethasone, which are also 
considered to be M2-inducing. PGE2 was also used, which has been shown to be anti-
inflammatory to macrophages. Genes that could be expressed by either M1 or M2 
phenotypes were examined. The M2 genes examined were for IL-10, the scavenger 
receptor CD36, the arginine-converting enzyme arginase I and the mannose receptor C 
type 1 (MRC-1). The M1 genes examined were for IL-1β and inducible nitric oxide 
synthase (iNOS or NOS2 gene).  
 
One very clear association was found between pro-inflammatory M1 stimuli and M1 
marker expression. LPS caused a 54-fold and LPS+IFN-γ caused a 25-fold up-
regulation of IL-1β expression compared to the non-stimulated (media) control (figure 
3.18C). The M2 marker genes that were investigated were up-regulated to an extent by 
both M1 and M2 stimuli. CD36 expression was up-regulated two-fold in response to the 
M2 stimulus dexamethasone but also 1.7-fold in response to the M1 stimulus IFN-γ 
(figure 3.18B). MRC-1 expression was up-regulated in response to the M2 stimuli IL-13 
(66-fold) and dexamethasone (40-fold) (figure 3.18F). It was also up-regulated in 
response to the anti-inflammatory prostanoid PGE2 (seven-fold). However, up-
regulation of MRC-1 was also seen in response to M1 stimuli LPS (12-fold), IFN-γ (20-
 127 
fold), LPS+IFN-γ (two-fold), and TNF-α (five-fold). Up-regulation of IL-10 (figure 
3.18A), arginase (figure 3.18D) or NOS2 (figure 3.18E) expression was not seen in 
response to any of the stimuli, compared to the non-stimulated control. 
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Figure 3.18. Gene expression of M1 and M2 markers in response to various 
stimuli. Macrophages (1 x 106) were incubated without or with LPS, IFN-γ, IFNγ+LPS, 
TNF-α, IL-13 (all 10 ng/ml), dexamethasone (Dex) (10-7 M) or PGE2 (10-6 M) for 22 h. 
Isolated RNA was converted to cDNA in the presence (+) or absence (−) of reverse 
transcriptase. Amplification of cDNA was carried out using IL-10, CD36, IL-1β, 
Arginase, NOS2 and MRC-1 specific primers. Expression levels for each gene were 
normalised to the housekeeping gene β-actin. Data shown are of 1 macrophage 




































































































































































































Methods were developed to isolate macrophages from human lung tissue. The level of 
macrophage purity of the resulting cell preparations was high and the cells exhibited 
good viability. Studies were then carried out to investigate the functional responses to 
relevant stimuli and the phenotype of the isolated macrophages. Analysis of cytokine 
production and marker expression, along with selective comparisons to MDMs enabled 
this.  
 
The release of key cytokines associated with macrophages was investigated in response 
to activation by the TLR4 agonist LPS. The release of the pro-inflammatory cytokines 
TNF-α, IL-6 and IL-8 was much higher than the release of anti-inflammatory IL-10. 
This is consistent with macrophages responding to pathogen-associated molecular 
patterns (PAMPs) with an inflammatory response (Taylor et al., 2005, Zhang and 
Mosser, 2008, Kaisho and Akira, 2006). The release of IL-8 was particularly high, both 
spontaneously and upon LPS challenge. Initial concerns that this was a result of 
endotoxin contamination in FCS were quashed by demonstrating that using ultra low 
endotoxin FCS or a lower percentage of FCS in the cell culture medium did not result in 
a significant decrease in IL-8 release, compared to release from cells cultured in the 
presence of the FCS that was routinely used. Other studies have also reported high 
release of IL-8 from lung macrophages (Thorley et al., 2007). As IL-8 is a powerful 
neutrophil chemoattractant, the data imply that the macrophages could play an active 
role in vivo in the recruitment of neutrophils in the lung. Neutrophilic inflammation is 
characteristic of COPD and higher numbers of neutrophils are found in the sputum of 




The release of TNF-α in response to LPS was concentration-dependent. However, at the 
highest concentration of LPS tested, a decrease in TNF-α was seen, indicating that the 
maximal release of TNF-α was with a concentration of LPS of ~10 ng/ml. The decrease 
in TNF-α seen at the higher concentration of LPS could be due to a number of reasons. 
Cytokine signalling can be both autocrine and paracrine (Kaisho and Akira, 2006). 
Release of one cytokine can lead to stimulation or inhibition of another. The higher 
strength of stimulus could have caused a more rapid concomitant release of other 
cytokines than stimulation with the lower LPS concentrations. These cytokines could 
have then resulted in the inhibition of TNF-α. It is possible for loss of cells, for example 
due to cell death during experiments, to result in a decrease in the cytokine levels 
detected. Variations in cell number between the wells containing the different 
concentrations of LPS were not measured at the end of the experiments. However, the 
viability was found to be unaltered from pre-experiment levels for all of the 
experimental conditions. 
 
Observation of the release of pro-inflammatory cytokines over a time course revealed 
that overall there was a marked increase in release from five hours onwards, indicating 
that stimulation with LPS had resulted in initiation of protein synthesis taking place. 
The maximal release of cytokines was reached between 16 and 22 h, except for IL-8, 
which continued to increase at 22 h. This could have implications for the role of 
macrophages in relation to lack of resolution of inflammation in lung diseases. 
 
In addition to bacterial proteins, macrophages in vivo can mount an inflammatory 
response to viral pathogens by activation of TLRs (Malmgaard et al., 2004). Therefore 
it was important to investigate the response to viral mimics. Macrophages responded to 
the TLR3 agonist poly(I:C) and the TLR7 agonist gardiquimod. Both agonists induced 
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the release of the pro-inflammatory cytokines IL-8, IL-6 and TNF-α but only low levels 
of IL-10, similar to the situation with LPS.  
 
In further studies, the wider release of cytokines was investigated using proteome 
profiler array. In response to LPS, poly(I:C) or gardiquimod challenge, the cytokines 
and chemokines released from lung macrophages were all consistent with immune 
activation. Altogether, in addition to IL-8, IL-6 and TNF-α, these were complement 
protein C5/C5a, IP-10 (CXCL10), MIF, MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β 
(CCL4), RANTES (CCL5), GROα (CXCL1), serpin E1 and IL-1ra.  
 
There were some differences between the cytokines released in response to each of the 
three stimuli and the reasons for these can be speculated. IP-10 and RANTES were 
detected upon challenge with LPS and poly(I:C) but not with gardiquimod. TLR 
signalling requires adaptor proteins, one of which is myeloid differentiation protein 88 
(MyD88). Gardiquimod exerts its effects through signalling through a MyD88-
dependent pathway, in contrast to LPS and poly(I:C) which can signal through MyD88-
independent pathways (Bjorkbacka et al., 2004, Lundberg et al., 2007, Kaisho and 
Akira, 2006). The MyD88 pathway leads to transcription of type I interferons 
(Buitendijk et al., 2013) and does not induce transcription of IFN-γ, which is a type II 
interferon. This could explain the absence of IP-10 (Fitzgerald et al., 2003). RANTES 
was perhaps not seen in response to gardiquimod as production of RANTES is MyD88 
independent (Fitzgerald et al., 2003). In response to poly(I:C) challenge, TNF-α was not 
detected on the proteome profiler array, despite being routinely detected in ELISAs 
throughout the study. The reason for this is not clear but it could be a result of cell 
preparation variation, where the cell preparation tested was one that did not respond 
strongly to the challenge, releasing TNF-α at a level too low to be detected by the array. 
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This could also be an explanation for the lack of detection of MIP-1β after poly(I:C) 
challenge. 
 
Comparison of lung macrophages and MDMs without and with LPS challenge using 
proteome profiler array revealed that overall the cytokines released by the two cell types 
were the same. One difference was that serpin E1 (plasminogen activator inhibitor-1) 
was expressed by lung macrophages but not MDMs. As plasminogen activator is 
involved in blood clot fibrinolysis, serpin E1 could be involved in fibrosis (Liu, 2008, 
Wynn, 2011). Although roles in fibrosis are outside the scope of this study, this is of 
interest as it indicates that macrophages from the lung have some features that are not 
seen in the in vitro differentiated MDMs. There were subtle differences between the 
arrays. Faint expression of I-309 (CCL1), which is secreted by activated T lymphocytes 
was seen with MDMs but not lung macrophages. Faint expression of I-TAC (CXCL11), 
which is induced by interferons and is chemotactic for activated T lymphocytes (Barnes, 
2008a), was also detected with MDMs but not lung macrophages. This indicates that 
there may have been contaminating lymphocytes in the MDM culture that were 
producing IFN-γ, rather than a difference between MDMs and lung macrophages 
themselves. The presence of lymphocytes is feasible as column purification of the 
PBMCs isolated from blood was not carried out, only purification by plastic adherence 
to the wells. This provides further reassurance of the reliability of the isolation 
procedure used to obtain lung macrophages, as any possible lymphocyte contamination 
of the lung macrophage preparations was not sufficient to result in detection of 
lymphocyte-associated factors. 
 
It is interesting to note that for both macrophages and MDMs, some spontaneous release 
of cytokines and chemokines was detected, which then either remained at similar levels 
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or increased upon challenge with the TLR agonists. This indicates that prior to 
challenge, the lung macrophages did not exhibit any obvious marked indication of 
having been activated in the lung before isolation, as their cytokine generation appeared 
to be comparable to that of MDMs at rest. Whether the cytokine response after 
stimulation is more marked for lung macrophages or MDMs is difficult to determine 
from the proteome profiler array.  
  
Some caution needs to be exercised in interpretation of the data from the proteome 
profiler arrays. The profiler arrays can only be used for semi-quantitative analysis, as 
the limits of cytokine detection are unknown. It is possible that some cytokines were not 
detected due to donor variation, for example TNF-α was not detected in response to 
poly(I:C), as mentioned earlier, although comprehensive ELISA data showed that it is 
usually released. IL-10, which is detected at low levels by ELISA was not detected at all 
on the array, probably as the signal was too weak. Another discrepancy between the 
array and ELISA data was that IL-8 appeared to decrease after LPS challenge on the 
array. This is likely to be due to the high levels of IL-8 generated being over the 
maximum detection limit of the array, leading to inaccurate pixel intensities. Caution 
also needs to be taken when comparing the different arrays, as different 
experiments/cell preparations were used for each one, therefore the quantitative pixel 
intensity levels of different arrays cannot be compared, only qualitiative expression. 
Therefore, it would be of benefit to investigate some of the wider cytokines released 
from macrophages that were identified on the arrays, by ELISA, such as MCP-1, MIP-
1α, MIP-1β and RANTES.  
 
In addition to being implicated in COPD, macrophages could have an important role in 
asthma (Sutherland and Martin, 2003). It has been demonstrated that macrophages 
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express high affinity and low affinity IgE receptors, known as FcεRI and FcεRII 
(CD23) respectively. It has been reported that the activation of the low affinity receptor 
results in release of pro- and anti-inflammatory cytokines (Gosset et al., 1999). 
Therefore, IgE-dependent responses were investigated to determine the possible 
involvement of macrophages in asthma. Only one cell preparation responded to anti-IgE 
with the extensive release of pro-inflammatory TNF-α, IL-6, IL-8 and anti-
inflammatory IL-10. By contrast, all of the cell preparations responded to LPS with the 
release of these cytokines. As the asthmatic lung has generally been considered to be a 
Th2 environment, release of Th2 cytokines other than IL-10 was investigated (Barnes, 
2008a). There was no release of IL-4 in response to anti-IgE or LPS. There was also no 
release of IL-17a, which has only over the last few years been reported to be a cytokine 
released from macrophages in allergic inflammation and not only from Th17 cells 
(Song et al., 2008). Passive sensitization of the cells with IgE specific for a particular 
antigen and subsequent challenge with the antigen did not elicit release of cytokines. 
This indicates that the isolated macrophages on the whole do not undergo IgE-
dependent activation leading to the release of either the pro-inflammatory or anti-
inflammatory cytokines measured in this study. 
 
The lack of response from all but one cell preparation implies that donor variation could 
have been an issue. It has been reported that a greater percentage of macrophages from 
atopic asthmatics express IgE receptors than control subjects (Rankin, 1989, Williams et 
al., 1992). It may be that cells from patients with asthma respond better to IgE challenge 
to release pro-inflammatory cytokines (Gosset et al., 1999). However, the cell 
preparation that responded to anti-IgE with the release of pro-inflammatory cytokines in 
this study was not believed to be from an asthmatic patient. It is also possible that 
investigation of a larger number of cell preparations may have revealed more 
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‘responders’. In a human lung mast cell study that used the same allergic stimulus and a 
similar experimental design, most of the cell preparations responded to IgE activation. 
However, the study also demonstrated that 1 in 7 cell preparations do not respond to 
anti-IgE (Havard et al., 2011). Due to the lack of response of lung macrophages to IgE-
dependent activation in the majority of experiments, further investigations into this 
process were not pursued in this study. 
 
Macrophages are believed to exhibit plasticity (Giorgio, 2013, Mosser and Edwards, 
2008). The phenotype is believed to be transient and able to switch upon changes in the 
local environment. Some preliminary experiments were performed to determine 
whether this may be the case in this system. The high release of pro-inflammatory 
cytokines observed upon stimulation with LPS indicated that the phenotype of the 
isolated macrophages could be closer to M1 than to M2. It has been reported that IL-4 
or IL-13 stimulation can result in an M1 phenotype changing to M2. The TNF-α 
response to LPS was dampened with IL-4. It was thought that this was possibly due to 
an alteration in phenotype. Investigation into whether anti-inflammatory IL-10 was 
simultaneously increased with IL-4 pre-incubation was negative and furthermore, IL-10 
was actually decreased. Therefore, this very preliminary investigation into plasticity 
was inconclusive but there is potential for further investigation.   
 
Comparison of expression of cell surface markers by flow cytometry showed that both 
lung macrophage and MDM preparations expressed CD206 on most cells. MDMs 
expressed both CD206 and CD14, on an almost equal percentage of cells, producing a 
double-stained profile of expression. By contrast, the CD14 expression on lung 
macrophages was very low. CD206 is generally regarded as being an M2 phenotype 
marker. However, more recently it has been suggested that CD206 is not exclusively 
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present on M2 cells. In a study investigating macrophage polarization, MDMs incubated 
with the M2 stimulus IL-4 resulted in up-regulation of CD206 but greater up-regulation 
was seen upon stimulation with GM-CSF, which is believed to induce an M1 phenotype 
(Ambarus et al., 2012). Therefore, in the present study, taking into account the high 
macrophage purity of the cell preparations as demonstrated by cytospins, the data 
suggest that all macrophages express CD206 to an extent. Therefore all of the cells 
expressing CD206 in the flow cytometry experiments in this study were regarded as 
being macrophages potentially of either M1 or M2 phenotype. To distinguish between 
M1 and M2 macrophages, it would be necessary to compare the levels of M1 and M2 
markers present simultaneously. The CD206 expression of M2 cells could be expected 
to be high whilst the expression of an M1 marker on the same cells could be expected to 
be low. For M1 cells, the opposite would be the case. 
 
The expression of CD14, which is predominantly a monocyte marker, is expected to be 
down-regulated during differentiation to a mature phenotype (Daigneault et al., 2010). 
MDMs at 12 days of differentiation have possibly not reached the maturity status of 
lung macrophages, as they still retain considerable CD14 expression. The preliminary 
data indicate that the CD14/CD206 expression profile of lung macrophages and MDMs 
is different. This suggests that it is difficult to make direct comparisons between MDM 
and macrophage experiment results based on surface marker expression. Markers other 
than CD14 would be used for determination of an M1 phenotype, although CD14 would 
still be used as part of flow cytometry gating strategies. Suggestions based on other 
flow cytometry studies are CD40 (Chana et al., 2014, Vogel et al., 2014) and CD80 
(Ambarus et al., 2012). A suggested M2 surface marker in addition to CD206 is CD163 
(Ambarus et al., 2012, Chana et al., 2014, Vogel et al., 2014). However, caution needs 
to be exercised as some of these studies were performed using MDMs, not lung 
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macrophages. Also, macrophages in disease conditions can have altered cell surface 
marker expression. It has been reported that lung macrophages from COPD patients 
show reduced expression of both M1 and M2 surface markers (Chana et al., 2014, Pons 
et al., 2005).  
 
Despite the CD14 expression on lung macrophages being low, this did not affect the 
consistent marked response to LPS seen in functional studies. It has been reported that 
LPS binding is not always related to the level of CD14, which could explain this 
(Haugen et al., 1998). In this current study, TLR2 surface marker expression was not 
investigated but no response to Pam3CSK4 was seen from lung macrophages. A recent 
study reported that MDMs had down-regulated surface expression of CD14 and TLR2 
compared to monocytes. The cytokine response of the MDMs to Pam3CSK4 
stimulation was more marked than to LPS stimulation (Daigneault et al., 2010). In 
another study, in which TLR2 was also down-regulated on MDMs and on alveolar 
macrophages compared to monocytes, the production of cytokines in response to the 
TLR2 agonist was lower compared to monocytes (Juarez et al., 2010). These studies 
indicate that surface expression of CD14 and TLR2 is down-regulated as cells undergo 
differentiation. However, there can be differences in functional responses to TLR 
agonists between different macrophage models, particularly as MDMs are often 
differentiated from monocytes using different methods. 
 
As it is important to utilize more than one approach to investigate macrophage 
phenotypes, a preliminary qPCR experiment was carried out using a panel of primers 
for markers that can be regarded as being indicative of the M1 and M2 phenotypes. The 
combination of LPS+IFN-γ is reported to induce an M1 phenotype (Mosser, 2003). 
Originally, it was believed that IFN-γ was required to prime the cells and the LPS was 
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believed to cause induction of TNF-α, the second signal required. LPS alone was not 
considered to be M1-inducing. However it has since been suggested that LPS 
stimulation alone can induce TNF-α and also IFN-β, which can replace IFN-γ (Mosser 
and Edwards, 2008). In this experiment, expression of IL-1β was investigated. IL-1β 
was not detected by ELISAs in this study, as a two-step stimulation with a TLR agonist 
and adenosine triphosphate (ATP) is required for the release of IL-1β from 
macrophages (Netea et al., 2009). However, this two-step stimulation is not required for 
induction of IL-1β mRNA. In this experiment, IL-1β gene expression increased greatly 
in response to LPS+IFN-γ suggesting that the M1 phenotype was induced by the action 
of the stimuli. However, LPS alone up-regulated IL-1β expression to a greater level 
than LPS+IFN-γ. It is possible that LPS alone was stimulating macrophages that were 
M1 at baseline and already primed, resulting in the greater IL-1β expression seen 
compared to that with LPS+IFN-γ, or that LPS alone was inducing TNF-α and IFN-β. 
 
Up-regulation of NOS2 was not seen in response to any of the stimuli in this 
experiment. There was a very slight increase above the level of the control in response 
to LPS+IFN-γ stimulation. The mRNA expression of NOS2 has been demonstrated in 
murine macrophages in response to M1 stimuli (Edwards et al., 2006). However, there 
is controversy in the literature regarding the expression of iNOS in human macrophages 
(Schneemann and Schoeden, 2007). Studies carried out in MDMs have shown no iNOS 
enzyme expression and activity (Schneemann et al., 1997) or none comparable to that 
seen in murine macrophages (Murray and Wynn, 2011b). A study using MDMs showed 
that the NOS2 gene was expressed in response to infection with mycobacterium (Jung et 
al., 2013). Another study using MDMs showed that iNOS protein expression was up-
regulated in response to pneumococcal infection (Marriott et al., 2004). It appears that 
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expression of the NOS2 gene and protein is seen in human macrophages in response to 
certain conditions. 
 
The expression of the M2 markers investigated was found to be up-regulated by both 
M2 and M1 stimuli. It is likely that the markers examined were not specific for the M2 
phenotype. Alternatively, again, it is possible that the cells were M1 at baseline and not 
completely converting to an M2 phenotype. However, the different levels of up-
regulation of markers seen in response to M1 and M2 stimuli could still assist in 
determining phenotype. An example in the present qPCR experiment is that greater up-
regulation was seen of M2 markers than M1 markers by M2 stimuli, for example, 
MRC-1 expression in response to IL-13. Other gene expression markers that may be 
considered to be more reliable for determining the M2 phenotype are CD163 in 
response to IL-10 and CD206 in response to IL-4 (Ambarus et al., 2012, Vogel et al., 
2014). Recent investigations have led to suggestions for other markers that may be 
suitable for determining M2 phenotypes, for example, CD200R upregulation in 
response to IL-4, although this was determined using MDMs and not lung macrophages 
(Ambarus et al., 2012, Hussell and Bell, 2014). Another suggestion is CD16 expression 
in response to IL-10 (Ambarus et al., 2012).  
 
Arginase I and IL-10 were not up-regulated in the present experiment. Arginase I 
converts L-arginine to ornithine rather than nitric oxide (Chang et al., 1998). Arginase I 
is generally considered to be a murine M2 macrophage marker (Murray and Wynn, 
2011b, Edwards et al., 2006, Martinez et al., 2009) but there are conflicting data 
demonstrating that expression can be induced by both M1 and M2 stimuli (Menzies et 
al., 2010). Although it has been reported that arginase can be expressed in human 
alveolar macrophages, for example in response to IL-4 in combination with cAMP-
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increasing agents (Erdely et al., 2006), the majority of reports state that arginase is not 
expressed in human macrophages (Murray and Wynn, 2011a) but is expressed 
constitutively in human neutrophils (Munder et al., 2005). The lack of IL-10 expression 
observed in the experiment supports the results of the ELISAs performed throughout 
this study, in which very little IL-10 release was seen in response to both pro and anti-
inflammatory stimuli.  
 
Overall, the results of the qPCR experiment indicate that the isolated lung macrophages 
are likely to have an M1 or M1-like phenotype at baseline, which can be enhanced upon 
stimulation with M1 stimuli and altered, to an extent, towards an M2 phenotype upon 
stimulation with M2 stimuli. There are limitations to drawing definitive conclusions 
regarding the phenotype of the cells from the results obtained here. Only one 
experiment was performed, using one macrophage preparation. Only one concentration 
of each of the stimuli was used and the gene expression was only measured after 24 h 
stimulation of the cells. It would be interesting to investigate the gene expression at 
other time points. The results of the experiment indicate that further studies using this 
technique would be useful, in combination with other approaches used in this study.  
 
The preliminary characterization of isolated lung macrophages demonstrates that the 
cells are active and respond to various stimuli to release a variety of cytokines and 
chemokines. The high release of pro-inflammatory cytokines compared to anti-
inflammatory cytokines indicates that the cells are likely to have predominantly an M1 
(classically activated) or M1-like phenotype upon stimulation with TLR agonists. 
Although the phenotype pre-stimulation is difficult to determine, particularly as 
phenotype is believed to be transient, the evidence suggests that it is closer to M1 than 
M2. For example, stimulation with IL-4 before LPS results in a decrease in pro-
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inflammatory TNF-α but not an increase in anti-inflammatory IL-10, which could imply 
that the initial phenotype was perhaps M1 and not completely switching to M2. Lung 
macrophages are fully differentiated compared to MDMs and although major 
differences were not seen between the functional responses compared between the two 
models in this study, wider investigations could reveal different results in experiments. 
These preliminary studies provide the foundation for further study of the function and 
phenotype of lung macrophages in the context of inflammation. 
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Chapter 4: Characterization of the EP receptor that mediates 




PGE2 is known to have wide-ranging effects on a variety of tissues. These effects of 
PGE2 are most likely to be mediated through specific EP receptors, of which four have 
been identified (Woodward et al., 2011, Coleman et al., 1994, Breyer et al., 2001). EP 
receptors are G protein-coupled receptors. EP1 receptors appear to be coupled to 
phospholipase C, EP2 and EP4 receptors are linked to activation of adenylyl cyclase 
leading to increases in cellular cyclic-AMP and EP3 receptors have variously been 
linked to adenylyl cyclase and phospholipase C (Breyer et al., 2001, Coleman et al., 
1994, Woodward et al., 2011, Irie et al., 1993, An et al., 1994). Agonists and 
antagonists at these receptors have been described although developing selective and 
potent ligands has proved difficult (Abramovitz et al., 2000, Wilson et al., 2004, Jones 
et al., 2009). 
 
The suggestion has been made that targeting EP receptors may be of benefit in the 
treatment of respiratory diseases. This stems from the finding that PGE2 causes 
bronchodilation (Kawakami et al., 1973, Melillo et al., 1994, Gauvreau et al., 1999). An 
undesirable effect of PGE2 is that it also induces cough (Maher et al., 2011). It appears, 
however, that cough and bronchodilation are mediated by different receptors suggesting 
that selective targeting of the beneficial receptor might be possible. The EP3 receptor 
has been linked to cough (Maher et al., 2011) whereas the EP2 receptor has been linked 
to bronchodilation (Norel et al., 1999). More recent studies suggest that EP4 receptors 
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are more likely to be responsible for bronchodilation (Buckley et al., 2011, Benyahia et 
al., 2012). 
 
In addition to effects on airway smooth muscle, PGE2 may also be anti-inflammatory in 
the lung (Vancheri et al., 2004). The activity of a number of respiratory cells may be 
affected by PGE2.  In this context, PGE2 has been shown to inhibit pro-inflammatory 
cytokine release from lung macrophages (Rowe et al., 1997, Buenestado et al., 2012, 
Ratcliffe et al., 2007). This effect of PGE2 on human lung macrophages has been 
reported to be mediated by EP2 and EP4 receptors (Ratcliffe et al., 2007). However, this 
conclusion was drawn at a time when the availability of selective pharmacological 
ligands at especially the EP2 receptor was limited.   
 
In the present study, a range of pharmacological ligands was utilized to investigate the 
effects of PGE2 on cytokine generation from LPS-stimulated human lung macrophages. 
A range of EP2-selective and EP4-selective antagonists that have emerged only recently 
was studied, including PF-04418948, the first potent and selective EP2 receptor 
antagonist reported (af Forselles et al., 2011). These compounds enabled re-evaluation 




4.2.1. Effects of PGE2 on cytokine generation 
In agreement with previous studies, PGE2 was found to inhibit LPS-induced TNF-α 
generation from human lung macrophages in a concentration-dependent manner. 
Macrophages were incubated with PGE2 (10-5-10-11 M) for 30 min before being 
challenged with LPS (1 ng/ml) for 22 h. This experiment was carried out in the absence 
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(figure 4.1A) and presence (figure 4.1B) of the cyclooxygenase (COX) inhibitor 
indomethacin (1 µM). PGE2 was a more potent (EC50; 3.2 ± 0.6 cf 10.8 ± 2.0 nM) and 
efficacious (Emax; 77 ± 1.8 cf 53.5 ± 2.0 % inhibition) inhibitor of LPS-induced TNF-α 
generation in the presence of indomethacin (figure 4.1C). Moreover, in the presence of 
indomethacin (1 µM), TNF-α generation induced by LPS was significantly (p<0.01) 
higher than in its absence (2657 ± 496 cf 1648 ±213 pg/ml; n=13). These experiments 
suggested that macrophages, in response to LPS, produce PGE2 which acts in a 
paracrine fashion to limit TNF-α generation. Further experiments confirmed that 
macrophages generate a small amount of PGE2 spontaneously and larger quantities 
following challenge with LPS (data shown in Chapter 5). In order to eliminate the 
potentially confounding influence of endogenous PGE2 generation in the context of 
receptor characterizations, in all subsequent functional studies, indomethacin was also 
included.  
 
In further studies, the effects of PGE2 on LPS-induced IL-6 and IL-8 as well as TNF-α 
generation were determined (figure 4.2). PGE2 inhibited TNF-α and IL-6 generation 
with similar potency (EC50; ~1.6 nM) but was less efficacious as an inhibitor of IL-6 
generation than of TNF-α. By contrast, PGE2 was ineffective as an inhibitor of IL-8 
generation. 
 145 
              
Figure 4.1. Effects of PGE2 on TNF-α generation from macrophages.  
Macrophages were pre-incubated without (A) or with (B) indomethacin (1 µM) for 30 
min and then with or without PGE2 for 30 min before challenge with LPS (1 ng/ml) for 
22 h, after which supernatants were harvested and assayed for TNF-α generation. The 
data in (A) and (B) were reworked as % inhibition of the control unblocked release of 
TNF-α and this is shown in (C). Values are mean ± SEM, for 9 individual experiments. 
(One-way ANOVA with Dunnett’s post test, *p<0.05, compared with unblocked 
control levels). 

























































       
 
 
Figure 4.2. Effects of PGE2 on cytokine generation from macrophages.  
Macrophages were pre-incubated (30 min) with indomethacin (1 µM) and then with or 
without PGE2 for 30 min before challenge with LPS (1 ng/ml) for 22 h, after which 
TNF-α, IL-6 and IL-8 were measured in the supernatants. Values are expressed as the % 
inhibition of control cytokine releases which were 2422 ± 510 pg/ml of TNF-α, 4992 ± 























4.2.2. Effects of prostanoids on LPS induced TNF-α generation 
A comparison was made between the effects of PGE2 and the effects of other 
prostanoids on LPS-induced TNF-α generation. The other prostanoids tested were 
prostaglandin D2 (PGD2), prostaglandin F2α (PGF2α), the prostaglandin H2 analogue 
U46619 and the prostaglandin I2 analogue iloprost. Macrophages were incubated for 30 
min with indomethacin (1 µM) and for a further 30 min with the prostanoids (all 10-6-
10-8 M) before challenge with LPS (1 ng/ml) for 22 h. No effect on LPS-induced TNF-α 
generation was seen with PGD2 and U46619 (figure 4.3A and 4.3C). Slight 
concentration-dependent inhibitions of TNF-α were observed with PGF2α and iloprost 
(figure 4.3B and 4.3D) but these were not significant (p>0.05). Only PGE2 significantly 
(p<0.05) inhibited LPS-induced TNF-α generation, in a concentration-dependent 
manner (figure 4.3E). 
 
4.2.3. EP receptor expression in lung macrophages  
RT-PCR was used to determine the expression of EP receptors by human lung 
macrophages. The data indicate that human lung macrophages express message for EP2 
and EP4 receptors but do not express message for EP1 or EP3 receptors (figure 4.4). 
Densitometric analysis showed that the expression of EP2 receptors remained consistent 
between cell preparations, relative to β-actin but there was some variability between cell 
preparations in the expression of EP4 receptors. The expression of EP2 and EP4 
receptors was further investigated after stimulation of the macrophages for 22 h with 
LPS (10 ng/ml). Up-regulation of both receptors was seen in response to LPS. A two-
fold up-regulation of the expression of EP2 receptors was seen in both cell preparations 




Figure 4.3. Effects of prostanoids on TNF-α generation from macrophages. 
Macrophages were pre-incubated (30 min) with indomethacin (1 µM) and then with or 
without (A) PGD2, (B) PGF2α, (C) U46619, (D) Iloprost or (E) PGE2 for 30 min before 
challenge with LPS (1 ng/ml). After 22 h, TNF-α was measured in the supernatants. 
Values are mean ± SEM for 3 individual experiments. (One-way ANOVA with 
Dunnett’s post test, *p<0.05, compared with LPS alone). 































































































Figure 4.4. EP receptor expression in macrophages.   
Isolated RNA was converted to cDNA in the presence (+) or absence (-) of reverse 
transcriptase. Amplification of cDNA was performed using primers specific for each of 
the EP receptor subtypes and β-actin. Expression profiles for three macrophage 
preparations (MAC1, MAC2 and MAC3) are shown. These findings are representative 
of a total of 4 different macrophage preparations in excess of 95% purity. Lanes at 
either end of each gel represent a 100 bp ladder. 
 +    -    +    -    +    -  











Figure 4.5. Effect of LPS on EP receptor expression in macrophages.  
Macrophages were incubated without or with LPS (10 ng/ml) for 22 h. Isolated RNA 
was converted to cDNA in the presence (+) or absence (-) of reverse transcriptase. 
Amplification of cDNA was performed using primers specific for each of the EP 
receptor subtypes and β-actin. Expression profiles for two macrophage preparations 
(MAC1 and MAC2) are shown. These findings are representative of a total of 2 
different macrophage preparations in excess of 95% purity. Lanes at either end of each 








+   − +   − +   − +   − 
Control LPS Control LPS 
MAC1 MAC2 
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4.2.4. Effects of PGE2 on cyclic-AMP 
Since EP2 and EP4 receptors are G-protein receptors coupled to adenylyl cyclase, it was 
investigated whether exposure (30 min) of macrophages to PGE2 (1 µM) induced 
increases in total cell cyclic-AMP. The data demonstrated that PGE2 induced 
statistically significant (p<0.05) increases in total cell cyclic-AMP levels over basal 
(figure 4.6). Further studies demonstrated that PGE2 maintained these increased cyclic-
AMP levels in macrophages for up to 5 hours (data not shown). 
 
4.2.5. Effects of EP agonists on cytokine generation 
The effects of alternative EP agonists on macrophage function were explored.  The 
effects of misoprostol (non-selective), butaprost (EP2-selective) and L-902,688 (EP4-
selective) on LPS-induced TNF-α generation from macrophages were investigated. 
Macrophages were incubated with the agonists (all 10-5-10-11 M) for 30 min before 
being challenged with LPS (1 ng/ml) for 22 h. The data show that misoprostol (figure 
4.7A) was about 25-fold less potent than PGE2 as an inhibitor of TNF-α generation 
(table 4.1). The EP4 agonist, L-902,688 (figure 4.7B), was six-fold more potent than 
PGE2 as an inhibitor of TNF-α generation whereas, by contrast, the EP2-selective 
agonist, butaprost (figure 4.7C), was about 300-fold less potent than PGE2 in this 
system (table 4.1). In further studies, the effects of an alternative EP2-selective agonist, 
ONO-AE1-259, were determined (figure 4.7D) and ONO-AE1-259 was about 60-fold 
less potent than PGE2 (table 4.1). 
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Figure 4.6. Effects of PGE2 on cyclic-AMP.  
Macrophages were pre-incubated (30 min) with or without indomethacin (indo; 1 µM) 
and then with or without PGE2 (1 µM) for a further 30 min. After this treatment, the 
cells were solubilised and total cell cyclic-AMP levels measured. Values are mean ± 
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Figure 4.7.  Effects of EP agonists on macrophages.  
Macrophages were pre-incubated (30 min) with indomethacin (1 µM) and then with or 
without either (A) misoprostol, (B) L-902,688, (C) butaprost (D) ONO-AE1-259 or 
PGE2 before challenge with LPS (1 ng/ml) for 22 h, after which TNF-α was measured 
in the supernatants. Values are expressed as the % inhibition of control cytokine 
releases which were (A, B, C) 1390 ± 505 pg/ml and (D) 2198 ± 1326 pg/ml, of TNF-α. 
Values are mean ± SEM for 4 (A, C, D) or 5 (B) individual experiments.  



































































Table 4.1. EC50 and Emax values for the inhibition of TNF-α generation by EP 
agonists. 
Agonist    EC50 (nM)   Emax (%) 
PGE2     1.8 ± 0.8   79 ± 3 
misoprostol    46 ± 11   82 ± 5 
L-902,688    0.3 ± 0.1   63 ± 7 
butaprost    501 ± 262   67 ± 7 
ONO-AE1-259   102 ± 18   41 ± 4 
 
Table 4.1 shows the EC50 and Emax values for the inhibition of TNFα generation by EP 
agonists, calculated from the data shown in figure 4.7. Values are means ± SEM from 4 
to 7 experiments. 
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4.2.6. Effects of EP antagonists on PGE2 inhibition  
The effects of the antagonists PF-04418948 (EP2-selective) and CJ-042794 (EP4-
selective) were investigated (af Forselles et al., 2011, Murase et al., 2008) on the PGE2 
inhibition of LPS-induced TNF-α generation. Macrophages were incubated for 1 h with 
either PF-04418948 (300 nM) or CJ-042794 (300 nM) before incubation with PGE2 for 
30 min and then challenged with LPS (1 ng/ml) for 22 h. CJ-042794 effectively 
antagonized the PGE2 inhibition of TNF-α generation (figure 4.8A).  No antagonism of 
the PGE2 inhibition was seen with PF-04418948 (figure 4.8B).   
 
An alternative EP4-selective antagonist, L-161,982 (Machwate et al., 2001), was also 
studied and in keeping with data obtained with CJ-042794, L-161,982 (300 nM) was 
found to be effective as an antagonist (figure 4.8C). An alternative EP2-selective 
antagonist, PF-04852946, structurally distinct from PF-04418948, was also studied. PF-
04852946 is about ten-fold more potent than PF-04418948 at EP2 receptors (Kay et al., 
2013). PF-04852946 (30 nM) was found to be an ineffective antagonist of the PGE2 
inhibition of TNF-α generation (figure 4.9).   
 
The pKB (antagonist affinity) estimates for the antagonism of PGE2 by CJ-042794 and 
L-161,982 were 8.77 ± 0.13 (KB, 1.7 nM) and 8.46 ± 0.12 (KB, 3.5 nM), respectively. 
These affinities are consistent with effects of these compounds at EP4 receptors (Jones 
et al., 2009). 
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Figure 4.8. Effect of EP receptor antagonists on PGE2 inhibition of TNF-α.  
Macrophages were pre-incubated with indomethacin (1 µM) for 30 min and then 
without or with EP-selective antagonists (300 nM) for 1 h and then without or with 
PGE2 for 30 min before challenge with LPS (1 ng/ml) for 22 h, after which TNF-α was 
measured in the supernatants. The effects on PGE2 of (A) the EP4-selective antagonist 
CJ-042794, (B) the EP2-selective antagonist PF-04418948 and (C) the EP4-selective 
antagonist L-161,982 were evaluated. Values are expressed as the % inhibition of 
control TNF-α releases which were, in the absence and presence of antagonist 
respectively, (A) 2646 ± 562 and 2582 ± 496 pg/ml, (B) 3274 ± 502 and 3155 ± 551 
pg/ml and (C) 2756 ± 882 and 2833 ± 862 pg/ml.  Values are mean ± SEM for 5, 4 and 
6 experiments for (A), (B) and (C), respectively. 






















































Figure 4.9. The effect of an alternative EP2 antagonist on PGE2 inhibition of 
TNF-α. 
Macrophages were pre-incubated with indomethacin (1 µM) for 30 min and then 
without or with an EP-selective antagonist (30 nM) for 1 h and then without or with 
PGE2 for 30 min before challenge with LPS (1 ng/ml) for 22 h, after which TNF-α was 
measured in the supernatants. The effects on PGE2 of the EP2-selective antagonist PF-
04852946, was evaluated. Values are expressed as the % inhibition of control TNF-α 
releases which were, in the absence and presence of antagonist respectively, 243 ± 26 
and 242 ± 21 pg/ml. Values are mean ± SEM for 2 individual experiments.  
 

















4.2.7. Effects of EP4-selective antagonists on misoprostol inhibition  
As antagonism of the PGE2 inhibition of TNF-α generation was observed with the EP4-
selective antagonists CJ-042794 and L-161,982, the effects of the antagonists on 
inhibition by an alternative agonist, misoprostol, were explored. Macrophages were 
incubated with either CJ-042794 or L-161,982 (both 300 nM) for 1 h before incubation 
with misoprostol for 30 min and then challenged with LPS (1 ng/ml) for 22 h. 
Antagonism of the misoprostol inhibition was seen with both antagonists (figure 4.10). 
The pKB estimates for the antagonism of misoprostol by CJ-042794 and L-161,982 




Figure 4.10. Effect of EP receptor antagonists on misoprostol inhibition of TNF-α.  
Macrophages were pre-incubated with indomethacin (1 µM) for 30 min and then 
without or with EP-selective antagonists (300 nM) for 1 h and then without or with 
PGE2 for 30 min before challenge with LPS (1 ng/ml) for 22 h, after which TNF-α was 
measured in the supernatants. The effects on misoprostol of the EP4-selective 
antagonists CJ-042794 and L-161,982 were evaluated. Values are expressed as the % 
inhibition of control TNF-α releases which were, in the absence and presence of 
antagonist respectively, (A) 1061 ± 166 and 1216 ± 183 pg/ml and (B) 1061 ± 166 and 
1199 ± 229 pg/ml. Values are mean ± SEM for 3 individual experiments. 
 




































Previous studies have shown that PGE2 is an inhibitor of macrophage function (Rowe et 
al., 1997, Buenestado et al., 2012, Ratcliffe et al., 2007). However, the receptor 
involved in mediating this inhibitory effect has not been fully elucidated. This is largely 
because many of the pharmacological probes that have been available to study EP 
receptors have lacked selectivity. The recent emergence of selective agonists and 
especially antagonists, has enabled definitive characterization of the receptor involved 
in preventing cytokine generation from human lung macrophages, in this study. 
 
In accord with previous studies, it has been shown that PGE2 is an effective inhibitor of 
LPS-induced TNF-α generation from lung macrophages. This study also demonstrated 
that LPS stimulation of macrophages induced PGE2 generation and it was evident that 
blocking this PGE2 generation with the COX inhibitor indomethacin led to an increase 
in TNF-α generation by macrophages. This suggests that under normal circumstances, 
activated macrophages generate PGE2 which acts in a paracrine fashion to limit the 
extent of TNF-α generation. These observations are followed up in more detail in 
Chapter 5. In further studies it was sought to establish the EP receptor through which 
PGE2 acts in human lung macrophages.     
 
In order to identify which EP receptors were expressed by human lung macrophages, 
RT-PCR studies were performed. These studies demonstrated that lung macrophages 
express mRNA for both EP2 and EP4 receptors but not EP1 or EP3 receptors. This 
suggests that EP2 and/or EP4 receptors are involved in mediating the effects of PGE2.  
That PGE2 induced increases in total cell cyclic-AMP in macrophages provides further 
support for the expression of EP2 and/or EP4 receptors in macrophages. This is because 
both EP2 and EP4 receptors are known to be coupled to adenylyl cyclase, so increases in 
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cyclic-AMP are consistent with the expression of EP2 and/or EP4 receptors in 
macrophages (Wilson et al., 2004). 
 
The inhibition of LPS-induced TNF-α generation from lung macrophages by PGE2 was 
compared to potential inhibition by other prostanoids. PGD2 acts on DP receptors and 
U46619 acts on TP receptors (Ricciotti and FitzGerald, 2011). However, inhibition of 
TNF-α was not seen with either PGD2 or U46619. A small amount of inhibition 
(although not significant) was seen with iloprost, which acts on IP receptors and with 
PGF2α which acts on FP receptors (Ricciotti and FitzGerald, 2011). PGE2 was the only 
one of the prostanoids tested, to effectively inhibit TNF-α generation. The expression of 
the receptors in the cells was not investigated. It may be the case that the receptors 
(other than EP receptors) that are linked to cAMP increases were expressed but not at a 
high enough level to lead to an inhibitory effect upon activation by their respective 
prostanoids. As the agonists utilized are not highly selective, it is also possible that 
iloprost and PGF2α are acting on EP2 or EP4 receptors to cause some inhibition. Iloprost 
and PGF2α are more potent agonists at the EP2 and EP4 receptors than PGD2 and 
U46619 (Alexander et al., 2013b), which could explain the small inhibitory effects of 
iloprost and PGF2α in this system. These data provide evidence that the PGE2/EP axis is 
the only prostanoid system that effectively attenuates cytokine generation from lung 
macrophages. This further supports the rationale for investigating the inhibitory effects 
of PGE2 and the EP receptor(s) mediating these effects, in lung macrophages. 
 
In attempts to characterize EP receptors further, a range of EP agonists were studied for 
effects on cytokine generation. The non-selective agonist, misoprostol, was about 25-
fold less potent than PGE2 as an inhibitor of TNF-α generation. This potency ratio is 
consistent with an effect of misoprostol at EP4 receptors since at EP2 receptors 
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misoprostol is only about 7-fold less potent than PGE2 (Abramovitz et al., 2000). 
Alternative agonists were also studied and it was of interest that the EP4 agonist L-
902,688, was about 6-fold more potent than PGE2. By contrast, the EP2-selective 
agonists, butaprost and ONO-AE1-259, were about 350 to 1500-fold less potent than L-
902,688. Overall, these data provide preliminary evidence that the EP4 receptor is 
responsible for mediating the effects of PGE2 and argue against an EP2 effect, since the 
concentrations of both butaprost and ONO-AE1-259 required for inhibition were higher 
than those usually associated with effects at EP2 receptors (Wilson et al., 2004, 
Benyahia et al., 2012, Clarke et al., 2004).   
 
In further studies the effects of EP2 and EP4 antagonists on the PGE2 response in 
macrophages were investigated. It is noteworthy that the EP2 antagonists, PF-04418948 
and PF-04852946 that were used in this study are highly selective ligands and 
considerably superior to AH6809 which until now was the only EP2 antagonist available 
(af Forselles et al., 2011, Kay et al., 2013). AH6809 shows poor selectivity and potency 
such that data generated with this antagonist are unlikely to be reliable (Abramovitz et 
al., 2000, Jones et al., 2009). Neither of the two EP2 antagonists used in this study had 
any effect on the PGE2 inhibition of TNF-α generation. By contrast, two EP4 
antagonists, CJ-042794 (KB; 1.7 nM) and L-161,982 (KB; 3.5 nM) effectively reversed 
the PGE2 inhibition of TNF-α generation with affinities consistent with antagonism at 
EP4 receptors (Jones et al., 2009). These data provide compelling evidence that the 
receptor that mediates the inhibitory effects of PGE2 in human lung macrophages is the 
EP4 receptor. Both EP4 antagonists CJ-042794 and L-161,982 also antagonized 
misoprostol inhibition. Although both were less potent antagonists of misoprostol 
inhibition than of PGE2 inhibition, these data further support the suggestion that PGE2 is 
acting at the EP4 receptor to attenuate TNF-α generation from activated macrophages. 
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The suggestion has been made that the EP4 receptor could be a target for respiratory 
diseases. This contention has been based largely on recent studies that have shown that 
PGE2 mediates bronchodilation via the EP4 receptor (Buckley et al., 2011, Benyahia et 
al., 2012). In addition to bronchodilation, the present study has demonstrated that 
targeting the EP4 receptor may also provide additional desirable anti-inflammatory 
effects by stabilizing lung macrophage activity.  
 
The prospect that the EP4 receptor could be targeted in order to limit pro-inflammatory 
cytokine generation from macrophages is tempered by the finding that there are marked 
differences in the effects of PGE2 on cytokine generation from macrophages. Whereas 
PGE2 effectively blocks TNF-α and IL-6 generation from macrophages, it is completely 
ineffective against IL-8. Similar findings have been reported elsewhere (Standiford et 
al., 1992). The reason for this difference is not immediately obvious since it is thought 
that the LPS-mediated signalling pathways leading to the generation of these cytokines 
are similar (Thorley et al., 2007). 
 
It has been reported in another study using human alveolar macrophages, that both EP2 
and EP4 receptors are activated by PGE2. The study reported that the activation of each 
receptor may be agonist concentration-dependent, where EP4 receptors are activated at 
low concentrations of PGE2 and EP2 receptors at higher concentrations (Ratcliffe et al., 
2007). However, it should be noted that this study was carried out using only the EP4 
antagonist ONO-AE2-227 and no EP2 antagonist. Although butaprost was used as 
diagnostic for EP2 receptors, butaprost can also have effects at EP4 receptors at high 
concentrations (Wilson et al., 2004). In the present study, utilizing a range of agonists 
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and antagonists provides compelling evidence that PGE2 acts at EP4 receptors and not 
EP2 receptors, to inhibit cytokine generation from lung macrophages. 
 
Despite evidence from functional studies to the contrary, the mRNA studies carried out 
demonstrate expression of both EP2 and EP4 receptors in human lung macrophages, 
suggesting a possible role for EP2 receptors in macrophages. The data also suggest that 
it is possible that the EP2 receptor is induced in response to LPS. This indicates that the 
EP2 receptor could also be a target for stabilization of macrophages following LPS 
activation. However, the protein expression of the receptors could not be demonstrated 
due to the lack of availability of reliable antibodies. Therefore, it is unknown whether 
translation to EP2 receptor protein expression occurs. It is possible that the EP2 receptor, 
if present, is involved in modulating other macrophage functions such as phagocytosis. 
Another study reported that PGE2 acts at the EP2 receptor to inhibit phagocytosis in rat 
alveolar macrophages (Aronoff et al., 2004). This was not investigated in the present 
study but would be of interest to explore in future investigations. 
 
In summary, this study demonstrates that although human lung macrophages may 
express both EP2 and EP4 receptors, PGE2 acts through the EP4 receptor to inhibit pro-




Chapter 5: Characterization of the cyclooxygenase (COX) 




Prostanoids are synthesized by the metabolism of arachidonic acid. The first step in the 
biosynthesis is the conversion of arachidonic acid to an endoperoxide intermediate, 
prostaglandin H2. This reaction is catalyzed by cyclooxygenase enzymes, of which there 
are two isoforms, COX-1 and COX-2. COX-1 is believed to be constitutively 
expressed, whereas COX-2 is believed to be the inducible isoform, induced for 
example, by inflammatory stimuli (Tilley et al., 2001). Prostaglandin H2 is converted by 
specific synthases, to specific prostanoids. These prostanoids include four 
prostaglandins and thromboxane A2 (Ricciotti and FitzGerald, 2011), which are 
differentially produced by different cells (Tilley et al., 2001). One of the prostaglandins 
known to be produced by macrophages is prostaglandin E2 (PGE2) and this was 
confirmed by the studies in Chapter 4 of this thesis. PGE2 has been demonstrated to 
have an inhibitory effect on cytokine release from human lung macrophages.  
 
The timing of synthesis of PGE2 resulting from COX-1 or COX-2 activation can be 
different, as COX-2 activation, unlike COX-1, requires de novo PGE2 mRNA and 
protein synthesis to occur (Williams and Shacter, 1997). It is feasible that the roles of 
PGE2 generated by the cell could be different, depending on whether it is driven by 
COX-1 or COX-2 activation. 
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In this study, a number of approaches were utilized to investigate the COX isoform(s) 
responsible for PGE2 production in human lung macrophages. The constitutive 
expression of COX-1 and COX-2, in addition to the expression following challenge 
with inflammatory stimuli, was investigated. The inflammatory stimuli used were the 
TLR agonists LPS and poly(I:C). In addition to these, the bacteria Staphylococcus 
aureus and Neisseria meningitidis were also tested. Expression of the COX isoforms 
was investigated using RT-PCR and Western blotting. COX-1 and COX-2-selective 
inhibitors were also utilized to further determine the involvement of each of the 
isoforms in PGE2 production from macrophages. The effect of the COX inhibitors on 
cytokine release was also investigated. 
 
5.2. Results 
5.2.1. Time dependency of LPS-induced PGE2 generation from lung macrophages 
Macrophages were challenged with LPS (10 ng/ml) for 2, 5, 16 and 22 h. The levels of 
spontaneously generated and LPS-induced PGE2 were measured after each time point. 
Although there were differences between three experiments (figure 5.1A, B and C) in 
the overall levels of PGE2 generated over the time course, generally the pattern was the 
same. Although PGE2 was generated spontaneously in all of the experiments, in 
response to LPS challenge, there was a time-dependent increase in the levels of PGE2. 
Maximal generation of PGE2 was observed 16 h after activation with LPS. 
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Figure 5.1. Time-dependent LPS-induced PGE2 generation. Macrophages were 
incubated without or with LPS (10 ng/ml). At 2, 5, 16 and 22 h, cell culture 
supernatants were harvested and assayed for PGE2. Graphs are of 3 individual 
experiments. (A) experiment 1, (B) experiment 2 and (C) experiment 3.  
 

















































5.2.2. Constitutive and LPS-induced gene expression of COX-1 and COX-2 
The expression of the two isoforms of COX was investigated in human lung 
macrophages at the mRNA level. Macrophages were solubilized with TRI Reagent® to 
enable RNA extraction. Reverse transcriptase PCR (RT-PCR) using primers specific for 
each of the COX isoforms demonstrated constitutive expression of both COX-1 and 
COX-2 in three separate cell preparations (figure 5.2). Densitometric analysis showed 
that although there was some variability between cell preparations, the expression of 
COX-1 and COX-2 was generally similar relative to β-actin. 
 
To determine whether the expression of either isoform was altered in response to LPS, 
macrophages were challenged with LPS (10 ng/ml) for 22 h. The RT-PCR results and 
the corresponding densitometric analysis demonstrated that expression of COX-1 was 
up-regulated in response to LPS compared to the control in just one of the two cell 
preparations tested, by a 23% increase. Expression of COX-2 however, was up-
regulated in response to LPS in both cell preparations tested and the up-regulation was 




Figure 5.2. Expression of COX-1 and COX-2 by RT-PCR. 
RNA from unstimulated macrophages was converted to cDNA in the presence (+) or 
absence (−) of reverse transcriptase. Amplification of cDNA was carried out using 
COX-1 and COX-2 specific primers. Data shown are of 3 different macrophage (MAC) 
preparations in excess of 95% purity. Lanes at either end of each gel represent a 100 bp 
ladder. 
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Figure 5.3. LPS-induced expression of COX-1 and COX-2.  
Macrophages were incubated without or with LPS (10 ng/ml) for 22 h. Isolated RNA 
from was converted to cDNA in the presence (+) or absence (−) of reverse transcriptase. 
Amplification of cDNA was carried out using COX-1 and COX-2 specific primers. 
Data shown are of 2 different macrophage (MAC) preparations in excess of 95% purity. 
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5.2.3. Effect of TLR agonists on COX induction 
Macrophages were challenged without or with increasing concentrations of the TLR4 
agonist LPS (0.1-10 ng/ml) for 22 h, after which protein lysis was performed. The 
protein lysates were analysed by SDS-PAGE followed by Western blotting using 
antibodies to COX-1 and COX-2. The constitutive expression of both isoforms was 
found to be low. COX-1 expression was not altered from constitutive levels, following 
LPS challenge, whereas there was an LPS concentration-dependent increase in COX-2 
protein expression. Densitometric analysis showed that there was a two-fold increase in 
COX-2 expression from the control level with 1 ng/ml LPS and a five-fold increase 
over the control with 10 ng/ml LPS (figure 5.4).  
 
Comparison of the effects of LPS and the TLR3 agonist poly(I:C) on protein expression 
in two separate cell preparations was then carried out. Macrophages were challenged 
with LPS (10 ng/ml) or poly(I:C) (10 µg/ml) for 22 h. LPS again induced up-regulation 
of COX-2 but not COX-1 in both cell preparations (figure 5.5A and 5.5B). 
Densitometric analysis showed that the up-regulation of COX-2 from the control was 
19-fold in one cell preparation and four-fold in the other in response to LPS. Poly(I:C) 
did not result in up-regulation of COX-1 or COX-2 in either cell preparation (figure 
5.5A and 5.5B). 
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Figure 5.4. LPS-induced protein expression of COX-1 and COX-2. 
Macrophages were incubated without or with LPS for 22 h, after which the cells were 
solubilized and cell lysates (9 x 105 cell equivalents) were subjected to SDS-PAGE 
electrophoresis. Separated proteins were transferred on to a nitrocellulose membrane 
and this was probed for COX-1, the membrane stripped and then probed for actin and 
following a further strip, probed for COX-2. Bands detected for COX-1 (~72 kDa), 




control 0.1 ng/ml 1 ng/ml 10 ng/ml 
LPS 
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Figure 5.5. Poly(I:C)-induced protein expression of COX-1 and COX-2.  
Macrophages were incubated without or with LPS (10 ng/ml) or poly(I:C) (1 µg/ml) for 
22 h, after which the cells were solubilized and cell lysates (9 x 105 cell equivalents) 
were subjected to SDS-PAGE electrophoresis. Separated proteins were transferred on to 
a nitrocellulose membrane and this was probed for COX-1, the membrane stripped and 
then probed for actin and following a further strip, probed for COX-2. Bands detected 
for COX-1 (~72 kDa), COX-2 (~72 kDa) and β-actin (42 kDa) are shown. Data shown 














5.2.4. Expression of COX-1 and COX-2 in response to pathogens 
Macrophages were infected with Staphylococcus aureus (Newman strain) at a 
multiplicity of infection (MOI) of 0.05, 0.5 and 5 or Neisseria meningitidis (MC58 type 
B) at MOI 10 for 16 h. The protein lysates were analysed by Western blotting. Neither 
of the pathogens resulted in induction of COX-1 expression. Slight up-regulation of 
COX-2 was observed in response to S.aureus at the highest MOI investigated (figure 
5.6). (The bands visible underneath the bands for COX-2 are likely to be a result of non-
specific binding of the antibodies to S.aureus Protein A, approximately 55 kDa). 
Exposure of macrophages to N. meningitidis resulted in a dramatic up-regulation of 
COX-2 (figure 5.6). Densitometric analysis showed that this was a 29-fold increase in 
COX-2 expression over the control level.  
 
5.2.5. The effect of COX inhibitors on LPS-induced PGE2 generation 
The effect of inhibiting COX on the generation of PGE2 was investigated. Macrophages 
were pre-treated for 30 min with the non-selective COX inhibitor indomethacin, the 
COX-1 selective inhibitor FR122047 or the COX-2 selective inhibitor celecoxib (all 10-
6 M), followed by incubation without or with LPS (10 ng/ml) for 22 h. In the absence of 
the inhibitors, PGE2 was spontaneously generated and there was a significant (p<0.01) 
increase upon LPS stimulation. LPS-induced PGE2 was significantly (p<0.01) inhibited 
by all three of the COX inhibitors, to levels below those of the spontaneous PGE2. 
Indomethacin inhibited by ~100%, FR122047 inhibited by ~88% and celecoxib resulted 





Figure 5.6. S.aureus and N. meningitidis-induced protein expression of COX-1 and 
COX-2.  
Macrophages were infected with S.aureus or N. meningitidis at the multiplicity of 
infection (MOI) indicated for 16 h. After this time, the cells were solubilized and cell 
lysates (9 x 105 cell equivalents) were subjected to SDS-PAGE electrophoresis. 
Separated proteins were transferred on to a nitrocellulose membrane and this was 
probed for COX-1, the membrane stripped and then probed for actin and following a 
further strip, probed for COX-2. Bands detected for COX-1 (~72 kDa), COX-2 (~72 
kDa) and β-actin (42 kDa) are shown. Data shown are representative of a total of 3 
individual experiments. 
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Figure 7: Effects of S. aureus and N. meningitidis infections on expression of COX-1 and 
COX-2. 
Both S. aureus and N. meningitidis had no effect on levels of COX-1 expression. S. aureus and 
ind ced only a slight dose-respons  increase in COX-2 expression (corr lated t  increase in MOI 
– multiplicity of infection, labelled above the samples), whereas N. meningitidis-infected alveolar 
macrophages had dramatically larger COX-2 expression levels. The effects seen are due to the fact 
that S. aureus does not contain LPS, whereas LPS is highly abundant in N. meningitidis. Bands 
immediately below the COX bands were thought to be non-specific binding of the antibodies used 
to the S. aureus protein A (approximately 55 kDa). In each condition alveolar macrophages were 
stimulated for 16 hours and then lysed for protein (approximately lysates of 9 x 105 alveolar 
macrophages per lane). Infections were carried out by Helen Marriot. P534 – preparation 534. 
Representative assays shown here, 3 experiments in total were performed for each bacterial species 
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Figure 5.7. Effect of COX inhibitors on LPS-induced PGE2 generation. 
Macrophages were pre-treated for 30 min with indomethacin (INDO), FR122047 (FR) 
or celecoxib (CELE) (all 10-6 M) before challenge with LPS (10 ng/ml). After 22 h, cell 
culture supernatants were harvested and assayed for PGE2. Drugs alone had no effect on 
spontaneous PGE2 release. Values are mean ± SEM for 4 individual experiments. (One-
way ANOVA with Dunnett’s post test, ##p<0.01 compared with spontaneous release, 
**p<0.01 compared with LPS alone). 
 


















To attempt to determine whether inhibition of PGE2 generation by FR122047 and 
celecoxib was concentration-dependent, macrophages were incubated with a range of 
concentrations of the inhibitors (10-12-10-7 M) for 30 min followed by challenge with 
LPS (1 ng/ml). Inhibition of LPS-induced PGE2 was not seen in response to FR122047 
(figure 5.8A). Celecoxib at the highest concentration studied (10-7 M) inhibited PGE2 
generation (figure 5.8B). 
 
5.2.6. The effect of COX inhibitors on LPS-induced TNF-α generation 
It has been demonstrated that macrophages produce PGE2 endogenously upon LPS 
challenge and in Chapter 4 of this thesis it was demonstrated that this generated PGE2 
can act in a paracrine fashion to inhibit cytokine release. Therefore, the effect of the 
COX inhibitors on LPS-induced TNF-α release was investigated. Macrophages were 
treated with increasing concentrations of indomethacin, FR122047 or celecoxib for 30 
min followed by challenge with LPS (1 ng/ml) for 22 h. Cell culture supernatants were 
assayed for TNF-α release. Indomethacin (figure 5.9A) and celecoxib (figure 5.9C) 
caused slight concentration-dependent increases in TNF-α release, whereas FR122047 
only caused a slight increase at the highest concentration tested. However, none of the 
increases were significant compared to LPS-induced TNF-α in the absence of COX 
inhibitors. 
 
To attempt to further determine whether there was a concentration-dependent effect of 
FR122047 and celecoxib on TNF-α release, macrophages were incubated with a range 
of concentrations (10-12-10-7 M) of FR122047 (figure 5.10A) or celecoxib (figure 
5.10B) for 30 min followed by challenge with LPS (1 ng/ml) for 22 h. Cell culture 
supernatants were assayed for TNF-α release. None of the COX inhibitors affected 
TNF-α generation.
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Figure 5.8. Effect of COX-1 and COX-2 selective inhibitors on PGE2 generation. 
Macrophages were pre-treated for 30 min with (A) FR122047 (FR) or (B) celecoxib 
(Cele) before challenge with LPS (1 ng/ml). After 22 h, cell culture supernatants were 
harvested and assayed for PGE2. Drugs alone had no effect on spontaneous PGE2 
release. Values are for 1 experiment. 





































         
 
 
Figure 5.9. Effect of COX inhibitors on TNF-α generation. 
Macrophages were pre-treated for 30 min with (A) indomethacin (Indo), (B) FR122047 
(FR) or (C) celecoxib before challenge with LPS (1 ng/ml). After 22 h, cell culture 
supernatants were harvested and assayed for TNF-α. Drugs alone had no effect on 
spontaneous cytokine release. Values are mean ± SEM for 4 individual experiments. 
(One-way ANOVA with Dunnett’s post test, all p>0.05 compared with LPS alone)














































              
 
Figure 5.10. Effect of COX inhibitor concentration on TNF-α generation from 
macrophages. 
Macrophages were pre-treated for 30 min with (A) FR122047 (FR) or (B) celecoxib 
(Cele) before challenge with LPS (1 ng/ml). After 22 h, cell culture supernatants were 
harvested and assayed for TNF-α. Drugs alone had no effect on spontaneous cytokine 
release. Values are for 1 experiment. 
 
 



































5.2.7. The effect of COX inhibitors on LPS-induced IL-6 generation 
The effect of COX inhibitors on LPS induced IL-6 release was investigated. 
Macrophages were incubated with indomethacin (figure 5.11A), FR122047 (figure 
5.11B) or celecoxib (figure 5.11C) (all 10-8-10-6 M) for 30 min before challenge with 
LPS (1 ng/ml) for 22 h. Cell culture supernatants were assayed for IL-6. All three COX 
inhibitors had virtually no effect on IL-6 release. 
  
5.2.8. Effects of EP antagonists on LPS-induced TNF-α generation 
The effects of the antagonists PF-04418948 (EP2-selective) and CJ-042794 (EP4-
selective) were investigated on concentration-dependent LPS-induced cytokine release 
(figure 5.12). Macrophages were incubated with the antagonists (300 nM) for 1 h before 
being challenged with LPS (0.1-10 ng/ml) for 22 h. CJ-042794 caused a significant 
increase (p<0.01) in TNF-α generation at all three concentrations of LPS. No significant 
(p>0.05) increase was observed in the presence of PF-04418948. 
 
5.2.9. Comparison of the effect of COX inhibitors on cytokine generation from 
MDMs and lung macrophages 
MDMs and lung macrophages were treated with indomethacin, FR122047 or celecoxib 
(10-6 M) for 30 min followed by challenge with LPS (1 ng/ml) for 22 h. Cell culture 
supernatants were assayed for TNF-α release. Indomethacin appeared to enhance LPS-
induced TNF-α release from MDMs, as did celecoxib to some extent. By contrast, 
FR122047 did not have much of an effect on TNF-α release (figure 5.13A). A similar 
trend in results was seen with these COX inhibitors on LPS-induced TNF-α release 
from lung macrophages, although the effects were less pronounced (figure 5.13B).
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Figure 5.11. Effect of COX inhibitors on IL-6 generation. 
Macrophages were pre-treated for 30 min with (A) indomethacin (Indo), (B) FR122047 
(FR) or (C) celecoxib before challenge with LPS (1 ng/ml). After 22 h, cell culture 
supernatants were harvested and assayed for IL-6. Drugs alone had no effect on 
spontaneous cytokine release. Values are mean ± SEM for 2 individual experiments. 
(One-way ANOVA with Dunnett’s post test, all p>0.05 compared with LPS alone). 














































           
 
 
Figure 5.12. Effect of EP receptor antagonists on LPS-induced cytokine release. 
Macrophages were incubated without or with the EP2-selective antagonist PF-04418948 
or the EP4-selective antagonist CJ-042794 (both 300 nM) for 1 h before challenge with 
LPS (0.1-10 ng/ml) for 22 h, after which TNF-α was measured in the supernatants. 
Antagonists alone had no effect on spontaneous cytokine release. Values are mean ± 
SEM for 4 individual experiments. (For each LPS concentration, one-way ANOVA 























                     
 
 
Figure 5.13. Comparison of the effect of COX inhibitors on TNF-α generation 
from MDMs and lung macrophages. 
(A) MDMs and (B) lung macrophages were pre-treated for 30 min with indomethacin 
(INDO), FR122047 (FR) or celecoxib (CELE) (all 10-6 M) before challenge with LPS 
(1 ng/ml). After 22 h, cell culture supernatants were harvested and assayed for TNF-α. 
Drugs alone had no effect on spontaneous cytokine release. Values are mean ± SEM for 
2 individual experiments (MDMs) and mean ± SEM for 4 individual experiments 
(macrophages). (One-way ANOVA with Dunnett’s post test, all p>0.05 compared with 
LPS alone for both cell types). 
 































There may be some differences in COX inhibition between the two cell systems, which 
requires further investigation. 
 
5.3. Discussion 
Human lung macrophages produce PGE2 (Monick et al., 2002, Hempel et al., 1994). 
This was confirmed in the present study. Macrophages were found to produce PGE2 
spontaneously and the levels of PGE2 increased about 3-fold in response to LPS 
stimulation. Further work was performed to investigate which isoform of COX was 
responsible for LPS-induced PGE2 generation in human lung macrophages. 
 
Constitutive gene expression of COX-1 and COX-2 was investigated using RT-PCR. 
Generally, expression of COX-2 is tightly regulated and restricted in the absence of 
induction (Tilley et al., 2001). In this study, constitutive expression of both COX-1 and 
COX-2 was seen at the mRNA level in unstimulated macrophages. Stimulation with 
LPS resulted in increased expression of COX-2, whereas the increase in expression of 
COX-1 in the presence of LPS stimulation was less obvious and was much lower than 
the increase in COX-2 expression. Although the constitutive mRNA expression of both 
COX-1 and COX-2 was strong, the constitutive protein expression was weak. The 
protein expression of COX-1 was not up-regulated in response to LPS. By contrast, the 
COX-2 protein expression was up-regulated in response to increasing concentrations of 
LPS. This suggests that LPS stimulation may result in induction of the translation of 
COX-2 mRNA. Studies by other researchers have also demonstrated that LPS 
stimulation results in induction of COX-2 mRNA and protein in human alveolar 
macrophages from bronchoalveolar lavage (BAL) fluid (Monick et al., 2002).   
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In addition to LPS, the effects of another TLR agonist, the viral mimic poly(I:C), on 
COX-1 and COX-2 protein expression was investigated. The expression of COX-1 or 
COX-2 was not up-regulated at the protein level in response to poly(I:C), which is in 
contrast to the effect of LPS. It may be that TLR4 activation is required for COX-2 
induction and therefore no COX-2 induction is observed in response to TLR3 activation 
by poly(I:C). Although COX-2 gene expression in response to poly(I:C) was not 
explored in the present study, in another study, LPS significantly induced COX-2 gene 
expression in murine lung tissue whereas the induction with poly(I:C) was negligible 
(Kirkby et al., 2013). However, it has been reported that COX-2 can be induced by 
poly(I:C) in murine macrophage-like RAW 264.7 cells (Pindado et al., 2007), which 
indicates that there are likely to be differences in responses to poly(I:C) between cell 
systems. 
 
As modulation of expression of COX-2 protein was observed in response to a bacterial 
product but not a viral mimic, it was of interest to determine the effect of infection of 
macrophages with bacteria on COX expression. The expression of COX-1 protein in 
response to infection with S. aureus and with N. meningitidis was not up-regulated as 
the multiplicity of infection (MOI) was increased. The expression of COX-2, however, 
differed. In response to S. aureus at the highest MOI, the expression of COX-2 
marginally increased. However, in response to N. meningitidis, COX-2 expression was 
strikingly up-regulated. This difference in response to the two pathogens could be 
attributed to N. meningitidis being gram-negative, whereas S. aureus is gram-positive. 
The LPS in the outer cell membrane of N. meningitidis could be activating the 
macrophages through TLR4 leading to the up-regulation of COX-2, whereas S. aureus 
is believed to be recognized by TLR2 (Pietrocola et al., 2011). 
 
 187 
To further investigate which isoform of COX may be responsible for LPS-induced 
PGE2 generation from human lung macrophages, the cells were treated with selective 
COX inhibitors. Indomethacin is a non-selective COX inhibitor but shows slight 
selectivity for COX-1 over COX-2 (Mitchell et al., 1993). The selective COX-2 
inhibitor celecoxib has been reported to be over 3000-fold more selective for COX-2 
over COX-1 (Gierse et al., 1999). However, this value is disputed by studies utilizing 
alternative assays for analysis (Mardini and FitzGerald, 2001). The selective COX-1 
inhibitor FR122047 is over 2000-fold more selective for COX-1 over COX-2 (Ochi et 
al., 2000). Overall, the reports in the literature support the assertion that the inhibitors 
are selective. The reported IC50 values for both celecoxib and FR122047 are in the 
nanomolar range (Alexander et al., 2013a). 
 
In the present study, when used at high concentrations (10-6 M), all of the COX 
inhibitors essentially abolished LPS-induced PGE2 release. As the concentrations of 
celecoxib and FR122047 used were at least 1000-fold higher than their reported IC50 
values, it is possible that the inhibitors could have had non-selective effects. It follows 
that the COX isoform responsible for PGE2 generation is not clear from the results of 
these experiments. Repeating these experiments using a wider concentration range of 
inhibitors may enable a clearer determination of their effects. Testing alternative 
selective COX inhibitors in this system may also be beneficial for confirmation of the 
effects observed.  
 
As LPS-induced PGE2 can act in a paracrine manner to inhibit pro-inflammatory 
cytokine release from macrophages, it was investigated whether inhibition of COX 
might modulate LPS-induced TNF-α release. Indomethacin and celecoxib caused 
concentration-dependent increases in LPS-induced TNF-α release, whereas FR122047 
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only had an effect at the highest concentration (10-6 M) used. Although the COX 
inhibitor-induced increases in TNF-α release were not statistically significant, the 
results provide an indication that inhibition of COX prevents production of PGE2, 
which leads to a modest enhancement of TNF-α release.  
 
In order to determine whether inhibition of COX might also affect the release of other 
cytokines, the effects of the COX inhibitors on LPS-induced IL-6 release were also 
investigated. It was found that none of the COX inhibitors had an effect on IL-6 release. 
This is in keeping with the demonstration in Chapter 4 that PGE2 is not as effective at 
inhibiting LPS-induced IL-6 than LPS-induced TNF-α. It has been reported that COX-2 
induced PGE2 results in synthesis of IL-6 in murine peritoneal macrophages (Williams 
and Shacter, 1997). The study reported that this was related to timing and that the 
delayed production of PGE2 by COX-2 in response to stimuli, as opposed to early 
production by COX-1, was required for IL-6 synthesis. The data in the present study 
compared to reports in the literature suggest that there are differences between model 
systems in the mechanism of PGE2 synthesis and its subsequent effects. 
 
It should also be noted that a brief investigation of whether there were any differences 
between MDMs and lung macrophages in the effects of COX inhibitors on TNF-α 
release suggested that the inhibitors may have a more pronounced effect on MDMs. 
This requires further investigation but it could be possible that results of studies using 
MDMs may not necessarily extrapolate to lung macrophages. 
 
In Chapter 4 it was demonstrated that exogenous PGE2 acts on the EP4 receptor to 
inhibit LPS-induced TNF-α release. Following on from this observation, in work 
described in the present chapter, EP receptor antagonists were utilized (in the absence of 
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COX inhibitors) to block the effects of PGE2 generated endogenously upon LPS 
stimulation. LPS-induced TNF-α generation increased in the presence of EP4 antagonist 
CJ-042794 but not in the presence of EP2 antagonist PF-04418948. This suggests that 
any PGE2 generated by the macrophages endogenously in response to LPS may be 
acting on the EP4 receptor to inhibit TNF-α release. These experiments also provide 
further confirmation that the prostanoid generated through COX activation by LPS to 
attenuate TNF-α generation was PGE2. 
 
The COX inhibitors used in this study are non-steroidal anti-inflammatory drugs 
(NSAIDs). NSAIDs are commonly used therapeutically, as painkillers and antipyretics. 
NSAIDs such as aspirin and ibuprofen are non-selective, targeting both COX-1 and 
COX-2. A common side-effect of these compounds is gastrointestinal problems due to 
inhibition of PGE2 driven by COX-1. PGE2 is known to inhibit acid secretion from 
gastric parietal cells. Therefore, inhibition of PGE2 due to COX-1 inhibition increases 
acid secretion leading to potential problems in the gut. Issues such as this with non-
selective inhibitors led to the development of selective COX-2 inhibitors such as 
celecoxib (Celebrex™), which have a gut-sparing effect (Warner and Mitchell, 2004). 
 
Other undesirable effects have also been reported with the use of NSAIDs. For example, 
10-20 % of asthmatics are sensitive to aspirin and other non-selective NSAIDs (Bennett, 
2000, Sanak, 2011). This condition is known as aspirin-exacerbated respiratory disease 
(AERD). Several mechanisms have been reported as being involved in AERD. The 
most widely cited of these indicates that inhibition of COX-1 leads to a build-up in 
arachidonic acid. This arachidonic acid is then converted via the 5-lipoxygenase 
pathway, to produce increased amounts of cysteinyl leukotrienes, rather than 
metabolized via the COX pathway (figure 5.14) (Picado, 2002, Varghese and Lockey, 
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2008). Cysteinyl leukotrienes are pro-inflammatory and cause bronchoconstriction. 
These deleterious effects may be further exacerbated by the decrease in PGE2 resulting 
from COX inhibition, as PGE2 is anti-inflammatory in the lung (Picado, 2002, 
Szczeklik, 1995). In keeping with this potential mechanism, the present study shows 
that inhibiting COX in lung macrophages leads to increased TNF-α generation. 
Therefore, caution needs to be exercised with the general use of any NSAIDs, including 
those that are COX-2 selective, for patients with underlying or accompanying 
respiratory conditions, as the drugs could potentially contribute to inflammation in the 
lungs. 
  
In summary, the results of this study indicate that in response to different stimuli, there 
are differences in the expression of COX-1 and COX-2 in human lung macrophages. In 
the absence of stimuli, the expression of both COX-1 and COX-2 is weak. It is therefore 
not clear in this study, which COX isoform is responsible for spontaneous PGE2 
generation. In keeping with results of others, LPS but not poly(I:C) stimulation appears 
to induce COX-2 expression. Up-regulation of COX-2 is also seen in response to gram-
negative but not gram-positive bacteria. Overall, the results indicate that LPS-induced 
PGE2 production from human lung macrophages occurs principally through the activity 
of COX-2. However, it is not possible to exclude the possible involvement of COX-1. 
Further investigations will enable a more complete evaluation of the contribution of 
COX isoforms to the generation of PGE2 from human lung macrophages. 
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Figure 5.14. Inhibition of COX results in increased production of CysLT in AERD. 
(A) A simplified figure of the eicosanoid and leukotriene production pathways. (B) A 
possible mechanism of AERD pathogenesis. The inhibition of COX by NSAIDS 
inhibits the production of PGE2. This results in a build-up of arachidonic acid which is 
then metabolized via the 5-LO pathway as opposed to the COX pathway, resulting in 
increased production of cysteinyl leukotrienes (CysLT) (Medeiros et al., 2012, Peters-
Golden et al., 2006). 
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Chapter 6: Evaluation of the anti-inflammatory effects of β-
adrenoceptor agonists on macrophages 
 
6.1. Introduction 
The current leading treatments available for chronic inflammatory lung diseases include 
β-adrenoceptor agonists (β2-agonists) and corticosteroids (Barnes, 2006b, Theron et al., 
2013). β2-agonists are used principally to alleviate symptoms, as they act on airway 
smooth muscle to cause relaxation and therefore exert bronchodilatory effects. 
Corticosteroids are used as anti-inflammatories to target the underlying disease 
pathology. These pharmacological agents are also used in combination. In recent years, 
combination inhalers have become a commonly prescribed treatment for asthma and 
COPD (Domingo, 2013). 
 
It has been reported that in addition to their bronchodilatory effects, β2-agonists can 
have anti-inflammatory effects (Linden, 1992, Donnelly et al., 2010, Ezeamuzie and 
Shihab, 2010). The ability of β2-agonists to act as effective anti-inflammatory agents 
would be useful as it could reduce the need for corticosteroids, which are not effective 
for all patients (Barnes, 2010), particularly those with severe cases of disease. High 
systemic concentrations of inhaled corticosteroids (ICS) can also result in side effects, 
particularly in children, such as endocrine disorders (Ahmet et al., 2011) and there is an 
increased risk of pneumonia in COPD patients (Calverley et al., 2011, Singh and Loke, 
2010). Despite these issues with the use of ICS, they are currently the most effective 
anti-inflammatory treatments available for chronic lung diseases (Barnes, 2006b). 
 
 193 
As macrophages are implicated in COPD and may also be important in asthma (Barnes, 
2008b, Yang et al., 2012, Peters-Golden, 2004), it would be of benefit if β2-agonists 
stabilized the macrophage inflammatory response. The reports in the literature regarding 
the anti-inflammatory effects of β2-agonists on macrophages do not enable a clear 
conclusion to be drawn. Also, some of these studies were carried out using monocytes 
and macrophage models, not human lung macrophages (Donnelly et al., 2010, 
Zetterlund et al., 1998, Ezeamuzie and Shihab, 2010). Determining the anti-
inflammatory effects of β2-agonists would allow evaluation of their potential to target 
macrophages in the lung. 
 
In this study, a range of β2-agonists was evaluated for inhibitory effects on pro-
inflammatory cytokine generation from human lung macrophages. The short-acting β-
agonists (SABA), which have bronchodilatory effects for 4-6 hours (Tashkin and 
Fabbri, 2010) were salbutamol and terbutaline. The non-selective SABA isoprenaline 
was also studied, for comparative purposes, as it is known to act as a full agonist at β-
adrenoceptors (Cazzola et al., 2012). The long-acting β-agonists (LABA) studied were 
formoterol, salmeterol and indacaterol. LABAs have bronchodilatory effects for 12 
hours. Indacaterol is classed as ultra long-acting as it has a 24 hour effect (Domingo, 
2013). Comparisons were made between the effects of these β2-agonists and the effects 
of the corticosteroid dexamethasone. 
 
6.2. Results 
6.2.1. Comparison of the effects of salbutamol and dexamethasone on cytokine 
release 
Macrophages were treated for 30 min with the β2-agonist salbutamol (10-5 M) or the 
corticosteroid dexamethasone (10-7 M) before being challenged with LPS (10 ng/ml). 
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After 22 h, the release of the pro-inflammatory cytokines TNF-α (figure 6.1A), IL-6 
(figure 6.1B) and IL-8 (figure 6.1C) into the cell culture media was measured by 
ELISA. Salbutamol did not cause significant inhibition of release of any of the 
cytokines (p>0.05). However, dexamethasone significantly inhibited LPS-induced TNF-
α by~99% (p<0.05), IL-6 by ~87% (p<0.001) and IL-8 by ~78% (p<0.0001). 
 
6.2.2. Effects of long and short-acting β2-agonists on cytokine release 
Macrophages were treated for 30 min with a range of β2-agonists. The short-acting β2-
agonists tested were isoprenaline, terbutaline or salbutamol (all 10-5 M). The long-acting 
β2-agonists were formoterol, salmeterol or indacaterol (all 10-5 M). Dexamethasone (10-
7 M) was used as a positive control for inhibition of LPS-induced cytokine release. The 
cells were then challenged with LPS (10 ng/ml). After 22 h, the cell culture supernatants 
were harvested and assayed for TNF-α (figure 6.2A), IL-6 (figure 6.2B) and IL-8 
(figure 6.2C). Only salmeterol and indacaterol significantly inhibited TNF-α and IL-6 
release. Salmeterol inhibited TNF-α by ~49% (p<0.01) and indacaterol inhibited TNF-α 
by ~36% (p< 0.05). Salmeterol inhibited IL-6 by ~56% (p<0.01) and indacaterol 
inhibited IL-6 by ~45% (p< 0.05). None of the β2-agonists tested, including salmeterol 
and indacaterol, had any effect on IL-8 release. Dexamethasone, however, was an 
effective inhibitor of IL-8 release (p<0.001) (figure 6.2C). 
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Figure 6.1. Effects of salbutamol and dexamethasone on LPS-mediated cytokine 
release. Macrophages were pre-treated for 30 min with salbutamol (Salb) (10-5 M) or 
dexamethasone (Dex) (10-7 M) before challenge with LPS (10 ng/ml). After 22 h, cell 
culture supernatants were harvested and assayed for (A) TNF-α, (B) IL-6 and (C) IL-8. 
Drugs alone had no effect on spontaneous cytokine release. Values are mean ± SEM for 
5 individual experiments. (One-way ANOVA with Dunnett’s post test, *p<0.05, 
***p<0.001, ****p<0.0001 compared with LPS alone). 

















































                   
 
Figure 6.2. Effects of β2-agonists on LPS-mediated cytokine release. Macrophages 
were pre-treated for 30 min with β2-agonists (10-5 M) or dexamethasone (10-7 M) before 
challenge with LPS (10 ng/ml). Short-acting β-agonists (SABA): isoprenaline (Iso), 
terbutaline (Ter), salbutamol (Salb). Long-acting β-agonists (LABA): formoterol (For), 
salmeterol (Salm), indacaterol (Ind). After 22 h, cell culture supernatants were 
harvested and assayed for (A) TNF-α, (B) IL-6 and (C) IL-8. Drugs alone had no effect 
on spontaneous cytokine release. Values are mean ± SEM for 6 (TNF-α) or 5 (IL-6, IL-
8) individual experiments. (One-way ANOVA with Dunnett’s post test, *p< 0.05, 
**p<0.01, ****p<0.0001 compared with LPS alone). 
 
 
























































6.2.3. Effects of long and short-acting β2-agonists on cytokine release from MDMs 
MDMs (monocyte-derived macrophages) were treated for 30 min with a range of β2-
agonists. The short-acting β2-agonists tested were isoprenaline, terbutaline or 
salbutamol (all 10-5 M). The long-acting β2-agonists were formoterol, salmeterol or 
indacaterol (all 10-5 M). Dexamethasone (10-7 M) was used as a positive control for 
inhibition of LPS-induced cytokine release. The cells were then challenged with LPS 
(10 ng/ml). After 22 h, the cell culture supernatants were harvested and assayed for 
TNF-α (figure 6.3). All of the β2-agonists tested inhibited TNF-α release. The range of 
inhibition was between 35% and 75%, although it was not possible to determine if this 
inhibition was statistically significant, as only two experiments were performed. 
Incubation with salmeterol or indacaterol resulted in the highest level of inhibition. 
Salmeterol inhibited TNF-α by ~75% and indacaterol inhibited TNF-α by ~47%. 
6.2.4. Influence of LPS concentration on inhibition of cytokine release by β2-agonists 
In order to determine whether the strength of the stimulus might influence the extent of 
inhibition, macrophages were activated with sub-optimal concentrations of LPS and the 
inhibitory effects of β2-agonists were evaluated. Macrophages were incubated for 30 
min with salbutamol, salmeterol or indacaterol (all 10-6 M) before challenge with 0.1, 1 
or 10 ng/ml LPS. After 22 h, TNF-α release was measured. All three β2-agonists 
significantly (p<0.01) inhibited LPS-induced TNF-α release when the LPS 
concentration was 0.1 ng/ml (23-28% inhibition) or 1 ng/ml (14-22% inhibition) (figure 
6.4). However, salmeterol and indacaterol did not inhibit 10 ng/ml LPS-induced TNF-α, 
in contrast to the results of the experiment in the previous section (figure 6.2), in which 
a significant inhibition was observed. However, it should be noted that in the present 
experiment, the concentration of β2-agonists used was lower (10-6 M) than the 




Figure 6.3. Effects of β2-agonists on LPS-mediated cytokine release from MDMs. 
MDMs were pre-treated for 30 min with β2-agonists (10-5 M) or dexamethasone (10-7 
M) before challenge with LPS (10 ng/ml). Short-acting β-agonists (SABA): 
isoprenaline (Iso), terbutaline (Ter), salbutamol (Salb). Long-acting β-agonists (LABA): 
formoterol (For), salmeterol (Salm), indacaterol (Ind). After 22 h, cell culture 
supernatants were harvested and assayed for (A) TNF-α. Drugs alone had no effect on 
spontaneous cytokine release. Values are mean ± SEM for 2 individual experiments.






















Figure 6.4. Effect of LPS concentration on β2-agonist inhibition. 
Macrophages were pre-treated for 30 min with salbutamol, salmeterol or indacaterol 
(10-6 M) before challenge with LPS (0.1, 1 or 10 ng/ml). After 22 h, cell culture 
supernatants were harvested and assayed for TNF-α. Drugs alone had no effect on 
spontaneous cytokine release. Values are mean ± SEM for 3 individual experiments. 
(For each LPS concentration, one-way ANOVA with Dunnett’s post test, **p<0.01, 
***p<0.001 compared with respective LPS alone controls).






















6.2.5. Effects of indacaterol addition pre and post-LPS challenge 
Routinely, β2-agonists were added to cells 30 min before LPS challenge. It was 
investigated whether addition of a β2-agonist after LPS challenge instead could result in 
a difference in the inhibition of TNF-α release. Macrophages were incubated with 
indacaterol (10-6 M) for 30 min before challenge with LPS (1 ng/ml). This was 
compared to indacaterol addition at 2, 4 or 6 h after LPS challenge. After a total of 22 h 
of incubation with LPS, cell culture supernatants were assayed for TNF-α. There was no 
significant (p>0.05) improvement in the inhibitory effects of indacaterol when added 







Figure 6.5. The effect of indacaterol addition at different timepoints pre or post- 
LPS challenge.  
Macrophages were treated with indacaterol (10-6 M) at different timepoints before or 
after challenge with LPS (1 ng/ml). After 22 h, cell culture supernatants were harvested 
and assayed for TNF-α. Indacaterol alone had no effect on spontaneous cytokine 
release. Values are mean ± SEM for 3 individual experiments. (One-way ANOVA with 
Dunnett’s post test, all p>0.05 compared with LPS alone or LPS with 30 min 
indacaterol pre-treatment). 
 


















6.2.6. Effects of β2-agonists on poly(I:C)-mediated cytokine release 
Macrophages were treated for 30 min with salbutamol, salmeterol, indacaterol (all 10-5 
M) or dexamethasone (10-7 M) before being challenged with LPS (10 ng/ml) or 
poly(I:C) (10 µg/ml). After 22 h cell culture supernatants were assayed for TNF-α 
release. In this experiment, only salmeterol significantly (p<0.01) inhibited LPS-
induced TNF-α release (figure 6.6). None of the β2-agonists significantly inhibited 
poly(I:C)-induced TNF-α release (p>0.05). Dexamethasone, however, significantly 
inhibited both LPS-induced (p<0.0001) and poly(I:C)-induced (p<0.01) TNF-α release. 
 
6.2.7. Concentration-dependent effects of β2-agonists on cytokine release 
Macrophages were incubated with a range of concentrations of salbutamol (figure 
6.7A), salmeterol (figure 6.7B) and indacaterol (figure 6.7C) for 30 min before 
challenge with LPS (1 ng/ml). After 22 h, cell culture supernatants were assayed for 
TNF-α release. It was observed that the concentration response ‘curves’ for each of the 
β2-agonists were relatively flat and the highest concentration of drug used (10-5 M) 





Figure 6.6. Effect of β2-agonists on LPS or poly(I:C)-mediated cytokine release. 
Macrophages were pre-treated for 30 min with either β2-agonists salbutamol (Salb), 
salmeterol (Salm) or indacaterol (Ind) (all 10-5 M) or with dexamethasone (10-7 M) 
before challenge with LPS (10 ng/ml) or poly(I:C) (10 µg/ml). After 22 h, cell culture 
supernatants were harvested and assayed for TNF-α. Drugs alone had no effect on 
spontaneous cytokine release. Values are mean ± SEM for 4 individual experiments. 
(One-way ANOVA with Dunnett’s post test, **p<0.01, ****p<0.0001 compared with 
LPS or poly(I:C) alone). 


















                        
 
Figure 6.7. Effect of β2-agonist concentration on LPS-mediated cytokine release. 
Macrophages were pre-treated for 30 min with β2-agonists (A) salbutamol, (B) 
salmeterol or (C) indacaterol before challenge with LPS (1 ng/ml). After 22 h, cell 
culture supernatants were harvested and assayed for TNF-α. Drugs alone had no effect 
on spontaneous cytokine release. Values are for one experiment. 
 














































6.2.8. Effect of β2-agonists on cAMP levels  
The effect of β2-agonists on total cyclic-AMP (cAMP) levels in macrophages was 
investigated. The short-acting β2-agonists tested were isoprenaline, terbutaline or 
salbutamol (all 10-5 M). The long-acting β2-agonists were formoterol, salmeterol or 
indacaterol (all 10-5 M). Macrophages were incubated with the drugs for 30 min before 
being solubilized and assayed for total cell cAMP levels. The values indicated that the 
cAMP levels increased over the spontaneous levels, in response to β2-agonists (figure 
6.8). However, no striking differences were observed between the responses to the 
different drugs. 
 
6.2.9. Inhibition of cytokine release by indacaterol in combination with 
dexamethasone 
As some current treatments combine long-acting β2-agonists with corticosteroids, the 
effect of indacaterol in combination with dexamethasone on LPS-induced cytokine 
release was investigated. Macrophages were incubated with a range of indacaterol 
concentrations (10-5-10-7 M) for 30 min before challenge with LPS (1 ng/ml) for 22 h. 
Indacaterol alone did not result in inhibition of LPS-induced TNF-α release (p>0.05) 
(figure 6.9A). In the same experiment, macrophages were incubated for 30 min with 
indacaterol and dexamethasone (10-9 M) before challenge with LPS (1 ng/ml) for 22 h. 
Cell culture supernatants were assayed for TNF-α release. Dexamethasone, at the sub-
optimal concentration used (10-9 M), did not significantly (p>0.05) inhibit LPS-induced 
TNF-α release (figure 6.9B). However a significant (p<0.05) decrease in LPS-induced 
TNF-α release was seen with dexamethasone in combination with all three 




Figure 6.8. Release of cAMP in response to β2-agonists. Macrophages were incubated 
without or with β2-agonists (10-5 M) for 30 min. Short-acting β-agonists (SABA): 
isoprenaline (Iso), terbutaline (Ter), salbutamol (Salb). Long-acting β-agonists (LABA): 
formoterol (For), salmeterol (Salm), indacaterol (Ind). After this treatment, the cells 
were solubilized and assayed for total cell cyclic-AMP levels. Values are for one 
experiment. 
























Figure 6.9. Effect of combination of indacaterol with dexamethasone on LPS-
induced cytokine release. Macrophages were pre-treated for 30 min with indacaterol 
(A) and with dexamethasone (10-9 M) for 30 min (B) before challenge with LPS (1 
ng/ml). After 22 h, cell culture supernatants were harvested and assayed for TNF-α. 
Drugs alone had no effect on spontaneous cytokine release. Values are mean ± SEM for 
4 individual experiments. (One-way ANOVA with Dunnett’s post test, *p< 0.05, 
**p<0.01, compared with LPS alone). 
 





































6.2.10. Inhibition of cytokine release by indacaterol in combination with an EP4 
antagonist 
In Chapter 4 of this thesis, it was demonstrated that PGE2 acts on the EP4 receptor to 
inhibit cytokine release from macrophages. It was possible that endogenously generated 
PGE2 could have influenced the inhibition of cytokine release seen with β2-agonists. 
Therefore, it was investigated whether blocking the effects of PGE2 on the EP4 receptor 
would alter the inhibition seen with β2-agonists. In this experiment, indacaterol alone at 
a range of concentrations (10-5-10-7 M) did not result in inhibition of LPS-induced TNF-
α release (p>0.05) (figure 6.10A). In the same experiment, macrophages were incubated 
with EP4 antagonist (CJ-042794) for 1 h and for a further 30 min with indacaterol 
before challenge with LPS (1 ng/ml). After 22 h, cell culture supernatants were assayed 
for TNF-α release. The EP4 antagonist resulted in a significant (p<0.01) increase in 
LPS-induced TNF-α release. This TNF-α release was not significantly (p>0.05) 
inhibited by indacaterol (figure 6.10B). This meant that there was no improvement in 
the inhibitory effects of indacaterol on LPS-induced TNF-α when the EP4 antagonist 
was present. 
 
6.2.11. Effect of indomethacin on inhibition of cytokine release by salbutamol 
Further investigation into the effects of the presence of endogenously generated PGE2 
on the inhibitory effects of β2-agonists was carried out. In this experiment, the 
cyclooxygenase (COX) inhibitor indomethacin was used to block endogenous PGE2 
production. Macrophages were incubated without or with indomethacin (1 µM) for 30 
min and then with salbutamol for 30 min. The cells were then challenged with LPS (1 
ng/ml) for 22 h, after which cell culture supernatants were assayed for TNF-α release. 
The inhibition curves showed that the presence of indomethacin did not improve the 




Figure 6.10. Effect of combination of indacaterol with EP4 antagonist on LPS-
induced cytokine release. Macrophages were pre-treated for 30 min with indacaterol 
(A) and with EP4 antagonist CJ-042794 (300 nM) for 1 h (B) before challenge with 
LPS (1 ng/ml). After 22 h, cell culture supernatants were harvested and assayed for 
TNF-α. Drugs alone had no effect on spontaneous cytokine release. Values are mean ± 
SEM for 4 individual experiments. (One-way ANOVA with Dunnett’s post test, *p< 
0.05, **p<0.01, compared with LPS alone and #p>0.05, compared with LPS+EP4 
antagonist alone). 








































Figure 6.11. Effect of indomethacin on salbutamol inhibition. Macrophages were 
pre-incubated (30 min) without or with indomethacin (1 µM) and then with salbutamol 
for 30 min before challenge with LPS (1 ng/ml). After 22 h, cell culture supernatants 
were harvested and assayed for TNF-α. Drugs alone had no effect on spontaneous 
cytokine release. Values are expressed as the % inhibition of the unblocked control 
TNF-α release. Values are mean ± SEM for 4 individual experiments (+ indomethacin) 
and values for 1 experiment (- indomethacin). 
 
 


















6.2.12. Functional desensitization of β2-agonist responses 
Macrophages were incubated in media without or with either indacaterol (10-5 M) or 
salmeterol (10-5 M) for 22 h before being washed twice. The cells were then incubated 
for 30 min without or with either indacaterol (10-5 M) or salmeterol (10-5 M) before 
being challenged with LPS (1 ng/ml) for 22 h. Cell culture supernatants were then 
assayed for TNF-α release. The results demonstrated that indacaterol significantly 
(p<0.05) inhibited LPS-induced TNF-α release (figure 6.12A). Salmeterol also 
significantly (p<0.05) inhibited LPS-induced TNF-α release (figure 6.12B). When the 
cells were incubated for 22 h with indacaterol, the subsequent ability of indacaterol to 
inhibit TNF-α release was significantly (p<0.05) abrogated (figure 6.12A). By contrast, 
after 22 h of pre-incubation with salmeterol, the subsequent inhibition by salmeterol 
was unaffected (figure 6.12B). This indicated that desensitization of the indacaterol 
response occurred whereas desensitization of the salmeterol response did not occur. 
Investigation of potential cross-desensitization indicated that pre-treatment with 
indacaterol had no effect on subsequent salmeterol inhibition (figure 6.13A) and that 





Figure 6.12. Effect of indacaterol and salmeterol on desensitization of the β2-
adrenoceptor mediated response. Macrophages were incubated without or with 
indacaterol or salmeterol (10-5 M) for 22 h, after which the cells were washed. The cells 
were then incubated without or with indacaterol or salmeterol (10-5 M) for 30 min 
before challenge with LPS (10 ng/ml) for 22 h. Cell culture supernatants were harvested 
and assayed for TNF-α. Drugs alone had no effect on spontaneous cytokine release. 
Values are mean ± SEM for (A) 5 and (B) 4 individual experiments. (One-way ANOVA 



































































Figure 6.13. Effect of indacaterol and salmeterol on cross-desensitization of the β2-
adrenoceptor mediated response. Macrophages were incubated without or with 
indacaterol or salmeterol (10-5 M) for 22 h, after which the cells were washed. The cells 
were then incubated without or with indacaterol or salmeterol (10-5 M) for 30 min 
before challenge with LPS (10 ng/ml) for 22 h. Cell culture supernatants were harvested 
and assayed for TNF-α. Drugs alone had no effect on spontaneous cytokine release. 






















































































Macrophage numbers are increased in the lung in inflammatory lung diseases and this 
could contribute to disease progression and severity (Barnes, 2008b). Although β2-
agonists used in current treatments are not designed to target macrophages specifically, 
their effects on the cells could be important to the overall benefits of the drugs. The 
reports of the effects of β2-agonists on macrophages are conflicting. Some reports show 
that certain β2-agonists have anti-inflammatory effects, whereas in other reports the 
same drugs do not. However, the same model systems were not used in all of the 
studies. In the present study, the effect of short and long-acting β2-agonists on pro-
inflammatory cytokine release from human lung macrophages was investigated. 
 
Investigations were carried out into the effects of the SABA salbutamol and terbutaline, 
on LPS-induced TNF-α, IL-6 and IL-8 release. Neither drug significantly inhibited any 
of the cytokines in these initial studies. As salbutamol and terbutaline are partial 
agonists at the β2-adrenoceptor (Cazzola et al., 2012), the effects of a full agonist, the 
SABA isoprenaline were also studied, for comparison. It was found that isoprenaline 
also did not cause significant inhibition of cytokine release. However, isoprenaline has a 
very short duration of action (1-2 h) as it is can be rapidly metabolized to 3-O-methyl-
isoprenaline (Cazzola et al., 2012), and it is possible that this may have limited its 
effects in these studies. 
 
Comparisons were made with the effects of LABAs, to determine whether drugs with a 
longer duration of action may be more effective at inhibiting pro-inflammatory cytokine 
release. Only two of the LABAs studied, salmeterol and indacaterol, consistently 
inhibited TNF-α and IL-6 release. Formoterol, surprisingly, did not cause any 
significant inhibition, despite being a full agonist at the β2-adrenoceptor (Cazzola et al., 
 214
2012). Formoterol, along with salmeterol, is reported to have inhibited TNF-α release in 
MDMs (Donnelly et al., 2010). Therefore the effects of the β2-agonists investigated here 
were also very briefly explored using MDMs. Although further repetitions of the 
experiment are required, the preliminary data suggest that all of the SABAs and LABAs 
tested inhibit TNF-α release from MDMs to some extent. This indicates that potential 
differences exist between lung macrophages and MDMs in functional responses. It has 
been suggested that β2-adrenoceptors are lost or down-regulated on monocytes as they 
differentiate into macrophages (Ezeamuzie et al., 2011). MDMs in vitro may not be as 
fully differentiated or as mature as lung macrophages, which could explain the better 
response to SABAs and LABAs that was observed. 
 
High levels of the neutrophil chemoattractant IL-8 are found in sputum, lavage and 
blood of COPD patients (Nocker et al., 1996, Garcia-Rio et al., 2010). IL-8 release from 
lung macrophages was not inhibited by any of the β2-agonists. As described in previous 
chapters in this thesis, the release of IL-8 from human lung macrophages was 
considerably higher than the other cytokines. In Chapter 3, investigation of the time 
course of IL-8 release in response to LPS revealed that IL-8 release continued to 
increase over 22 h whereas the release of the other cytokines was maximal at 16 h and 
then plateaued. Lack of inhibition of IL-8 by β2-agonists has been reported elsewhere. 
Donnelly et al. showed that LPS-induced IL-8 release from MDMs was not attenuated 
by cAMP increases resulting from the action of β2-agonists. This is the process that is 
generally believed to lead to inhibition of LPS-induced cytokines (Donnelly et al., 2010, 
Ezeamuzie and Shihab, 2010). The selective inhibition of certain cytokines but not IL-8 
by β2-agonists could be considered to be undesirable, as it could lead to an increase in 
neutrophilia in the lung. 
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Generally, it is believed that the mode of action of β2-agonists to inhibit LPS-induced 
cytokine release is to act on the β2-adrenoceptor to cause increases in intracellular 
cAMP (Donnelly et al., 2010, Ezeamuzie and Shihab, 2010). The transcription factor 
NF-κB can be inhibited by cAMP, resulting in inhibition of transcription of cytokine 
genes. Measurement of cAMP in response to a range of β2-agonists including the ones 
found to be most effective at inhibiting cytokine release in this study (salmeterol and 
indacaterol) showed that there were no striking differences in the extent of cAMP levels 
induced. This could indicate that the inhibitory effects of LABAs seen in this study may 
not be linked to cAMP increases. It has been suggested elsewhere that not all β2-
agonists work through a cAMP-dependent pathway to exert anti-inflammatory effects 
(Donnelly et al., 2010). However, in the present study, cAMP was measured after 30 
min exposure to agonists and whether the increased cAMP levels are sustained over 
longer time periods was not evaluated. It is possible that increased cAMP levels are 
sustained by LABAs but not by SABAs. These considerations make it difficult to 
determine the relationship between cAMP increases and cytokine inhibition. 
 
Overall, the results of these initial investigations implied that β2-agonists had limited 
effects as inhibitors of cytokine release. Therefore, it was investigated whether the 
inhibition could potentially be improved by modification of certain experimental 
conditions. The inhibition of cytokine release was found to be dependent on a 
combination of both the strength of the LPS stimulus (and therefore the level of 
cytokine generation) and on the concentration of drug used. In the presence of a sub-
maximal concentration of stimulus, the SABA salbutamol was able to cause inhibition 
of TNF-α release, which it was unable to do when a maximally-effective concentration 
of stimulus was used. In the initial investigations discussed at the start of this section, 
the LABAs salmeterol and indacaterol inhibited TNF-α release when a maximally-
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effective concentration of stimulus was used. However, when a lower concentration of 
salmeterol and indacaterol was used in the presence of this maximally-effective 
concentration of stimulus, they failed to inhibit TNF-α release. These results highlight 
that β2-agonists show some limited inhibitory effects on macrophages in this system. 
However, it is possible that in vivo, macrophages may produce lower cytokine levels in 
response to stimuli. Therefore, it is feasible that under such conditions, β2-agonists 
could be more effective in vivo. 
 
In order to determine whether the moderate inhibitory activity observed with β2-
agonists might be influenced by timing, this issue was investigated. Addition of 
indacaterol at time points up to six hours after LPS stimulation did not alter the 
inhibition of TNF-α release compared to pre-incubation with indacaterol. The results 
indicate that inhibition by indacaterol is not improved if added at a time point that is 
likely to be after the initiation of cytokine gene transcription.  
 
In addition to inhibition of LPS-induced cytokine release, the inhibition of cytokines 
induced by another stimulus associated with macrophage activation was investigated. 
The viral mimic poly(I:C), a TLR3 agonist, was used. Salbutamol, salmeterol and 
indacaterol did not inhibit poly(I:C) induced TNF-α release. It could be that there is a 
difference in β2-agonists inhibiting cytokines generated by a viral infection than a 
bacterial infection, perhaps due to differences in the transcription factors activated that 
lead to cytokine generation. This could be important as it could be the case that β2-
agonists have a slightly beneficial anti-inflammatory effect in bacterial infections but 
not in virus-induced exacerbations. This requires further investigation. 
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In Chapter 4 of this thesis, it was confirmed that macrophages produce PGE2 
endogenously and that PGE2 inhibited cytokine release by acting at the EP4 receptor. It 
was possible that the effects of endogenous PGE2 produced upon LPS stimulation could 
be masking inhibition seen with β2-agonists. It was of interest to determine whether 
inhibition by the β2-agonists was altered after attenuation of the actions of PGE2. Using 
an EP4 antagonist to block endogenous PGE2 acting on the EP4 receptor resulted in an 
increase in TNF-α. However, combining the EP4 antagonist with indacaterol did not 
improve the inhibitory effects of indacaterol. This indicates that the presence of 
endogenous PGE2 did not affect inhibition by β2-agonists. This was investigated further 
by using indomethacin to block endogenous PGE2 generation and the effect of 
salbutamol on cytokine release was then examined. Salbutamol alone was found to 
inhibit TNF-α release by ~30% and the presence of indomethacin did not improve this 
inhibition. 
 
The corticosteroid dexamethasone was used in this study as a positive control for 
inhibition of LPS-induced cytokine release. Dexamethasone inhibited all of the 
cytokines investigated, including IL-8, confirming that corticosteroids have potent anti-
inflammatory activity in this system. It has been reported that macrophages in some 
cases can be corticosteroid insensitive, for example in COPD (Rossios et al., 2012). It is 
believed that the oxidative stress in COPD can affect the mechanism of action of 
corticosteroids at a molecular level. However, other researchers have reported that there 
are no issues of corticosteroid insensitivity in COPD macrophages compared to controls 
(Plumb et al., 2013, Higham et al., 2014). Corticosteroid insensitivity was not found to 




As β2-agonist and corticosteroid combination therapy is used for patients, the 
combination of indacaterol and dexamethasone on TNF-α release from macrophages 
was investigated. In this study, dexamethasone at a nanomolar concentration did not 
inhibit LPS-induced TNF-α release. However, in the presence of indacaterol, 
dexamethasone was able to cause inhibition. This could be considered to be a steroid-
sparing effect (Taylor and Hancox, 2000). Considering the issues associated with 
corticosteroids in therapy, the ability to use a lower concentration could be beneficial. It 
has been proposed that β2-agonists and corticosteroids can work synergistically (Taylor 
and Hancox, 2000). There are several mechanisms that have been proposed for 
synergistic effects. For example, β2-agonists may activate transcription factors which 
cross-talk with glucocorticoid receptor transcription factors, leading to enhancement of 
glucocorticoid receptor function (Korn et al., 1998). Glucocorticoids may enhance β2-
agonist responses by counteracting β2-adrenoceptor desensitization and downregulation 
(Johnson, 2004). The data in the present study suggest that there may be a modest 
additive inhibitory effect of dexamethasone and indacaterol on macrophage function. 
 
To attempt to delineate the mode of action of salmeterol and indacaterol, experiments 
were carried out investigating functional desensitization of the β2-agonist responses. 
Long-term incubation of macrophages with indacaterol led to abrogation of the 
inhibitory effects of indacaterol. By contrast, long-term incubation of macrophages with 
salmeterol had no effect on the inhibitory effects of salmeterol on TNF-α release. These 
data suggest that the effects of indacaterol are receptor-mediated whereas those of 
salmeterol are not. Potential cross-desensitization of the functional response was also 
investigated. Incubation of macrophages with indacaterol followed by incubation with 
salmeterol did not affect the ability of salmeterol to inhibit cytokine release. This 
suggests that salmeterol and indacaterol exert their inhibitory effects through different 
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mechanisms. These findings further support the idea that inhibition by salmeterol may 
not be β2-adrenoceptor-mediated (Chong et al., 1998), whereas indacaterol is likely to 
be acting at the macrophage β2-adrenoceptor to exert its inhibitory effects. It has been 
reported that salmeterol inhibits via a cAMP-independent mechanism in MDMs 
(Donnelly et al., 2010) but further work is required to determine whether this is 
specifically the case in this study. For any definitive conclusions to be drawn, it would 
be necessary to carry out further work to determine the mechanism by which these 
drugs work. 
 
In this study, it was found that the LABAs salmeterol and indacaterol were more 
effective than the SABA in inhibiting LPS-induced cytokine release from human lung 
macrophages. The physicochemical properties of these two LABAs contribute to their 
long-acting effects. Both drugs are highly lipophilic and therefore likely to be 
sequestered in the plasma membrane of the cell. This means that they are well situated 
potentially to repeatedly activate the β2-adrenoceptor (Domingo, 2013). Lipid rafts in 
the cell membrane have a high density of β2-adrenoceptors (Domingo, 2013). 
Indacaterol has a high affinity for lipid raft microdomains and this affinity is higher than 
that of salmeterol (Cazzola et al., 2012). β2-agonists exert their effects by binding to the 
active site of the β2-adrenoceptor. In addition to this, reports suggest that salmeterol can 
also bind to the ‘exosite’ of the β2-adrenoceptor by its lipid tail, which makes the 
association with the receptor more secure. Formoterol is less lipophilic than salmeterol 
(Anderson et al., 1994) but its lipophilicity is comparable to that of indacaterol (Cazzola 
et al., 2013). Like indacaterol, formoterol is also unable to access the ‘exosite’ of the β2-
adrenoceptors (Cazzola et al., 2012). Despite having similar physicochemical properties 
to indacaterol, formoterol lacked inhibitory activity on macrophages in this study. The 
reason for this is difficult to conclude. It could be the case that formoterol has a lower 
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affinity for lipid raft microdomains than indacaterol, which perhaps leads to the 
difference in effect on lung macrophages. 
 
In summary, β2-agonists inhibited the release of TNF-α and IL-6 to a limited extent but 
had no effect on IL-8 generation from macrophages. LABAs were found to be slightly 
better as inhibitors than SABAs. However, it is difficult to establish from the results of 
these studies whether these drugs would be effective in the clinical context. It is 
possible that the β2-agonists could be more effective in vivo if, for example, the 
cytokine generation is lower than in these studies. Nevertheless, this is in contrast to the 
effective and blanket inhibition of cytokine generation seen with the corticosteroid 
dexamethasone. The limited effects of the β2-agonists observed in this study suggest 
that any major anti-inflammatory effects that may be seen in patients following 




Chapter 7: Final Discussion 
 
Macrophages are important cells in the lungs in the context of homeostasis and in the 
physiological response to infections. However, inappropriate activation of macrophages 
could cause aberrant inflammation, which may implicate the cells in inflammatory 
diseases. A greater understanding of the characteristics of macrophages may enable 
determination of their possible roles in these diseases. At present, one of the major 
interests in macrophage biology research is the phenotypic heterogeneity of 
macrophages. This is a complex area and many questions remain to be answered. 
Although a body of knowledge is available based on studies using murine macrophages, 
surprisingly little is known of the different markers that define human macrophage 
phenotypes. Characterization of human macrophage phenotype may be an important 
contribution to determination of the potential roles macrophages play in different 
diseases. In addition to this, the plasticity of macrophages, which enables change of 
phenotype in different conditions, is also an exciting area, particularly in the context of 
how a particular phenotype might be linked to a certain disease state. 
 
In the present study, macrophages were isolated from human lung tissue to be used as a 
model for investigations. It was found that the cells were highly responsive to 
stimulation by TLR agonists, releasing considerable amounts of pro-inflammatory 
cytokines and chemokines. This spectrum of cytokine generation indicated that the cells 
expressed an M1-like phenotype. 
 
As well as generating cytokines in response to stimulation, macrophages also generated 
some cytokines spontaneously. In particular, considerable levels of spontaneous IL-8 
release were measured. This was surprising, since activation of macrophages is believed 
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to be tightly regulated in the steady state in vivo. Comparison of the use of ultra-low 
endotoxin FCS with the FCS routinely used in the cell culture media allayed the initial 
concern that the cells may have been activated inappropriately by endotoxin 
contamination in vitro. It was also found that the cytokine response to LPS was not 
altered even when the cells were cultured over the course of five days, indicating that 
the cells were unlikely to be inappropriately activated whilst being cultured. However, 
the possibility of the responsiveness of macrophages changing after being removed 
from lung tissue into an artificial cell culture environment cannot be excluded as a 
reason for the cells being highly responsive to stimuli and for the elevated spontaneous 
generation of some cytokines. 
  
Flow cytometry was used to investigate cell surface markers in an attempt to gain some 
insight of macrophage phenotype. It was found that CD206 was expressed on virtually 
all non-stimulated macrophages but the expression of CD14 was low. This suggested 
that the cells were mature macrophages, as CD14 is down-regulated during 
differentiation from monocyte to macrophage (Daigneault et al., 2010). This was in 
contrast to MDMs, which expressed similar levels of both CD206 and CD14. However, 
further studies are required to determine if this apparent difference in maturity translates 
to a difference in functional responses between the two cell types. As CD206 is 
generally regarded as being an M2 marker, the data implied that the phenotype of lung 
macrophages may be M2 but the functional data from this study suggested otherwise. 
 
One thing that emerged when investigating macrophage markers was that simply 
investigating the expression of a certain set of markers in a static context is not 
sufficient for determining phenotypes. A comparison of expression levels before and 
after stimulation is required. For example, observation of whether the CD206 
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expression changes upon stimulation of macrophages would possibly assist in revealing 
the phenotype and this approach would be taken in future studies. The flow cytometry 
studies also reinforced the notion that investigation of the expression of more than two 
markers is required to enable a clearer determination of phenotype. However, 
exploration of cell surface markers by flow cytometry was hampered by the high 
autofluorescence exhibited by many of the cell preparations. This is an issue for human 
macrophage researchers worldwide and a limitation of using cells from patients who are 
overwhelmingly likely to be current or ex-smokers. In any case, a multi-pronged 
approach consisting of determining markers in conjunction with functional studies is 
required for phenotype determination. 
 
Another technique that can be used for investigating phenotypic markers is qPCR. 
Preliminary qPCR studies were found to be promising. The expression of certain genes 
was changed upon stimulation of the cells with certain M1 or M2 stimuli. The term 
‘spectrum of macrophage activation’, that is used in the literature (Mosser and Edwards, 
2008), was found to be accurate, as the data indicated skewing towards a particular 
phenotype and not complete switching following activation. The qPCR data indicate 
that the macrophages can exhibit plasticity when stimulated. The question is whether 
the cells have the ability to change phenotype repeatedly, or whether there are a finite 
number of changes that can take place.    
 
Overall, it seemed that the isolated cells predominantly exhibited an M1 phenotype. 
This was based on the high levels of pro-inflammatory cytokines released in response to 
TLR agonists and low levels or virtually no release of anti-inflammatory cytokines. The 
qPCR data also indicated that the cells expressed an M1 phenotype at baseline before 
stimulation. Although the flow cytometry studies were inconclusive with regards to 
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determining phenotype, data from further studies investigating more markers may be 
useful when considered alongside the results of mediator release and gene expression 
studies. 
 
Although macrophages are implicated in COPD, they may also be involved in asthma. 
It has been reported that IgE-dependent activation of macrophages can result in 
cytokine release, potentially contributing to asthma. However, this effect was not 
generally reproduced in this study, with the exception of one cell preparation, which 
responded with the release of pro-inflammatory cytokines. Passive sensitization of the 
cells with IgE and challenge with antigen also did not activate the cells. As direct IgE-
dependent activation overwhelmingly did not occur, this line of research was not 
pursued further in this project. A greater number of cell preparations need to be tested to 
enable any firm conclusions to be drawn about the IgE-dependent responsiveness of the 
cells. It may be the case that cells from asthmatics express more IgE receptors and may 
therefore respond with the release of cytokines. Although only weak evidence for IgE-
dependent activation of macrophages was found in this study, the possibility of 
macrophages contributing to exacerbations in asthma, following infections, cannot be 
excluded. 
 
Although LPS stimulation was effective at inducing cytokine release, it also resulted in 
production of PGE2. Previous studies have shown macrophages produce PGE2 in 
response to LPS but the high levels produced by lung macrophages in the present study 
were surprising. This PGE2 acts in paracrine fashion, presumably to inhibit cytokine 
release from macrophages as a mechanism to attenuate inflammatory responses. 
Induction of COX-2 is an important mechanism in the inflammatory response. Indeed, it 
was found that LPS and N. meningitidis, a gram-negative bacterium, up-regulated COX-
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2. However, excessive PGE2 production as a result of increased COX-2 induction may 
attenuate inflammatory responses excessively, decreasing the ability of the macrophage 
to manage an infection. Further studies would be beneficial, investigating the effects of 
other relevant pathogens such as Haemophilus influenzae and Streptococcus 
pneumoniae to determine whether these pathogens interfere with the COX/PGE2 axis 
and how this might impact on macrophage function.  
 
The utilization of novel, selective ligands for the EP2 and EP4 receptors enabled the 
determination that PGE2 acts at the EP4 receptor and not the EP2 receptor to inhibit 
LPS-induced cytokine release. This is contrary to reports of both the EP2 and EP4 
receptors being responsible for this effect (Ratcliffe et al., 2007). It has been suggested 
that it may be possible for an EP4 agonist to be used to target the EP4 receptor as a 
bronchodilator (Buckley et al., 2011). The present study suggests an EP4 agonist could 
also be used as an anti-inflammatory. 
 
In the present study, LPS caused up-regulation of both EP2 and EP4 receptors at the 
mRNA level. Although the EP4 receptor is likely to be the principal functional receptor 
initially, it is possible that LPS activation induces EP2 receptor expression in a time-
dependent fashion. This could mean that after LPS activation the EP2 receptor could 
also mediate the effects of PGE2 but this was not investigated. Further studies 
investigating this and any changes to the functional responses are required. It may also 
be the case that EP2 receptors regulate macrophage functions other than cytokine 
generation, such as phagocytosis, which warrants investigation. 
 
It is of interest that EP agonists were found to be much more potent than β2-agonists as 
anti-inflammatory agents. This is despite the fact that both EP receptors and β2-
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adrenoceptors activate adenylyl cyclase to cause cAMP increases. As Gs protein, 
adenylyl cyclase and downstream amplification events are expected to be the same for 
both receptors in the same cell preparation, the data suggest that the density of EP4 
receptors available for coupling with Gs is greater than the density of β2-adrenoceptors. 
Alternatively, there are reports of cAMP signalling being compartmentalized, resulting 
in the cAMP generated upon activation of the different receptors leading to differential 
effects on the cell. The extent of cAMP signalling may be regulated by cAMP-
dependent phosphodiesterases (PDEs) (Zaccolo, 2006). The cAMP signals generated by 
PGE2 may be regulated by a different PDE to the PDE regulating cAMP generated by 
β2-agonists. This may have some bearing on the efficacy of these agonists and may 
warrant further study.    
  
The results of the studies in this thesis provide a contribution to the information 
available on human lung macrophages in the context of inflammation. The issues of 
performing these studies in lung macrophages have been highlighted. Preliminary 
characterization of phenotype has indicated that the cells have a predominantly M1, pro-
inflammatory phenotype. Knowledge of the functional EP receptors expressed by 
macrophages that mediate the effects of PGE2 was extended. These studies indicated 
that targeting EP4 receptors may be a promising approach for stabilizing macrophages 
in inflammation. Although further work is clearly required, the studies in this thesis 
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FORM 1: Information Sheet 
 
STUDIES ON LUNG CELLS INVOLVED IN RESPIRATORY DISEASES  
 
Introduction 
We invite you to participate in studies aimed at understanding how lung cells are 
activated and how drugs affect the activation. Please read this leaflet carefully.   
 
Background 
We are interested in different types of lung cell and the triggers that activate these 
cells.  Lung cell activation could contribute to respiratory diseases such as asthma.  
We are also interested in establishing mechanisms by which established drugs used 
for respiratory disorders, such as inhalers, work on cells found in the lung.  We are 
also interested in testing alternative drugs on these cells either to assess how the 
cells work or because some of these drugs may be of potential therapeutic benefit.  
Some of these drugs will, therefore, have been developed by the pharmaceutical 
industry.  Overall, these studies will identify (a) how lung cells are activated and (b) 
novel approaches to treating lung diseases. 
 
What is involved? 
During your operation, it is possible that lung tissue will be removed by the surgeons.  
Part of this tissue will be examined under the microscope for a diagnosis to be made 
and then the remainder disposed of according to proper hospital guidelines.  We 
would like to take a part of the lung tissue, which would normally be disposed of, to 
use in our studies. You will not have extra lung tissue removed for research 
purposes.  The tissue would be processed and analysed in our laboratory.  A small 
portion of the tissue would be deposited in a research tissue bank designed to aid 
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arrangements we would be grateful if you could please complete the accompanying 
short questionnaire and consent form. 
 
What are the possible disadvantages and risks of taking part? 
There are no disadvantages or risks associated with participation in this study other 
than the small inconvenience of filling in the accompanying short questionnaire and 
consent form. 
 
What are the possible benefits of taking part? 
There are no direct benefits in taking part but the information we get from the study 
may help to improve the treatment of people with respiratory diseases in the future. 
 
What if I do not wish to take part? 
This is entirely up to you.  If you choose not to participate, you need not give a 
reason and this will not affect your current or future medical care in any way. 
 
What about confidentiality? 
The information provided is treated with the strictest confidence and is seen only by 
the people running the study.  Indeed, the study will be conducted anonymously.  
Your name will not appear in any publications.  
 
What if I wish to complain about the way the study has been conducted? 
If you have any cause to complain about any aspect of the way in which you have 
been approached to take part in the study, the normal NHS complaints mechanisms 
are available to you. 
 
If you have any complaints and concerns, please contact the project co-ordinator: 
Dr P Peachell  Telephone 0114-271-2063 
 
Otherwise, you can contact the Patient Advice and Liaison Service for further 
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Will I be able to find out the results? 
If you wish, we can let you know the results at the end of the study. 
 
What if I change my mind about participating? 
You can withdraw from participation at any time that you so wish without giving a 
reason.  Any information and materials that you may have contributed to the study 
will be deleted.  If you decide to withdraw from the study then please contact Dr 
Peter Peachell by telephone (0114-271-2063) or in writing (see address on 
letterhead).  Using standard operating procedures, any stored materials in the 
research tissue bank will be traced and disposed of.  Also, any scientific information 
generated from the donated tissue, which has not been published, will be deleted.  
However, any data generated from the donated sample that has already been 









  Version 1.5, August 2010 
                                    
 
FORM 2: Short Questionnaire 
 
STUDIES ON LUNG CELLS INVOLVED IN RESPIRATORY DISEASES 
 
NAME    ________________________ 
 
CONTACT ADDRESS ________________________ 
 
    ________________________ 
 
DATE OF BIRTH  ________________________ SEX   ________ 
 
 
DO YOU HAVE ANY OF THE FOLLOWING MEDICAL CONDITIONS? 
 
ASTHMA    YES/NO 
   
EMPHYSEMA/COPD  YES/NO 
   
ALLERGIES    YES/NO 
  (if yes, please specify what  




  SMOKER    YES/NO/EX 
 
PLEASE LIST YOUR CURRENT MEDICATION 
 
______________  ________________  ________________ 
 
______________  ________________  ________________ 
 
______________  ________________  ________________ 
  
 
THANK YOU FOR YOUR HELP 
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RESEARCH CONSENT FORM 
 
PROJECT TITLE: 
STUDIES ON LUNG CELLS INVOLVED IN RESPIRATORY DISEASES 
 












I confirm that I have read and understand the information sheet 



















I understand that my participation is voluntary and I am free to 
withdraw from participation:  
       at any time 
       without having to give a reason  
       without affecting my future medical care 






I agree to donate a sample of my lung tissue for use in this 




















(Please place this completed form in the provided envelope and bring with you  
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PARTICIPANT INFORMATION SHEET 
Study: Investigation of how macrophage responses to micro-organisms programme the innate immune response to human 
disease. 
 
You are being asked to allow us to take a blood sample for use in a research study.  Before you decide whether to give 
consent for this to be done it is important for you to understand why the research is being done and what it will involve.  
Please take time to read the following information carefully and ask us about it if you wish.  Ask us if there is anything 
that is not clear or if you would like more information.  Take time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
We wish to determine how white blood cells called macrophages contribute to the bodies host defence against micro-
organisms including bacteria and viruses. These cells represent the first line of resistance to infection and are able to 
respond in a variety of ways to these micro-organisms.  These pre-programmed responses are general and non-specific 
and are often referred to as part of the body’s innate immune system. We are discovering however that there is great 
diversity in the innate immune responses to different micro-organisms and this is particularly true of how the 
macrophages react when challenged by infections.  Since the macrophages are able to both initiate the early response to 
micro-organisms but also to co-ordinate the overall immune response involving other components of the immune response 
we believe they are a central cell to investigate in order to build up a better understanding of how the innate immune 
system works.  Improving our understanding of the diversity of macrophage responses will enable a more complete 
understanding of how these cells work. 
 
To better characterise the macrophages response to infection we will isolate cells from your blood called peripheral blood 
mononuclear cells.  A subset of these cells, when grown in the laboratory, will give rise to macrophages.  Since it is only a 
small subset of your overall white blood cells that will become macrophages we need to collect 300-500 ml of blood.  
Once matured in the laboratory your macrophages will be exposed to certain bacteria or viruses and we will determine 
how they kill the micro-organisms, the proteins they express in response to challenge, how they interact with other 
components of the immune system (including cells and proteins) and how regulation of their lifespan influences their 
functions.  In certain experiments we may isolate other cells or soluble factors from your blood and examine their 
response to micro-organisms, whether in the presence of macrophages or to contrast their responses to that of 
macrophages. By contrasting these responses to a variety of micro-organisms we will build up a better idea of the 
essential elements of this response and the ways in which micro-organisms subvert it. 
 
What will be involved if I agree to take part in the study? 
We would like to take a blood sample from you.  The blood will be drawn using a phlebotomy bag similar to those used 
by the blood transfusion service and will be drawn by a qualified doctor. We will ask you to lie down while the blood is 
drawn. If necessary we can put some anaesthetic cream on your arm so that you will barely feel any discomfort at all. You 
may want a plaster to be put on your arm after the test has been taken. Occasionally people feel dizzy or sweaty during 
blood donation and if you do you can ask the doctor to stop drawing the blood. Some individuals experience a small 
bruise. There should be no other effects of the blood donation. If you wish to donate blood in the future (at least 4-6 
months after the first donation) we will ask you some questions to determine if you have symptoms of anaemia and offer 
to perform a full blood count. If you agree to this test and it is abnormal we will ask that you contact your GP and we will 










Do I have to take part? 
No.  You are free to refuse to participate.  If you say no there will be no other consequences. 
 
Are there any reasons why I should not take part? 
In screening potential volunteers for the study we will ask if you have any ongoing medical conditions or take any regular 
medicines. If so we will ask you to not take part unless they are conditions such as minor asthma requiring use of an 
inhaler. We will also ask if you have had any illness in the last month or received a vaccine. We also want to make sure 
you have not donated blood for any  
 
reason in the last 6 months, been told you are anaemic or have any symptoms to suggest possible anaemia such as 
shortness of breath, chest pain on exertion, fatigue or excessive pallor 
 
How long will you keep my cells and DNA in the laboratory? 
We will do experiments on your cells approximately 2 weeks after the blood sample is taken.  Most of the experiments 
will be done on your cells or the proteins we isolate from your cells.  Protein, RNA or DNA maybe isolated from your 
cells but will only be used by the investigators in this study or their collaborators and will only be used for our studies on 
the interactions of macrophages and related cells with micro-organisms. Any materials isolated from your cells will be 
stored for a maximun period of 5 years after which time it will be destroyed.  The sample will be anonymised so that the 
results obtained will not be recognised as coming from your sample. 
 
Will any genetic tests be done? 
Genetic tests may be performed to see what ‘Human Leucocyte Antigen (HLA) type’ you are. HLAs are proteins on 
your cells that help the immune system recognise foreign matter like bacteria and viruses. Knowing what HLA type 
you are will allow in depth evaluation of your immune system’s response to certain pathogens.  
 
Will the information obtained in the study be confidential? 
Anything you say will be treated in confidence, no names will be mentioned in any reports of the study, and care will be 
taken so that individuals cannot be identified from details in reports of the results of the study. In screening you for 
participation in the study we will certain questions such as do you have any medical conditions or take any medicines. The 
answers to these questions will be kept confidential and if they are deemed to result in your exclusion from participating 
the results will not be kept.  
 
Will the results generated lead to any other possible outcomes? 
It is possible that we may identify new ways of regulating the body’s response to common infections. If that were to 
happen we may need to apply for a patent which would protect our right to try and exploit this finding in the 
diagnosis or treatment of relevant infections. We would do this through the University of Sheffield and would use 
the patent to support the development of research and treatment of infectious diseases. 
 
Will I benefit from the study? 
There will be no direct benefits to participation. 
 
When can I next donate blood? 
Since we take up to 500ml of your blood we recommend you do not participate in a further study involving blood 
donation and do not donate blood for 6 months after this study. 
 
What if I wish to complain about the way in which the study has been conducted? 
If you have any cause to complain about any aspect of the way in which you have been approached or treated during 
the course of this study, the normal National Health Service complaints mechanisms are available to you. The 
research lead is Professor David Dockrell.  If you wish to discuss the study further please contact Professor 
Dockrell, by telephoning him directly on 01142712160.  Otherwise you can complain directly to the Medical 
Director who manages Professor Dockrell: Dr.David Throssell, Medical Directorate, 8 Beech Hill Road, Sheffield 
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Consent form for healthy volunteers. Version 4.2  02/06/2014.   
CONSENT FORM 
Title of Project: Investigation of how macrophage responses to micro-organisms programme the 
innate immune response to human disease. 
Name of Researchers: Professor. David Dockrell. 
 
1.  I have read and understand the information sheet dated 16-04-2014 
(Version5.1) for the above study, answered the screening questions 
and have had the opportunity to ask questions.  
 
2. I understand that my participation is voluntary and that I am free 
 to withdraw at any time, without giving any reason, without any 
 medical care or legal rights being affected. 
 
3. I understand that my details as a donor will be recorded by Professor.  
            Dockrell but that my blood sample will be anonymised. 
 
4. I understand that since I will donate up to 500ml of blood I should  
not donate blood or participate in other studies involving blood donation 
for 6 months. 
 
5.         I give consent for my DNA to be used for this study  
 




____________________________   ______________  
Name of volunteer    Date   Signature 
 
 
____________________________   ______________          
Name of person taking consent  Date   Signature 
(if different from researcher) 
 
 
____________________________   
Researcher     Date   Signature 
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      Professor D H Dockrell   
The University of Sheffield Medical School 
Department of Infection and Immunity 
Room K127, K Floor 





Tel: +44 (0)114 271 2160 
Fax: +44 (0)114 271 3892 
Email: d.h.dockrell@sheffield.ac.uk 
Secretary - Mrs Sue Clary 
Tel: +44 (0)114 226 8961 
Email: s.clary@sheffield.ac.uk 
Version 3 15 10 12 
 
SCREENING FORM 
Title of Project: Investigation of how macrophage responses to micro-organisms programme the 
innate immune response to human disease. 







Place √ in box to 
confirm   
1.  The volunteer has received the patient information sheet, 
has had the principles of the study explained and has had  
the opportunity to ask questions. 
 
The volunteer  
2. has not received a vaccine within the last week. 
 




4. has no history of chronic medical conditions. 
 




6. is not known to be anaemic 
 
7. has not donated blood for any reason I the last 6 months 
 
8. has no symptoms of shortness of breath, chest pain, fatigue  
or excessive pallor 
 
__________________________   ______________  
Name of volunteer    Date   Signature 
 
____________________________   ______________          
Name of person screening   Date   Signature 
 
____________________________   
Researcher     Date   Signature 
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Appendix III. 
Lung preparations information. 
Information table of the lung preparations carried out in this project. The table contains 
details of 230 preparations. The lung numbers relate to the coding system used in the 
laboratory. Any missing cell viability information is due to the viability assessment 
protocol initially not being well established or due to the type of experiments being 
performed. For example, some experiments required a high number of cells, which may 
have resulted in a lack of available cell culture wells to use for assessing viability. Very 
few of the macrophage purity values are missing. The reason for missing values is the 













A417 M 68 14.91 48     
A418 M 65 6.1 6     
A419 F 72 9.19 8.9 98   
A420 M 64 23.48 146     
P1 M 79 11 9 97   
P2 M 79 11.84 35 96   
P3 F   10.4 13 92   
P5 F 36 6 8 91   
P9 M 42 15.05 22 92   
P14 M 55 9.2 59 96 65 
P17 M 75 18.3 17 82 48 
P19 M 82 16 18.6 98   
P22 M 60 7.5 31 76   
P23 F 83 14 21 88   
P24 M 53 4.04 9.5 96   
P25 F 67 3.5 0     
P26 M 74 7 1.5     
P27 F  72 12.4 23.5 81   
P29 F 64 8 21 82   
P33 M 69 8.9 54.5 96   
P35 M 76 7.85 44 94 96 
P37 M 52 5.98 32 84 91 
P39 M 64 7.3 33 76   
P42 F 66 12.8 5.2 68   
P47 M 24 11 3 64   
P51 F 72 13.25 22 87 92 
P54 M 70 7.5 24 93   
P55 M 76 13 4.3 86   
P58 F 66 5.9 5.1 90   
P59 M 67 5 5.4 90   
P60 M 78 22 51 93   
P63 M 72 8.7 4.7 80   
P64 F 77 9.35 50 98 91 
P66 M 56 23 21 81 91 
P67 M 44 20.76 39 95 95 
P69 M 68 8.18 18.6 93 90 
P71 M 77 16.25 13 93 90 
P72 F 59 23 26 90 94 
P75 M 32 6.3 2.7 76   
P76 M 81 9 3.8 74   
P79 M 43 14.23 22.5 90 90 
P80 M 67 6.45 11.8 93 95 
P81 F 71 5.37 14 96 93 
P85 M 71 9.2 38.8 97 82 
P86 M 61 7.5 56.6 92 85 
P88 M 60 20 51.8 88 92 
P90 M 75 18 42 97 97 
P93 F 79 7.28 7 84 93 
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P95 M 72 15.8 6 89 93 
P97 F 65 11.8 14.9 81 82 
P98 F 72 7.35 15.9 96 87 
P102 M 80 26 18.7 71 92 
P103 F 60 19 36 93 86 
P104 F 72 9.5 48.7 90 96 
P106 M 79 15 16.3 83 93 
P111 F 52 5.5 35.5 95 85 
P114 M 63 8 4.7     
P116 M 70 27.21 59.6 83   
P117 F 66 4.5 11.6 93   
P119 M 83 36 29.8 86   
P124 F 62 13.8 1.5 79 94 
P125 F 79 6.5 6.3 90 95 
P126 F 53 21 29 85 80 
P128 M 67 19.75 66 90 88 
P131 M 53 16.8 4.65     
P132 M 78 14 12 97 95 
P133 F 75 5.77 5.5     
P134 F 78 11.8 3.8 86 93 
P136 F 72 10.1 16   90 
P139 F 58 14.22 0     
P140 F 73 13.75 23 92 96 
P141 M 71 4.66 28 97 96 
P143 M 75 10 5     
P156 F 54 17 14 84 98 
P159 F 47 7.01 5.18 70   
P163 F 70 3 7.5 81 95 
P165 F 62 18.7   83 91 
P170 M 60 17 74 97 86 
P171 F 60 5 4 77   
P173 F 59 26 11.6     
P176 M 77 14 32 80 91 
P177 F 60 6 4 86   
P179 M 73 16.38 27 81 74 
P180 F 68 4.2 8 90   
P185 M 88 15 18.5 88 92 
P189 M 61 8.5 24 90 95 
P190 M 64 17 30 92 87 
P200 F 70 9.32 2.9 78   
P210 M 82 25.68 11 62 96 
P214 F 52 13.68 13 92 90 
P220 M 56 26 17.25 74 97 
P221 M 61 9.5 28.5 99 96 
P227 M 72 13.32 19.6 82 96 
P228 F 76 15.89 5.3 87 92 
P230 M 76 13.23 37.4 94 97 
P231 F 68 10.19 2.3 82 98 
P235 M 69 10 17.8 89 95 
P241 M 79 20 25 87 94 
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P244 F 22 9.65 36 59 96 
P248 F 86 10.53 7.6 91 95 
P249 F 57 8.7 8 91   
P250 M 71 29 11.9 75 93 
P258 M 27 15 32 86 94 
P259 F 76 14 23   92 
P262 M 70 13.58 42 91 96 
P263 M 82 5.68 6.6 88 94 
P265 M 61 20 12 88 90 
P268 F 79 14.99 16 90 96 
P270 M 78 14.8 18 95 92 
P272 M 66 19.48 6 87 91 
P275 M 69 14.76 14 86 97 
P278 M 67 13 36 87 91 
P282 F 80 3.75 7 68 92 
P292 M 63 8.92 5.5 88 66 
P293 F 59 23.16 44 96 96 
P296 M 43 9.12 4.35 83 90 
P297 M 77 10 42 86 93 
P298 M 47 5 20 94 99 
P302 M 77 14 15 73 94 
P303 M 62 23.64 10.43 77 97 
P306 M 69 13.42 20 93 84 
P309 F 60 13.78 14.6 77 93 
P313 M 68 12.6 20 89   
P317 M 77 11.07 49 84 90 
P320 F 76 10.74 19 95 95 
P324 M 41 11 2.25   94 
P325 M 61 14 12   93 
P329 M 74 20 11.5 72 97 
P330 F 76 5.87 43   98 
P331 M 72 17 41 76 95 
P340 M 74 10 33 90 93 
P345 F 65 8 5.6   59 
P348 M 82 10.61 15   91 
P355 F 62 9 21.5 95 88 
P356 F 51 16 1.5 89   
P360 F 66 5 4.6 88 92 
P361 F 59 5.76 29   87 
P364 M 49 15 66 95 90 
P369 M 74 4.5 10.4 82 90 
P370 F 52 6.4 3.3 63 88 
P371 M 76 20 68 89 98 
P373 M 73 3.35 15 92 93 
P378 F 73 10 7 90 95 
P380 F 65 28.28 8.6 77 99 
P381 F 52 8 23 94 92 
P382 F 82 16.93 51 88 93 
P383 F 74 6 9 87   
P384 M 60 10.4 8.3 68 93 
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P387 F 59 17 9 60 94 
P389 M 70 7.47 19 86 95 
P391 M 70 28 19.8 87 95 
P393 M 68 13 24 94   
P394 M 48 8.3 7 87   
P397 M 69 3.5 7.6 90   
P398 F 59 11.7 9.8 90   
P401 M 53 16 14 91   
P403 F 68 3.6   57   
P405 F 73 18 7 82   
P406 F 77 5.4 7.5 93 85 
P407 F 71 28 3 86   
P409 F 69 4 13 97   
P411 F 45 20 40 90   
P412 F 58 18 54 92 93 
P413 F 74 10 21 91 93 
P416 M 74 12.81 47 92 90 
P421 M 73 11 6 88 80 
P422 M 70 6.8 21 96 89 
P423 M 84 19 14 69 98 
P424 F 71 10.73 13 85 89 
P438 F 61 19.06 7.8 59 85 
P440 F 66 13 10.7 80 95 
P441 F 61 10.42   92   
P444 M 63 23.56 14.8 91 81 
P445 F 72 25 23.7 87 90 
P447 M 79 16.2 11.8 89   
P448 F 51 25.13 24 86   
P450 F 65 9.9 7.4 80   
P455 M 56 15 10.4 92 92 
P458 M 70         
P460 M 72 5.93 3.6 89   
P462 F 67 9 4.9 70   
P463 M 78 7.35 18 90 92 
P464 F 74 10.36 3.3 63   
P465 F 54 9 7 90 90 
P468 F 53 9.7 23 88 90 
P469 M 77 10 23 87 82 
P473 M 70 14.28 23.9 81 86 
P476 M 66 16 24.6 91 92 
P477 M 68 14.6 6 76   
P479 F 76 18.93 21.1 94 82 
P484 M 59 6.11 19 81 92 
P485 F 76     58   
P486 F 82 7.5 7 83   
P488 M 50 9.84 45 97 92 
P489 M 68 13.91 6.8 68   
P490 F 70 12 6 89 92 
P492 F 71 14.61 10 83   
P493 F 69 21 14 96   
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P497 F 75 10.37 18.5 88 95 
P498 F 80 10.6 44 92 93 
P500 F 67 6.75 23 89 96 
P505 F 69 10.5 16.9 78 95 
P510 F 70 17.7 7.5 76   
P513 F 67 9.02 29.5 90 95 
P522 F 62 16.43 11.4 71   
P524 F 77 13.86 75 81 93 
P525 M 78 8.35 58 88 92 
P527 M 84 9.51 5.9 89   
P530 F 54 15.33 7.3 82 93 
P532 F 78 20 32.6   80 
P534 M 59 15 47 94 94 
P535 F 71 2.4 4.9 74 85 
P536 F 66 9.1 2.2 76 78 
P538 F 71 6.25 3.6 90   
P539 F 69 10.32 6.9 60   
P544 M 73 28 7.4 65   
P545 F 83 6.32 4.5 78   
P546 F 68 10.19 23.3 84   
P547 M 54 13 27.4 95   
P551 M 77 11.2 10.2 93   
P552 F 72 13.72 8.4 95 97 
P554 F 56 8.14 45.9 90   
P556 F 73 19.32 45.9 82   
P559 F 72   7.6   91 
P570 F 60 25.46 5.7 57   
P571 F 64 6.5 4.5 71   
P574 F 84 9.49 14.8 80 93 
P576 F 65 7.85 24.9 83 91 
P581 F 68 5.8 9.2 81 78 
P582 F 58 6.7 60.6 97 93 
 
 
 
 
 
 
